

**СПИСЪК С ЦИТИРАНИЯ НА НАУЧНИТЕ ТРУДОВЕ  
НА ПРОФ. Д-Р ЛЮДМИЛА БОЯНОВА ГЕОРГИЕВА, ДМ, ДМН,  
професор в Катедра по медицинска микробиология, Медицински университет – София  
ЗА ПОСЛЕДНИТЕ 5 ГОДИНИ (2016-2020 г.)**

**(КАНДИДАТЪТ УЧАСТВА В КОНКУРСА С ВСИЧКИ НАУЧНИ ТРУДОВЕ)**

Брой на цитиранията	Общо	В посл. 5 г.
<b>Общо брой цитирания</b>	<b>2767</b>	<b>1118</b>
в международни и чуждестранни списания	<b>2166</b>	914
в български списания	<b>49</b>	9
в чуждестранни монографии/книги	<b>175</b>	66
в български монографии/книги	<b>9</b>	5
в чуждестранни дисертации	<b>341</b>	118
в български дисертации	<b>27</b>	6
<b>Общо цитирания в международни и чуждестранни трудове</b>	<b>2682</b>	<b>1098</b>
<b>Общо цитирания в български трудове</b>	<b>85</b>	<b>20</b>

Над 40% от цитиранията на всички публикации са от последните 5 години.

Цитиранията са подредени по азбучен ред на първия автор на цитиращия, първо на латиница, след това на кирилица.

**-В СПИСАНИЯ В ЧУЖБИНА:**

**ЦИТИРАНА: 1А:** Megraud F, Trimoulet P, Lamouliatte H, **Boyanova L**. Bactericidal effect of amoxicillin on *Helicobacter pylori* in an vitro model using epithelial cells. Antimicrob Agents Chemother. 1991; **35**(5): 869 -872. **Цитирана от:**

- 1) Arulnathan E, Lakshminarasimmaiah BN, Naik HJ. Gastric Microenvironment Enables Persistence of *Helicobacter pylori*: a physician's combat towards eradication and directions for the future. Journal of Young Investigators, 2018;**35**(6).
- 2) Dacoll C, Sánchez-Delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for *Helicobacter pylori* eradication achieves high cure rates in Uruguay. Gastroenterologia y hepatologia. 2017; **40**(7):447-454.
- 3) Ghosh P, Sarkar A, Ganguly M, Raghwan, Alam J, De R, Mukhopadhyay AK. *Helicobacter pylori* strains harboring babA2 from Indian sub population are associated with increased virulence in ex vivo study. Gut Pathog. 2016;**8**:1. doi: 10.1186/s13099-015-0083-z. eCollection 2016.
- 4) Hussein Salim R, Karim Hassan A, Qasim Al-tamemi N, M Saeed A, AL-Obaidi Z, M Almusawi J, & H Alaaeyedi M. Effect of Hydroxy Propyl Methyl Cellulose (HPMC) on Amoxicillin Floating Tablet. Kerbala journal of pharmaceutical sciences. 2017; **8**(13): 311-319.
- 5) Jan HM, Chen YC, Yang TC, Ong LL, Chang CC, Muthusamy S, ... & Lin CH. Cholesteryl  $\alpha$ -D-glucoside 6-acyltransferase enhances the adhesion of *Helicobacter pylori* to gastric epithelium. Communications biology. 2020; **3**(1), 1-13.
- 6) Kane-Dumbre S, Momin M, Ravikumar P, Khatri R. Drug delivery strategies for *Helicobacter pylori* infection management: An overview. Indian Drugs. 2019; **56**(10): 7-21.
- 7) Kwack WG, Lim YJ, Lim CY, Graham DY. High dose ilaprazole/amoxicillin as first-line regimen for *Helicobacter pylori* infection in Korea. Gastroenterol Res Pract. 2016; **2016**: Article ID 1648047. doi:10.1155/2016/1648047
- 8) Puig I, Baylina M, Sanchez-Delgado J, Lopez-Gongora S, Suarez D, Garcia-Iglesias P, Munoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for *Helicobacter pylori* first-line treatment. J Antimicrob Chemother. 2016;**71**(10):2740-53..
- 9) Thombre NA, Gide PS. Floating-bioadhesive gastroretentive *Caesalpinia pulcherrima*-based beads of amoxicillin trihydrate for *Helicobacter pylori* eradication. Drug Deliv. 2016;**23**(2):405-419.

**ЦИТИРАНА: 2А:** Megraud F, **Boyanova L**, Lamouliatte H. Activity of lansoprazole against *Helicobacter pylori*. Lancet. 1991; **337**: 1486. **Цитирана от:**

- 10) Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract—evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020; **51**(5): 505-526.

**ЦИТИРАНА: 6А:** **Boyanova L**, Stancheva I, Todorov D, Kumanova R, Petrov S, Vladimirov B, Pehlivanov N, Mitova R, Chakarski I, Churchev I. Comparison of three urease tests for detection of *Helicobacter pylori* in gastric biopsy specimens. Eur J Gastroenterol Hepatol. 1996; **8**(9): 911-914. **Цитирана от:**

- 11) Talebi Bezmin Abadi A. Diagnosis of *Helicobacter pylori* using invasive and noninvasive approaches. J Pathog. **2018**;2018.

**ЦИТИРАНА: 7А:** **Boyanova L**, Koumanova R, Jelev Chr, Petrov S. *Helicobacters* in Bulgarian children. J R Soc Med. 1997; **90** (10): 588-589. **Цитирана от:**

- 12) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016;**43**(4):514-33.

**ЦИТИРАНА: 10A: Boyanova L, Neshev G.** Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; **48**: 705-706. **Цитирана от:**

- 13) Bhattamisra SK, Yan VL, Lee CK, Kuean CH, Candasamy M, Liew YK, Sahu PS. Protective activity of geraniol against acetic acid and *Helicobacter pylori*-induced gastric ulcers in rats. J Tradit Complement Med. 2018; **9**(3): 206-214.
- 14) Bhattamisra SK, Kuean CH, Chieh LB, (...), Candasamy M, Sahu PS. Antibacterial activity of geraniol in combination with standard antibiotics against *Staphylococcus aureus*, *Escherichia coli* and *Helicobacter pylori*. Natural Product Communications 2018; **13**(7): 791-793.
- 15) Kara A, Algur Öf, Köseoğlu Mş. Bazı Şifalı Bitkilerin *Helicobacter pylori* üzerindeki Antimikrobiyal Aktiviteleri. Cumhuriyet Science Journal. 2016;**37**(2):129-140.
- 16) Moulaei H, Namakin K, Namaei MH, Azarkar Z. The effect of red rose extract on *Helicobacter pylori* eradication: A randomized controlled clinical trial. International Journal of Pediatrics. 2019; **7**(12): 10473-10480.

**ЦИТИРАНА: 11A: Petrov S, Churtchev J, Mitova R, Boyanova L, Tarassov M.** Xanthoma of the stomach-some morphometrical peculiarities and scanning electron microscopy. Hepato- Gastroenterology. 1999; **46**: 1220-1222. **Цитирана от:**

- 17) Xiao D, Tong X, Yuan X, Wu Y, Chen P. Gastric xanthelasma may be a warning sign of intestinal metaplasia: A cross-sectional study. Oncology Reports. 2020; **44**(3): 1275-1281.
- 18) Xiong Q, Wang Z, He L, Zhang Y. Relationship Between Gastric Xanthelasma and Atrophic Gastritis: A Single center retrospective study. Chinese Journal of Gastroenterology. 2017; **22**(9):529-533.

**ЦИТИРАНА: 13A: Boyanova L.** Comparative evaluation of two methods for testing metronidazole susceptibility of *Helicobacter pylori* in routine practice. Diagn Microbiol Infect Dis. 1999; **35** (1): 33 - 36. **Цитирана от:**

- 19) Kataria R, Khatkar A. In-silico design, synthesis, ADMET studies and biological evaluation of novel derivatives of Chlorogenic acid against Urease protein and *H. pylori* bacterium. BMC Chemistry. 2019; **13**(3):41.

**ЦИТИРАНА: 14A: Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R.** Primary and combined resistance to four antimicrobial agents in *Helicobacter pylori* in Sofia, Bulgaria. J. Med. Microbiol. 2000; **49**: 415–418. **Цитирана от:**

- 20) Alarcón-Millán J, Fernández-Tilapa G, Cortés-Malagón EM, Castañón-Sánchez CA, de Sampedro-Reyes J, Carmen IC, Betancourt-Linares R, Román-Román A. Clarithromycin resistance and prevalence of *Helicobacter pylori* virulent genotypes in patients from Southern Mexico with chronic gastritis. Infect Genet Evol. 2016; **44**:190-198.
- 21) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016;**43**(4):514-33.
- 22) Ubani UA, Timothy CO, Ihesiulor GC. Assessment of *Helicobacter pylori* in glaucoma disease in abia state of Nigeria. International Educational Applied Scientific Research Journal. 2017;**2**(3): 2456-5040.

**ЦИТИРАНА: 15A: Boyanova L, Petrov D, Osmanliev D, Mitov I, Usunova I, Minchev Tz, Goranov E, Plochev M, Dimitrov J.** Anaerobic bacteriology in 75 cases of thoracic empyema in Sofia, Bulgaria. Anaerobe, 2000; **6**: 81-85. **Цитирана от:**

- 23) Demirci M, Gemicioğlu B, Saribas S, (...), Kocazeybek BS, Bahar-Tokman H. A retrospective analysis of anaerobic bacteria isolated in 236 cases of pleural empyema and their prevalence of antimicrobial resistance in Turkey. Clinical Laboratory. 2018; **64**(7-8):1269-1277.

**ЦИТИРАНА: 16A: Boyanova L, Osmanliev D, Petrov D, Mitov I, I. Usunova, Petrov S, Minchev Tz.** Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. Clin. Microbiol. Infect. 2000; **6**: 622-624. **Цитирана от:**

- 24) Shenoy PA, Lobo S, Shetty S, Vishwanath S, Chawla K. Antimicrobial susceptibility profile of clinical isolates of *Peptostreptococcus anaerobius*. Journal of Pure and Applied Microbiology. 2018;**12**(3):1239-46.

**ЦИТИРАНА: 17A: Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarcheken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M.** The status of antimicrobial resistance of *Helicobacter pylori* in eastern Europe. Clin Microbiol Infect. 2002; **8**(7): 388-396. **Цитирана от:**

- 25) Apostolopoulos P, Koumoutsos I, Ekmeztoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of *Helicobacter pylori* infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;**51**(2):145-151.
- 26) Chaudhary P, Gupta V, Sachdev A. Pattern of antibiotic resistance in *Helicobacter pylori*. Journal of Gastrointestinal Infections. 2016; **6**(1):16-21.
- 27) Zografos K, Laoudi F, Sgouras D, Mentis A, Kasapidis P, Michopoulos S. Randomized clinical trial comparing ten day concomitant and sequential therapies for *Helicobacter pylori* eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016; **32**:84-90.
- 28) Ghasemi A, Mohammad N, Mautner J, Karsabet MT, Ardjmand A, Moniri R. Immunization with recombinant FliD confers protection against *Helicobacter pylori* infection in mice. Molecular immunology. 2018;**94**:176-82.
- 29) Lin LC, Chattopadhyay S, Lin JC, Hu CM. Advances and opportunities in nanoparticle-and nanomaterial-based vaccines against bacterial infections. Advanced healthcare materials. 2018; **7**(13):1701395.
- 30) Liu W, Tan Z, Xue J, Luo W, Song H, Lv X, Zheng T, Xi T, Xing Y. Therapeutic efficacy of oral immunization with a non-genetically modified *Lactococcus lactis*-based vaccine CUE-GEM induces local immunity against *Helicobacter pylori* infection. Appl Microbiol Biotechnol. 2016; **100**(14):6219-6229.
- 31) Maçin S, Alp A, Şener B, Sökmensüer C, Orhan D, Özen H, Kav T, Akyön Y. Comparison of culture, Real-time-PCR, ELISA, and histopathological examination methods for identification of *Helicobacter pylori*. Istanbul Medical Journal. 2018;**19**(2).
- 32) Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of *Helicobacter pylori* isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter. 2017; **22**(1). doi: 10.1111/hel.12327
- 33) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016; **43**(4):514-533.

- 34) Yuk YS, Kim GY. Rates of clarithromycin resistance in *Helicobacter pylori* sampled from healthy subjects in Cheonan, Korea. Australasian Medical Journal (Online). 2019;12(1):15-20.

**ЦИТИРАНА: 18А: Boyanova L, Koumanova R, Gergova G, Popova M, Mitov I, Kovacheva Y, Derejian S, Katsarov N, Nikolov R, Krastev Z. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children. J Med Microbiol. 2002; 51:786-790.**

**Цитирана от:**

- 35) Asfaw T. Prevalence and emergence of drug resistance in *Helicobacter pylori*. Int. Res. J. Microbiol. 2018; 7(2):056-066.
- 36) Chaudhary P, Gupta V, Sachdev A. Pattern of antibiotic resistance in *Helicobacter pylori*. Journal of Gastrointestinal Infections. 2016; 6(1):16-21.
- 37) Goudarzi M, Seyedjavadi SS, Fazeli M, (...), Navidinina M, Goudarzi H. Identification of a novel cassette array in integron-bearing *Helicobacter pylori* strains isolated from Iranian patients. Asian Pacific Journal of Cancer Prevention. 2016; 17(7): 3309-3315.
- 38) Green KA, Gregorchuk BS, Reimer SL, Cartwright NH, Beniac DR, Hiebert SL, ... & Bay DC. Phenotypic and multi-omics characterization of *Escherichia coli* K-12 adapted to quaternary ammonium compounds identifies lipid A and cell envelope alterations regulated by mar-sox-rob and stress inducible pathways. 2020; bioRxiv.
- 39) Rossi A, Conti C, Colombo G, Castrati L, Scarpignato C, Barata P, Sandri G, Caramella C, Bettini R, Buttini F, Colombo P. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Dev Ind Pharm. 2016;42(2):332-339.
- 40) Асланова Х.Р. Частота встречаемости *H. pylori* в различных социальных группах населения. SAĞLAMLIQ. 2019; № 2:67-70.

**ЦИТИРАНА: 19А: Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of *Helicobacter pylori* growth in vitro by Bulgarian propolis: preliminary report. J. Med. Microbiol. 2003; 52: 417-419. Цитирана от:**

- 41) de Mendonça MA, Ribeiro AR, Lima AKD, Bezerra GB, Pinheiro MS, de Albuquerque-Júnior RL, ... & Cardoso JC. Red propolis and its dyslipidemic regulator formononetin: evaluation of antioxidant activity and gastroprotective effects in rat model of gastric ulcer. Nutrients. 2020; 12(10), 2951.
- 42) Osho A, Otuechere CA, Adeosun CB, Oluwagbemi T, Atolani O. Phytochemical, sub-acute toxicity, and antibacterial evaluation of *Cordia sebestena* leaf extracts. J Basic Clin Physiol Pharmacol. 2016; 27(2):163-170.
- 43) Peraza S, Medina J, Casanova R, Akiko S, Silva O, Castro D, Otero W, Fierro W. Cáncer gástrico en una zona con alto potencial para la cultura apícola y su aplicación en la prevención de las lesiones gástricas premalignas y malignas. Revista GEN. 2016;67(3):170-174.
- 44) Pobiega K, Gniewosz M, Kraśniewska K. Antimicrobial and antiviral properties of different types of propolis. Zeszyty Problemowe Postępów Nauk Rolniczych. 2017;589.
- 45) Shapla UM, Raihan MJ, Islam MA, Alam F, Solayman M, Gan SH, Hossen MS, Khalil MI. Propolis: The future therapy against *Helicobacter pylori*-mediated gastrointestinal diseases. 2018;16(2):81-99.

**ЦИТИРАНА: 20А: Boyanova L, Koumanova R, Lazarova E, Jeleu C. *Helicobacter pylori* and *Helicobacter heilmannii* in children. A Bulgarian study. Diagn Microbiol Infect Dis. 2003; 46: 249-252. Цитирана от:**

- 46) Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2018(3).
- 47) Guendulain C, Sibilla ML. *Helicobacter* gástricos en perros y gatos y su significancia en la salud humana. Ab Intus. 2018 17;1(2):93-100.
- 48) Hernández C, Serrano CA, Villagrán A, Torres J, Venegas A, Harris PR. *Helicobacter pylori vacA* virulence factor in uncultured *Helicobacter heilmannii* sensu lato from an infected child. JMM Case Rep, 2016. 3. doi: 10.1099/jmmcr.0.005026.
- 49) Kanani, B., Khosrowshahi, A., Khaledabad, M. A., & Pourahmad, R. Probiotic yogurt formulated with Nettle (*Urtica Dioica*) extract, a compound with dual functionalities: *Bifidobacterium* growth promoter and *Helicobacter Pylori* growth inhibitor. Biomed J Sci & Tech Res, 2018; 10 (1).
- 50) Matos R, De Witte C, Smet A, Berlamont H, De Bruyckere S, Amorim I, ... & Haesebrouck F. Antimicrobial susceptibility pattern of *Helicobacter heilmannii* and *Helicobacter ailurogastricus* isolates. Microorganisms. 2020; 8(6), 957.

**ЦИТИРАНА: 21А: Boyanova L. Influence of transport conditions and media on *Helicobacter pylori* isolation. J. Med. Microbiol. 2003; 52(Pt 12): 1129-1130. Цитирана от:**

- 51) Sarma A, Hazarika BB, Patgiri SJ, Saikia L, Begum S, Hussain MD. Isolation of *Helicobacter pylori* from gastric biopsy specimens and evaluation of common contaminants associated with *H. pylori* cultures. Int J Res Prof. 2016;2(2):161-164.

**ЦИТИРАНА: 23А: Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z.**

***Campylobacter* infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease and other chronic intestinal diseases. Diagn Microbiol Infect Dis. 2004; 49(1): 71-74. Цитирана от:**

- 52) Abd El Tawab, A. A, Ammar, A. M, Ahmed, H. A, & Hefny, A. A. Macrolides and Fluoroquinolones Resistance Mechanisms in *Campylobacters* and their Incidence in Egypt; a Review Article. Zagazig Veterinary Journal, 2017; 45(Supplementary 1), 1-19.
- 53) Arora Z, Mukewar S, Wu X, Shen B. Risk factors and clinical implication of superimposed *Campylobacter jejuni* infection in patients with underlying ulcerative colitis. Gastroenterol Rep (Oxf). 2016;4(4):287-292.
- 54) Casey E, Fitzgerald E, Lucey B. Towards understanding clinical *campylobacter* infection and its transmission: time for a different approach?. British Journal of Biomedical Science. 2017;74(2):53-64.
- 55) Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of *Helicobacter* and *Campylobacter* species in IBD: a systematic review and meta-analysis. Gut. 2017; 66(2):235-249.
- 56) Fu Y, Almansour A, Bansal M, Alenezi T, Alrubaye B, Wang H, Sun X. Microbiota attenuates chicken transmission-exacerbated *campylobacteriosis* in IL10-/- mice. Scientific reports. 2020; 10(1): 1-10.

- 57) Guérin A, Sulaeman S, Coquet L, Ménard A, Barloy-Hubler F, Dé E, Tresse O. Membrane proteocomplexome of *Campylobacter jejuni* using 2-D blue native/SDS-PAGE combined to bioinformatics analysis. *Frontiers in microbiology*. 2020; 11.
- 58) Heimesaat M M, Genger C, Biesemeier N, Klove S, Weschka D, Mousavi S, Bereswill S. Inflammatory immune responses and gut microbiota changes following *Campylobacter coli* infection of IL-10<sup>-/-</sup> mice with chronic colitis. *Pathogens*. 2020; 9(7), 560.
- 59) Lobatón T, Domènech E. Bacterial intestinal superinfections in Inflammatory Bowel Diseases beyond *Clostridium difficile*. *Inflammatory Bowel Diseases*. 2016; 22 (7):1755-1762.
- 60) Pavlova M, Velev V, Dobрева E, Asseva G, Mangarov A, Tomova I, Kantardjiev T. Advantages of Eva Green real-time mPCR compared to culture methods for differentiating *C. jejuni/coli* directly from feces. *Merit Research Journal of Medicine and Medical Sciences*. 2017; 5(5):259-262.
- 61) Pavlova M, Velev V, Dobрева E, Asseva G, Ivanov IN, Tomova I, Kantardjiev T. Advantages of eva green real-time mpcr with culture and immunochromato-graphic methods for differentiating *C. jejuni/coli* directly from feces. *Acta Medica Mediterranea*. 2018;34(4):1027-1030.
- 62) Pavlova M, Alexandrova E, Donkov G, Mitova-Mineva Y, Kantardjiev T, Velev V. *Campylobacter* infections among Bulgarian children: molecular characterization and antimicrobial susceptibility. *Biotechnol Biotechnol Equip*. 2020; 34(1): 1038-1042.
- 63) Shariati A, Fallah F, Pormohammad A, Taghipour A, Safari H, chirani AS, Sabour S, Alizadeh-Sani M, Azimi T. The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. *Journal of cellular physiology*. 2019; 234(6), 8550-8569.
- 64) Sulaeman S, Hernould M, Schaumann A, Coquet L, Bolla JM, Dé E, Tresse O. Enhanced Adhesion of *Campylobacter jejuni* to Abiotic Surfaces Is Mediated by Membrane Proteins in Oxygen-Enriched Conditions. *PLoS One*. 2012;7(9):e46402.
- 65) Sun X, inventor; University of Arkansas, assignee. Bile acid compositions and methods of use. United States patent application US 16/009,398. 2018 Dec 20.
- 66) Velev V, Pavlova M, Mangarov A, Ivanov I, Kantardjiev T. Establishment of *Campylobacter* infection with immunochromatographic test. *Merit Research Journal of Medicine and Medical Sciences*. 2017; 5(11):597-599.
- ЦИТИРАНА: 25A: Boyanova L, Djambazov V, Gergova G, Iotov D, Petrov D, Osmanliev D, Minchev Z, Mitov I. Anaerobic microbiology in 198 cases of pleural empyema. A Bulgarian study. *Anaerobe*. 2004; 10(5): 261-267. Цитирана от:**
- 67) Alves J, Peres S, Gonçalves E, Mansinho K. Anaerobic bacteria with clinical relevance: Morphologic and taxonomic classification, distribution among human microbiota and microbiologic diagnosis. *Acta Médica Portuguesa*. 2017;30(5):409-417.
- 68) Barrera-López, L., Macía-Rodríguez, C., Ferreiro-Fernández, L., & Díaz-Peromingo, J. A. *Fusobacterium nucleatum* Empyema: An Atypical Presentation. *European journal of case reports in internal medicine*. 2020; 7(7).
- 69) Bedawi EO, Hassan M, Rahman NM. Recent developments in the management of pleural infection: a comprehensive review. *The clinical respiratory journal*. 2018;12(8):2309-20.
- 70) Bedawi EO, Hassan M, McCracken D, Rahman NM. Pleural infection: a closer look at the etiopathogenesis, microbiology and role of antibiotics. *Expert review of respiratory medicine*. 2019 Apr 4(just-accepted).
- 71) Cargill TN, Hassan M, Corcoran JP, Harriss E, Asciak R, Mercer RM, McCracken DJ, Bedawi EO, Rahman NM. A systematic review of comorbidities and outcomes of adult patients with pleural infection. *Eur Respir J*. 2019; 54(3): 1900541.
- 72) Chaini E, Chainis ND, Ioannidis A, Magana M, Nikolaou C, Papaparaskevas J, Liakata MV, Katopodis P, Papastavrou L, Tegos GP, Chatzipanagiotou S. Pneumonia and pleural empyema due to a mixed *Lactobacillus* spp. infection as a possible early esophageal carcinoma signature. *Front Med (Lausanne)*. 2016; 3: 42. doi: 10.3389/fmed.2016.00042
- 73) Cobo F, Borrego J, Rodríguez-Granger J, Sampedro A, Navarro-Marí JM. A rare case of pleural infection due to *Propionibacterium acnes* (*Cutibacterium acnes*). *Revista Española de Quimioterapia*. 2018;31(2):173.
- 74) Demirci M, Gemicioğlu B, Saribas S, (...), Kocazeybek BS, Bahar-Tokman H. A retrospective nalysis of anaerobic bacteria isolated in 236 cases of pleural empyema and their prevalence of antimicrobial resistance in Turkey. *Clinical Laboratory*. 2018; 64(7-8): 1269-1277.
- 75) Denes E, Barraud O. *Fusobacterium nucleatum* infections: clinical spectrum and bacteriological features of 78 cases. *Infection*. 2016; 44(4):475-481.
- 76) Esquibel A, Dababneh AS, Palraj BR. *Lactobacillus gasseri* causing bilateral empyema. *Case reports in infectious diseases*. 2017;2017.
- 77) Granov Đ, Bekić D, Đulić EJ, Dedeić-Ljubović A. Prevalence and susceptibility pattern of anaerobic bacteria isolated from wound swabs in Clinical Centre University of Sarajevo. *Acta Medica Saliniana*. 2019; 49.
- 78) Hassan M, Cargill T, Harriss E, Asciak R, Mercer RM, Bedawi EO, ... & Rahman NM. The microbiology of pleural infection in adults: a systematic review. *European Respiratory Journal*. 2019; 54(3).
- 79) Hassan M, Corcoran JP, Daneshvar C. Factors associated with variations in the rate of referrals and microbiology of pleural infection. *Expert Review of Respiratory Medicine*. 2020; 14(11), 1165-1171.
- 80) Jwa H, Lee J, Seong GM, Kim C. Iatrogenic pleural empyema caused by *Propionibacterium acnes*. *Allergy, Asthma & Respiratory Disease*. 2019;7(1):61-4.
- 81) Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, Kasahara K, Kadota J, Kishida N, Kobayashi O, Sakata H, Seki M, Tsukada H, Tokue Y, Nakamura-Uchiyama F, Higa F, Maeda K, Yanagihara K, Yoshida K. JAID/JSC Guidelines for the treatment of respiratory infectious diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to clinical management of infectious disease/Guideline-preparing Committee Respiratory Infectious Disease WG. *J Infect Chemother*. 2016;22(7S):S1-S65.
- 82) Mitsuhashi S, Kryukov K, Nakagawa S, Takeuchi JS, Shiraishi Y, Asano K, Imanishi T. A portable system for rapid bacterial composition analysis using a nanopore-based sequencer and laptop computer. *Sci Rep*. 2017;7(1):5657.

- 83) Nagaoka K, Yanagihara K, Harada Y, Yamada K, Migiyama Y, Morinaga Y, Izumikawa K, Kohno S. Quantitative detection of periodontopathic bacteria in lower respiratory tract specimens by real-time PCR. *Journal of Infection and Chemotherapy*. 2017;**23**(2):69-73.
- 84) Nagaoka K, Yanagihara K, Morinaga Y, Kohno S. Detection of *Fusobacterium nucleatum* in two cases of empyema and lung abscess using paromomycin-vancomycin supplemented Brucella HK agar. *Anaerobe*. 2017; **43**:99-101.
- 85) Strange, C., Ramirez, J. A., & Bond, S. Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults. Up to date. 2020; <https://www.uptodate.com/contents/epidemiology-clinical-presentation-and-diagnostic-evaluation-of-parapneumonic-effusion-and-empyema-in-adults>
- 86) Hyeyoung Jwa, Jaechun Lee, Gil Myeong Seong, Changhwan Kim. [Iatrogenic pleural empyema caused by *Propionibacterium acnes*.] *Allergy, Asthma & Respiratory Disease*, 2019; **7**(1), 61-64.
- ЦИТИРАНА: 26А: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54** (Pt 5):481-483. Цитирана от:**
- 87) Abd Elkodous M, El-Sayyad GS, Youssry SM, Nada HG, Gobara M, Elsayed MA, ... Matsuda A. Carbon-dot-loaded Co x Ni 1– x Fe 2 O 4; x= 0.9/SiO 2/TiO 2 nanocomposite with enhanced photocatalytic and antimicrobial potential: An engineered nanocomposite for wastewater treatment. *Scientific Reports*. 2020; **10**(1):11534-11534.
- 88) Akkaoui S, Johansson A, Yagoubi M, Haubek D, Rida S, Claesson R, Ennibi O. Chemical composition, antimicrobial activity, in vitro cytotoxicity and leukotoxin neutralization of essential oil from *Origanum vulgare* against *Aggregatibacter actinomycetemcomitans*. *Pathogens*. 2020, **9**:3: 192.
- 89) Alasmay FA, Awaad AS, Alqahtani SM, El-Meligy RM, Abdullah DA, Alqasoumi S I. Evaluation of the chemical constituents and potential biological activities of *Cunninghamella blakesleeana*. *Saudi Pharmaceutical Journal*, 2020; **28**(10): 1197-1202.
- 90) Aleixo MLM, Galbiati C, Lemos LMS. Produtos naturais anti - *Helicobacter pylori*: revisão. *Revista Ibero-Americana de Ciências Ambientais*. 2018;**9**(1). <http://www.sustenere.co/index.php/rica/article/view/CBPC2179-6858.2018.001.0005/1049>
- 91) Aytar M, Oryaşın E, Başbülbul G, Bozdoğan B. Agar well difüzyon yönteminde standardizasyon çalışması. *Bartın Üniversitesi Uluslararası Fen Bilimleri Dergisi*. 2019; **2**(2), 138-145.
- 92) Azimi G, Hakakian A, Ghanadian M, Joumaa A, Alamian S. Bioassay-directed isolation of quaternary benzylisoquinolines from *Berberis integerrima* with bactericidal activity against *Brucella abortus*. *Research in Pharmaceutical Sciences*. 2018;**13**(2):149.
- 93) Babiker EE, Al-Juhaimi FY, Alqah HA, Adisa AR, Adiamo OQ, Ahmed IAM., ... Ozcan MM. The effect of *Acacia nilotica* seed extract on the physicochemical, microbiological and oxidative stability of chicken patties. *Journal of food science and technology*. 2019; **56**:8: 3910-3920.
- 94) Bektas H, Albay C, Sökmen BB, Aydın S, Menteşe E, Aydın G, Şen D. Synthesis, Antioxidant, and Antibacterial Activities of Some New 2-(3-fluorobenzyl)-1H-benzimidazole Derivatives. *Journal of Heterocyclic Chemistry*. 2018;**55**(10):2400-7.
- 95) Boztepe C, Tosun E, Bilenler T, Sislioglu K. Synthesis and characterization of acrylamide-based copolymeric hydrogel–silver composites: Antimicrobial activities and inhibition kinetics against *E. coli*. *International Journal of Polymeric Materials and Polymeric Biomaterials*. 2017;**66**(18):934-942.
- 96) Brahmi F, Haddad S, Bouamara K, Yalaoui-Guellal D, Prost-Camus E, de Barros JPP, Lizard G. Comparison of chemical composition and biological activities of Algerian seed oils of *Pistacia lentiscus* L., *Opuntia ficus indica* (L.) mill. and *Argania spinosa* L. Skeels. *Industrial Crops and Products*. 2020; **151**:112456.
- 97) Chakotiya AS, Chawla R, Thakur P, Tanwar A, Narula A, Grover SS, Goel R, Arora R, Sharma RK. In vitro bactericidal activity of promising nutraceuticals for targeting multidrug resistant *Pseudomonas aeruginosa*. *Nutrition*. 2016; **32**(7-8):890-897.
- 98) Chandra JS, Parvathi V, Sunandamma Y. Growth, characterization, NLO and biological activities of Fe (III) ions doped Mn (II) L-Histidine hydrochloride monohydrate crystals. *Materials Today: Proceedings*. 2018;**5**(13):26380-8.
- 99) Chauhan HPS, Joshi S, Carpenter J. Mixed bismuth(III) complexes with sulfur donor ligands. *Journal of Thermal Analysis and Calorimetry*. 2016; **124**(1):117-130.
- 100) Chowdhury FT, Sarker M, Islam MS, Nur HP, Islam MR, Khan H. Bioresearch Communications. *Journal Homepage: www.bioresearchcommunications.com*. 2018 Jan;**4**(01).
- 101) Chuokeatirote E, Jenjai N. Antimicrobial activity of wood vinegar from *Dimocarpus longan*. *EnvironmentAsia*. 2018;**11**(3).
- 102) Deb A, Saikia R, Chowdhury D. Nano-Bioconjugate Film from Aloe vera to detect hazardous chemicals used in cosmetics. *ACS omega*, 2019; **4**(23): 20394-20401.
- 103) DeNaan DN. Natural product (*Abutilon hirtum* extracts) in treating environment-related infections (Salmonellosis and Typhoid fever). *GSC Biological and Pharmaceutical Sciences*, 2020;**13**(2), 128-135.
- 104) El-Refai AA, Sharaf AM, Azzaz NAE., El-Dengawy MM. Antioxidants and antibacterial activities of bioactive compounds of clove (*Syzygium aromaticum*) and thyme (*Tymus vulgaris*) extracts. *Journal of Food and Dairy Sciences*. 2020; **11**(9), 265-269.
- 105) Feroze N, Arshad B, Younas M, Afridi MI, Saqib S, Ayaz A. Fungal mediated synthesis of silver nanoparticles and evaluation of antibacterial activity. *Microscopy Research and Technique*. 2020; **83**(1): 72-80.
- 106) Gönen F, Tekinerdoğan G. Synthesis of Specific ZnF Based Nanoparticles (ZnFe2O4): Antimicrobial Properties, Surface Characteristics, and Adsorption Activity for AB 29 Textile Dye. *Journal of Nanotechnology*. 2020: Article ID 3139701.
- 107) Governa P, Biagi M. *Copaifera langsdorffii* Desf.: in vitro investigation on anti-*Helicobacter pylori* and anti-inflammatory activities of oleoresin and fruit methanolic extract. *Plant Biosystems-An International Journal Dealing with all Aspects of Plant Biology*. 2020, **154**:1: 117-124.
- 108) Guna V, Ilangovan M, Adithya K, Srinivas CV, Yogesh S, Nagananda GS, ... Reddy N. Carbohydrate polymers. 2019, **218**: 243-249.

- 109) Hamayeli H, Shoshtari AN, Hassanshahian M, Hesni MA. Journal of Coastal Life Medicine. Journal of Coastal Life Medicine. 2016;**4**(8):612-615.
- 110) Hamayeli H, Hassanshahian M, Hesni MA. The antibacterial and antibiofilm activity of sea anemone (*Stichodactyla haddoni*) against antibiotic-resistant bacteria and characterization of bioactive metabolites. International Aquatic Research. 2019; **11**(1): 85-97.
- 111) Hasali NH, Zamri AI, Lani MN, Mubarak A. Antibiotic susceptibility, antibacterial activity and probiotic characterisation of isolated *Lactobacillus brevis* strains from *Heterotrigona itama* honey. Malaysian Applied Biology. 2018; **47**(6):105-112.
- 112) Hosseini M, Jamshidi A, Raeisi M, Azizzadeh M. The Antibacterial and antioxidant effects of clove (*Syzygium aromaticum*) and lemon verbena (*Aloysia citriodora*) essential oils. Journal of Human, Environment and Health Promotion. 2019; **5**(2), 86-93.
- 113) Islam NU, Jalil K, Shahid M, Rauf A, Muhammad N, Khan A, ... Khan MA. Green synthesis and biological activities of gold nanoparticles functionalized with *Salix alba*. Arabian Journal of Chemistry. 2019; **12**:8: 2914-2925.
- 114) Islam NU, Jalil K, Shahid M, Muhammad N, Rauf A. *Pistacia integerrima* gall extract mediated green synthesis of gold nanoparticles and their biological activities. Arabian Journal of Chemistry. 2019; **12**(8): 2310-2319.
- 115) Jain R, Jain SC. Studies on antimicrobial and antioxidant potentials of triterpenoidal saponins from *Mimosa Hamata* Willd. International Journal of Pharmaceutical and Phytopharmacological Research. 2017;**4**(6):337-339.
- 116) Junjian R, Xinhong L, Ruixiang Z, Lili Z, Gang L. Purification, characterization of a novel lactobacillin LA1 produced by *Lactobacillus rhamnosus* ZRX01. Research Journal of Biotechnology. 2017; **12**(11): 46-53
- 117) Kakanejadifard A, Khojasteh V, Zabardasti A, Azarbani F. New azo-schiff base ligand capped silver and cadmium sulfide nanoparticles preparation, characterization, antibacterial and antifungal activities. Organic Chemistry Research. 2018; **4**(2):210-26.
- 118) Kalia P, Kumar NR, Harjai K. Studies on the therapeutic effect of propolis along with standard antibacterial drug in *Salmonella enterica* serovar Typhimurium infected BALB/c mice. BMC complementary and alternative medicine. 2016;**16**(1):485.
- 119) Kalia P, Kumar NR, Harjai K. Preventive effect of honey bee propolis on *Salmonella enterica* serovar Typhimurium infected BALB/c mice: A Hematological Study. Research Journal of Pharmacy and Technology. 2020; **13**(7): 3389-3393.
- 120) Kalidoss R, Ayyappadasan G, Gnanamangai BM, Ponmurugan P. Antibacterial activity of lichen *Parmotrema* spp. International Journal of Pharmaceutical and Biological Science Archive. 2020; **8**(2).
- 121) Karadağ A, Korkmaz N, Aydın A, Tekin Ş, Yanar Y, Yerli Y, Korkmaz ŞA. In vitro biological properties and predicted DNA–BSA interaction of three new dicyanidoargentate (i)-based complexes: synthesis and characterization. New Journal of Chemistry. 2018; **42**(6):4679-92.
- 122) Kaur H, Amini MH, Prabhakar PK, Singh A, Suttee A. Phytochemical screening and antimicrobial activity of *Caesalpinia sappan* L. leaves. International Journal of Pharmacognosy and Phytochemical Research 2016; **8**(6):1040-1045.
- 123) Khalil WF, El-Sayyad GS, El Roubi WM, Sadek MA, Farghali AA, El-Batal AI. Graphene oxide-based nanocomposites (GO-chitosan and GO-EDTA) for outstanding antimicrobial potential against some *Candida* species and pathogenic bacteria. International Journal of Biological Macromolecules. 2020; **164**: 1370-1383.
- 124) Khan H, Badshah A, Said M, Murtaza G, Sirajuddin M, Ahmad J, Butlere IS. Synthesis, structural characterization and biological screening of heteroleptic palladium(II) complexes. Inorganica Chimica Acta. 2016; **447**:176–182.
- 125) Korkmaz N, Aydın A, Karadağ A, Yanar Y, Maşoğlu Y, Şahin E, Tekin Ş. New bimetallic dicyanidoargentate (I)-based coordination compounds: Synthesis, characterization, biological activities and DNA-BSA binding affinities. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2017;**173**:1007-1022.
- 126) Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmanski Ł, Migdał P, Gościński G. In Vitro Activity of 3-bromopyruvate, an anticancer compound, against antibiotic-susceptible and antibiotic-resistant *Helicobacter pylori* strains. Cancers. 2019;**11**(2):229.
- 127) Labská K, Plodková H, Pumánová M, Sensch KH. Antiviral activity of propolis special extract GH 2002 against Varicella zoster virus in vitro. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2018;**73**(12):733-6.
- 128) Lee AR, Niu KM, Kang SK, Han SG, Lee BJ, Kim SK. Antioxidant and antibacterial activities of *Lactobacillus*-fermented *Artemisia annua* L. as a potential fish feed additive. Journal of Life Science. 2017;**27**(6):652-660.
- 129) Lekhak B, Singh A, Bhatta DR. Antibacterial and Antifungal Property of *Actinomyces* Isolates from Soil and Water of Nepal. Journal of Nepal Health Research Council. 2018;**16**(2):136-9.
- 130) Lima VHMD, Almeida KDCR, Alves CCF, Rodrigues ML, Crotti AEM, Souza JMD, ... & Miranda MLD. Biological properties of volatile oil from Brazilian brown propolis. Revista Brasileira de Farmacognosia. 2019; **29**(6): 807-810.
- 131) Maheswari RU, Priya K. Studies on influence of ascorbic acid & correlance with anti-fungal possessions of *Cymbopogon Citratus* treated with various organic manure and its texture analysis using sem. World Journal of Pharmacy and Pharmaceutical Sciences. 2016; **5**(9):1647-1657.
- 132) Marand SK, Yazdi FT, Mortazavi SA, Babaei AB. Inhibitory and bactericidal effects of artichoke (*Cynara scolymus*) on pathogenic strains and their comparison with antibiotics in vitro. Qom Univ Med Sci J. 2016;**10**(2):31-42.
- 133) More NV, Kharat KR, Kharat AS. Berberine from *Argemone mexicana* L exhibits a broadspectrum antibacterial activity. Acta Biochimica Polonica. 2017; **64**(4): 653-660.
- 134) Naik GG, Alam MB, Pandey V, Mohapatra D, Dubey PK, Parmar AS, Sahu AN. Multi-Functional Carbon Dots from an Ayurvedic Medicinal Plant for Cancer Cell Bioimaging Applications. Journal of Fluorescence. 2020; 1-12.
- 135) Nobakht M, Trueman SJ, Wallace HM, Brooks PR, Streeter KJ, Katouli M. Antibacterial properties of flavonoids from Kino of the Eucalypt Tree, *Corymbia torelliana*. Plants. 2017;**6**(3):39.
- 136) Noel DD, Solomon OO, John NB. Impact of *Vitex doniana* extract in elimination of *Salmonella* infection-a tropical neglected disease. Merit Research Journal of Microbiology and Biological Sciences. 2016; **4**(5): 248-254.

- 137) Park JY, Moon KS, Jeong SH, Kim JM, Oh SH. Visible Light Triggered Chlorhexidine Release of Nitrogen-Doped TiO<sub>2</sub> Nanoparticle Dental Desensitizer. In Journal of Nano Research 2016; **43**: 57-62. Trans Tech Publications.
- 138) Ponnuragan P, Aldhafiri FK, Balakrishnan S. Antibacterial Activity of Green Tea Leaves. Int. J. Curr. Microbiol. App. Sci. 2016; **5**(11):472-477.
- 139) Pourhojat F, Sohrabi M, Shariati S, Mahdavi H, Asadpour L. Evaluation of poly  $\epsilon$ -caprolactone electrospun nanofibers loaded with *Hypericum perforatum* extract as a wound dressing. Research on Chemical Intermediates. 2017;**1**(43):297-320.
- 140) Pradhan S, Dubey RC. Evaluation of phytochemical, antimicrobial and time-killing assay of *Camellia* species. Vegetos, 2020;**33**(4), 759-765.
- 141) Quintino RL, Reis AC, Fernandes CC, Martins CHG, Colli AC, Crotti AEM., ... & Miranda MLD. Brazilian green propolis: chemical composition of essential oil and their in vitro antioxidant, antibacterial and antiproliferative activities. Brazilian Archives of Biology and Technology, 2020; 63.
- 142) Qu Z, Yu M, Zhang A, Wang A, Shun L. An Experimental bacteriostasis of the banxiaxiexin decoction and 7 kinds of single taste traditional Chinese medicine on *Helicobacter pylori* resistant strains in vitro. American Journal of Internal Medicine. 2020; **8**(3): 138-142.
- 143) Raeisi M, Hashemi M, Aminzare M, Sadeghi M, Jahani T, Keshavarzi H, Jebelli Javan A, Mirahahidi M, Tepe B. Comparative evaluation of phytochemical, antioxidant, and antibacterial properties from the essential oils of four commonly consuming plants in Iran. Journal of Food Quality and Hazards Control. 2016;**3**:107-113.
- 144) Rabie G, Taha M, Youssef K. Antifungal activity of petroleum ether and ethanol extracts of *Moringa Oleifera* seeds. Asian Journal of Applied Sciences: 2019; **7**(1).
- 145) Ray A, Jena S, Dash B, Kar B, Halder T, Chatterjee T, Ghosh B, Panda PC, Nayak S, Mahapatra N. Chemical diversity, antioxidant and antimicrobial activities of the essential oils from Indian populations of *Hedychium coronarium* Koen. Industrial Crops and Products. 2018;**112**:353-362.
- 146) Ray T, Brahma D, Mitra R, Dutta D. Effective decolorization of malachite green using kocuria marina DAGII and its toxicological study Effective decolorization of malachite green using kocuria marina DAGII and its toxicological study. ACM International Conference Proceeding Series. 2018; 113-117.
- 147) Romero M, Freire J, Pastene E, García A, Aranda M, González C. Propolis polyphenolic compounds affect the viability and structure of *Helicobacter pylori* in vitro. Revista Brasileira de Farmacognosia, 2019; **29**(3): 325-332.
- 148) Saha R, Karthik S, Balu KS, Suriyaprabha R, Siva P, Rajendran V. Influence of the various synthesis methods on the ZnO nanoparticles property made using the bark extract of *Terminalia arjuna*. Materials Chemistry and Physics. 2018; **209**:208-16.
- 149) Saha R, Subramani K, Raju SA, Rangaraj S, Venkatachalam R. *Psidium guajava* leaf extract-mediated synthesis of ZnO nanoparticles under different processing parameters for hydrophobic and antibacterial finishing over cotton fabrics. Progress in Organic Coatings. 2018;**124**:80-91.
- 150) Sahib AM, Jwad SM, Taha TM. Study the protection effect of alcoholic extract of Iraqi propolis on some of liver and kidney functions at male albino rats administered with a combination of amoxicillin/clavulanic acid (augmentin) antibiotic. IJBPA, June, 2016, **5**(6): 1418-1454.
- 151) Salman HD. Antibacterial activity of propolis extracted in three different solvents and in three different pH values on some pathogenic bacteria. International Journal of Science and Research.2016; **5**(4):1514-1521.
- 152) Santhoshkumar A, Kavitha HP, Suresh R. Preparation, Characterization and antibacterial activity of NiO nanoparticles. Asian Journal of Chemistry. 2017; **29**(2):239-241.
- 153) Sharifi A, Azizi M, Moradi-Choghakabodi P, Aghaei S, Azizi A. In vitro anti-*Helicobacter pylori* activity of aqueous extract from Persian Oak testa. Chinese Herbal Medicines. 2019; **11**(4): 394-399.
- 154) Shapla UM, Raihan MJ, Islam MA, Alam F, Solayman M, Gan SH, Hossen MS, Khalil MI. Propolis: The future therapy against *Helicobacter pylori*-mediated gastrointestinal diseases. Journal of Applied Biomedicine. 2018; **16**(2):81-99.
- 155) Soltani EK, Cerezuela R, Charef N, Mezaache-Aichour S, Esteban MA, Zerroug MM. Algerian propolis extracts: Chemical composition, bactericidal activity and in vitro effects on gilthead seabream innate immune responses. Fish & shellfish immunology. 2017;**62**:57-67.
- 156) Suresh S, Bhuvanesh N, Raman A, Sugumar P, Padmanabhan D, Easwaramoorthi S, ... Nandhakumar R. Experimental and theoretical studies of imidazole based chemosensor for Palladium and their biological applications. Journal of Photochemistry and Photobiology A: Chemistry. 2019; **385**:112092.
- 157) Thammasit P, Iadnut A, Mamoon K, Khacha-ananda S, Chupradit K, Tayapiwatana C, Kasinrer W, Tragoolpua Y, Tragoolpua K. A potential of propolis on major virulence factors of *Cryptococcus neoformans*. Microbial pathogenesis. 2018;**123**:296-303.
- 158) Thangamuneswari P, Revathi S. In vitro anti-diabetic and antibacterial analysis - "*Erythrina variegata*" leaves. World Journal of Pharmaceutical and Life Sciences. 2017; **3**(2):138-141.
- 159) Venegas, A., Touma, J. H., Bravo, J., & Perez-Perez, G. Progress in use of natural products and their active components against *Helicobacter pylori*. Advances in Microbiology. 2016; **6**(14), 1091.
- 160) Younis K, Ahmad S, Osama K, Malik MA. Optimization of de-bittering process of mosambi (*Citrus limetta*) peel: Artificial neural network, Gaussian process regression and support vector machine modeling approach. Journal of Food Process Engineering. 2019; **42**.6: e13185.
- 161) Zhao J, Han L, Yu M, Cao P, Li D, Guo X, ... Xiang, W. Characterization of *Streptomyces sporangiiformans* sp. nov., a novel soil actinomycete with antibacterial activity against *Ralstonia solanacearum*. Microorganisms. 2019; **7**.9: 360
- ЦИТИРАНА: 27A: Boyanova L, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol. 2006; **55**: 65-68. Цитирана от:**
- 162) Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance and the success of tailored triple therapy in *Helicobacter pylori* strains isolated from Slovenian children. Helicobacter. 2017;**e12400**:1-6.



- 163) Liu, D. S., Wang, Y. H., Zhu, Z. H., Zhang, S. H., Zhu, X., Wan, J. H., ... & Xie, Y. Characteristics of *Helicobacter pylori* antibiotic resistance: data from four different populations. *Antimicrobial Resistance & Infection Control*. 2019; 8(1), 1-7.
  - 164) Liu, W., Zhu, J., Liu, Y., Wang, Y., Wang, Y., & Wang, X.. Effects of addition of probiotic and/or bismuth to triple therapy of *H. pylori* and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance. *Pakistan journal of pharmaceutical sciences*. 2019; 32.
  - 165) Shmueli, H., Domniz, N., & Yahav, J. Regional antibiotic resistance of *helicobacter pylori*. *JSM Gastroenterol Hepatol*. 2016; 4, 1074.
- ЦИТИРАНА: 28A: Boyanova L, Kolarov R, Gergova G, Deliverska E, Madjarov J, Marinov M, Mitov I. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillo-Facial Surgery, Sofia, Bulgaria. J. Med. Microbiol. 2006, 55 (Pt 9): 1285-1289. Erratum in: J Med Microbiol. 2006; 55(Pt 12): 1759-1760. Цитирана от:**
- 166) Abdulaziz SM. Occurrence and pattern of antibiotic resistance among dental plaque bacteria from gingivitis patients and their clinical correlation. *Journal of baghdad college of dentistry*. 2018;**30**(2):51-8.
  - 167) Alegbeleye BJ. Deep neck infection and descending mediastinitis as lethal complications of dentoalveolar infection: two rare case reports. *Journal of medical case reports*. 2018;**12**(1):195.
  - 168) Arianto, D. R., & Romdhoni, A. C. Pola Kuman, Hasil Uji Sensitifitas Antibiotik dan Komplikasi Abses Leher dalam di RSUD DR. Soetomo. *Jurnal Ilmiah Kedokteran Wijaya Kusuma*. 2019; 8(1), 88-98.
  - 169) Bacalan F, Çakir F, Özcan N, Akpolat N. Identification and antimicrobial susceptibility testing of anaerobic bacteria isolated from clinical samples. *Journal of Bacteriology & Mycology: Open Access*. 2020. JBMOA-08-00269.pdf
  - 170) Bancescu A, Bancescu G, Didilescu A, Hirjau M. Antibiotic susceptibility testing of some *Prevotella* strains isolated from vestibular abscesses. *Farmacia*. 2017;**65**(1):132-135.
  - 171) Chan YC, Cheng SW. Mycotic aneurysm of the common carotid artery as a presenting symptom for early colorectal malignancy. *Ann Vasc Surg*. 2016;**30**:306.e9-e12.
  - 172) Cordesmeier R, Kauffmann P, Markus T, Sömmer C, Eiffert H, Bremmer F, Laskawi R. Bacterial and histopathological findings in deep head and neck infections: a retrospective analysis. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*. 2017; **124**(1): 11–15.
  - 173) da Silva Junior AF, de Magalhães Rocha GS. Deep neck infection after third molar extraction: A case report. *J Dent Res Dent Clin Dent Prospects*. 2017;**11**(3):166-169.
  - 174) Korivipati, N. K., Irvineti, S., & Mallikarjun Rao, M. Deep neck space infections: our experience. *International Journal of Otorhinolaryngology and Head and Neck Surgery*. 2018; 4(1), 132.
  - 175) Loyola-Rodriguez, J. P., Franco-Miranda, A., Loyola-Leyva, A., Perez-Elizalde, B., Contreras-Palma, G., & Sanchez-Adame, O. Prevention of infective endocarditis and bacterial resistance to antibiotics: A brief review. *Special Care in Dentistry*. 2019; **39**(6), 603-609.
  - 176) Masocatto DC, Oliveira MM, de Mendonça JC. Osteomyelitis crônica mandibular: relato de caso. *Archives of Health Investigation*. 2017;**6**(2).
  - 177) Rijal S, Romdhoni AC. Bacteria Pattern, Results of Antibiotic Sensitivity Test, and Complications of Deep Neck Abscess Patients in Dr. Soetomo General Hospital. *Biomolecular and Health Science Journal*. 2018; **26**;1(2):124-30.
  - 178) Shenoy PA, Vishwanath S, Gawda A, Shetty S, Anegundi R, Varma M, Mukhopadhyay C, Chawla K. Anaerobic bacteria in clinical specimens—frequent, but a neglected lot: a five year experience at a tertiary care hospital. *Journal of clinical and diagnostic research: JCDR*. 2017;**11**(7):DC44.
  - 179) Suesongtham, P., Charoensombatom, S., & Ungkhara, G. Deep Neck Infection in Faculty of Medicine Vajira Hospital, Navamindradhiraj University. *Vajira Medical Journal: Journal of Urban Medicine*. 2018; 62(5), 365-374.
  - 180) Tent PA, Juncar RI, Onisor F, Bran S, Harangus A, Juncar M. The pathogenic microbial flora and its antibiotic susceptibility pattern in odontogenic infections. *Drug metabolism reviews*. 2019; **51**(3), 340-355.
  - 181) Vishnoi N, Singh S, Bishnoi RS, Gupta MK. Antibiotic evaluation of odontogenic microbiological spectrum of orofacial infection. *Journal of Drug Delivery and Therapeutics*. 2018; 2018 (6):179-82.
  - 182) Zeng F, Zhou Q, Zhou P, Wu M, Tang H. A secret path: severe deep neck space infection led to axilla and lateral chest abscesses. *Int J Clin Exp Med* 2016;**9**(2):5068-5070.
  - 183) Zirk M, Buller J, Goeddert P, Rothamel D, Dreiseidler T, Zöller JE, Kreppel M. Empiric systemic antibiotics for hospitalized patients with severe odontogenic infections. *Journal of Cranio-Maxillofacial Surgery*. 2016;**44**(8):1081-1088.
- ЦИТИРАНА: 29A: Boyanova L, Kolarov R, Gergova G, Mitov I. In vitro activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe 2006; 12 (4):173-177. Цитирана от:**
- 184) Alsayed, M. F. S., Hashem, A., Al-Hazzani, A. A., & Abd Allah, E. F. Biological control of yeast contamination of industrial foods by propolis. *Saudi journal of biological sciences*. 2020; 27(3), 935-946.
  - 185) Ambreen S, Maryam R, Tipu HN. Propolis, A Hope for the Future in Treating Resistant Periodontal Pathogens. *Cureus*. 2016;**8**(7).
  - 186) Bartkiene, E., Lele, V., Sakiene, V., Zavistanaviciute, P., Zokaityte, E., Dauksiene, A., ... & Ruzauskas, M. Variations of the antimicrobial, antioxidant, sensory attributes and biogenic amines content in Lithuania-derived bee products. *LWT*. 2020; 118, 108793.
  - 187) Demir Özer, E. The effects of propolis and nisin on *Listeria monocytogenes* in contaminated ice cream. *Journal of Food Processing and Preservation*. 2020; e14598.
  - 188) Djauharie N, Kemala N. Antibacterial efficacy of 5% ethanolic extract of propolis (EEP) solution against *Enterococcus faecalis* (Laboratory Experiment). *J Int Dent Med Res* 2017; **10**(1):19-23.
  - 189) Ebadi, Z., Khodanazary, A., Hosseini, S. M., & Zanguee, N. The shelf life extension of refrigerated *Nemipterus japonicus* fillets by chitosan coating incorporated with propolis extract. *International journal of biological macromolecules*. 2019; 139, 94-102.



- 190) Gajger IT, Pavlović I, Bojić M, Kosalec I, Srećec S, Vlainić T, Vlainić J. The components responsible for the antimicrobial activity of propolis from continental and Mediterranean regions in Croatia. *Czech Journal of Food Science*. 2017;**35**(5).
  - 191) Heyman L, Houri-Haddad Y, Heyman SN, Ginsburg I, Gleitman Y, Feuerstein O. Combined antioxidant effects of Neem extract, bacteria, red blood cells and Lysozyme: possible relation to periodontal disease. *BMC complementary and alternative medicine*. 2017;**17**(1):399.
  - 192) Djauharie N, Kemala N. Antibacterial Efficacy of 5% Ethanolic Extract of Propolis (EEP) Solution against *Enterococcus faecalis* (Laboratory Experiment). *Journal of International Dental and Medical Research*. 2017;**10**(1):19.
  - 193) Mohamed WF, Shady HM, Sayed-Ahmed ES, Amer SA. Antibacterial activity of Egyptian propolis and pollen extracts and their synergistic/antagonistic effect with lactic acid bacteria (LAB) against food borne pathogenic bacteria. *Egypt J Exp Biol (Bot)*. 2016; **12**(1):31-43.
  - 194) Peycheva S, Apostolova E, Gardjeva P, Peychev Z, Kokova V, Angelov A, Slavov A, Murdjeva M. Effect of Bulgarian propolis on the oral microflora in adolescents with plaque-induced gingivitis. *Revista Brasileira de Farmacognosia*. 2019; **29**(3), 271-277..
  - 195) Przybyłek, I., & Karpiński, T. M. Antibacterial properties of propolis. *Molecules*. 2019; **24**(11), 2047.
  - 196) Seibert, J. B., Bautista-Silva, J. P., Amparo, T. R., Petit, A., Pervier, P., dos Santos Almeida, J. C., ... & Dos Santos, O. D. H. Development of propolis nanoemulsion with antioxidant and antimicrobial activity for use as a potential natural preservative. *Food chemistry*. 2019; **287**, 61-67.
  - 197) Shabbir A-, Rashid M, Tipu HN. Propolis, a hope for the future in treating resistant periodontal pathogens. *Cureus*. 2016; **8**(7): e682. doi:10.7759/cureus.682
  - 198) Shubar H, Gawad MA, Doro B, Sufya N, Alatery A, Mohamed SB, Al Magrha N. Activity of honey and propolis on bacteria isolated from diabetic foot. *Journal of Advances in Microbiology*. 2018; **16**:1-8.
  - 199) Thamnopoulos IA, Michailidis GF, Fletouris DJ, Badeka A, Kontominas MG, Angelidis AS. Inhibitory activity of propolis against *Listeria monocytogenes* in milk stored under refrigeration. *Food Microbiology*. 2018;**73**:168-176.
  - 200) Tlak Gajger I, Pavlović I, Bojić M, Kosalec I. The Components Responsible for the antimicrobial activity of propolis from continental and mediterranean regions in Croatia. *Czech J Food Sci*. 2017; **35**(5):376–385.
  - 201) Vras N, EN A, FPCL P, Santos VR. Propolis gel versus benzydamine in preventing oral mucositis for patients irradiated in head and neck: a preliminary study. *Cancer Rep Rev*, 2017; **1**(2):1-4.
  - 202) Wang X, Sankarapandian K, Cheng Y, Woo SO, Kwon HW, Perumalsamy H, Ahn YJ. Relationship between total phenolic contents and biological properties of propolis from 20 different regions in South Korea. *BMC Complement Altern Med*. 2016;**16**:65.
- ЦИТИРАНА: 31A: Boyanova L, Lazarova E, Jeleu C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. *J Med Microbiol*. 2007; **56**(Pt 8):1081-1085. Цитирана от:**
- 203) Ali B, Chloë DW, Mehmet A, Sofie DB, Annemieke S, Gökhan T, Tülin GG, Freddy H, Fatih K. Presence of gastric *Helicobacter* species in children suffering from gastric disorders in Southern Turkey. *Helicobacter*. 2018;**23**(5):e12511.
  - 204) Bahadori, A., De Witte, C., Agin, M., De Bruyckere, S., Smet, A., Tümgör, G., ... & Köksal, F. Presence of gastric *Helicobacter* species in children suffering from gastric disorders in Southern Turkey. *Helicobacter*. 2018; **23**(5), e12511.
  - 205) Dimitrova-Dikanarova DK, Lazarov VV, Tafradjiiska-Hadjiolova R, Dimova II, Petkova NU, Krastev ZA. Association between *Helicobacter pylori* infection and the presence of anti-sperm antibodies. *Biotechnology & Biotechnological Equipment*. 2017;**31**(1):1-8.
  - 206) Ortiz-Princz D, Daoud G, Salgado-Sabel A, Cavazza ME. *Helicobacter pylori* infection in children: should it be carefully assessed? *Eur Rev Med Pharmacol Sci*. 2016;**20**(9):1798-813.
  - 207) Øverby A, Murayama SY, Michimae H, Suzuki H, Suzuki M, Serizawa H, Tamura R, Nakamura S, Takahashi S, Nakamura M. Prevalence of gastric non-*Helicobacter pylori*-*Helicobacters* in Japanese patients with gastric disease. *Digestion*. 2017;**95**(1):61-66.
  - 208) Øverby A, Yamagata Murayama S, Matsui H, Nakamura M. In the aftermath of *Helicobacter pylori*: Other *Helicobacters* rising up to become the next gastric epidemic? *Digestion*. 2016;**93**(4):260-265.
  - 209) Tarhane, S., & Otlü, S. Investigation of some gastric *Helicobacter* species in saliva and dental plaque of stray cats by cultural and PCR methods. *Journal of the Hellenic Veterinary Medical Society*. 2019; **70**(2), 1573-1578.
  - 210) Yee EU, Kuo E, Goldsmith JD. Pathologic features of infectious gastritis. *Advances in anatomic pathology*. 2018; **25**(4):238-53.
  - 211) Ихсанов, С. Д., Сергиенко, Д. Ф., & Деточкин, А. Н. Особенности клинического течения язвенной болезни двенадцатиперстной кишки и эрозивных гастродуоденитов у детей. *Астраханский медицинский журнал*. 2019; **14**(2).
- ЦИТИРАНА: 32A: Boyanova L, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. *Expert Rev. Anti Infect. Ther*. 2007; **5**(4):685-701. Цитирана от:**
- 212) Fatima N, Muhammad SA, Zaidi SS, Rehman N, Hussain I, Amirzada I, Mannan A. Prioritizing and modelling of putative drug target proteins of *Candida albicans* by system biology approach. *Acta Biochimica Polonica*. 2018;**65**(2):209-18.
- ЦИТИРАНА: 34A: Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jeleu C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. *Diagn Microbiol Infect Dis*. 2008; **60**(4): 409-415.**
- \*Включена в Most Cited Diagnostic Microbiology and Infectious Disease Articles <http://www.journals.elsevier.com/diagnostic-microbiology-and-infectious-disease/most-cited-articles/>**
- 213) Bertrant, E. B., Danny, T. N. L., Serge, F. C., Agnes, M., Roger, A. M., Roger, K. J., & Brigitte, K. M. L. Evolution of Susceptibilities of *Helicobacter pylori* Strains Circulating in Cameroon to Usual Antibiotics: A Three-year Study. *International Journal of Gastroenterology*. 2020; **4**(2), 63.
  - 214) Bhattamisra SK, Yan VL, Lee CK, Kuean CH, Candasamy M, Liew YK, Sahu PS. Protective activity of geraniol against acetic acid and *Helicobacter pylori*-induced gastric ulcers in rats. *J Tradit Complement Med*. 2018; **10**;9(3):206-214.

- 215) El-Zahaby SA, Kassem AA, El-Kamel AH. Non-antibiotic therapies for treatment of *Helicobacter pylori* infection. *Inventi Rapid: Pharm Biotech & Microbio*. 2016; **2016**(2):1-5.
  - 216) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. *Turk J Gastroenterol*. 2020; **31**(3): 221.
  - 217) Farahmand F, Mohammadi T, Najafi M, Fallahi G, Khodadad A, Motamed F, Mahdi Marashi S, Shoaran M, Nabavizadeh Rafsanjani R. Comparison of ciprofloxacin-based triple therapy with conventional triple regimen for *Helicobacter pylori* eradication in children. *Acta Med Iran*. 2016; **54**(6):395-400.
  - 218) Hafizi M, Shafigh Ardestani MH, Tamadon MR, Kavehzadeh K, Amiri M. Comparison of standard triple therapy regimen with sequential therapy regimen containing levofloxacin used for the eradication of *Helicobacter pylori* in patients with gastrointestinal infection caused by *Helicobacter pylori*. *World Family Medicine/Middle East Journal Of Family Medicine*. 2017;**15**(6):26-32.
  - 219) Hashemi SJ, Sheikh AF, Goodarzi H, Yadyad MJ, Seyedian SS, Aslani S, Assarzagdegan MA. Genetic basis for metronidazole and clarithromycin resistance in *Helicobacter pylori* strains isolated from patients with gastroduodenal disorders. *Infection and drug resistance*. 2019; 12, 535.
  - 220) Jeyamani, L., Jayarajan, J., Leelakrishnan, V., & Swaminathan, M. Resistance to Amoxicillin and Clarithromycin in *Helicobacter pylori* isolates in a tertiary care hospital. *Indian Journal of Microbiology Research*. 2019; 6(4), 294-298.
  - 221) Racha S, Wongrattanakamon P, Raiwa A, Jiranusornkul S. Discovery of novel potent small natural molecules able to enhance attenuation of the pathobiology of gastric cancer-associated *Helicobacter pylori* by molecular modeling. *International Journal of Peptide Research and Therapeutics*. 2018 Jul 17:1-6.
  - 222) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. *Gastroenterology*. 2018;**155**(5):1372-82.
  - 223) Suzuki H, Mori H. World trends for *H. pylori* eradication therapy and gastric cancer prevention strategy by *H. pylori* test-and-treat. *Journal of gastroenterology*. 2018;**53**(3):354-61.
  - 224) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther*. 2016;**43**(4):514-33.
  - 225) Бадритдинова, М. Н., & Орзикулова, Ш. (2020). Основные аспекты гастродуоденальной патологии в подростковом возрасте (обзор литературы). *Биология и интегративная медицина*, (5 (45)).
  - 226) Григориади Г.С., Мельник ИВ. Григориади Г.С., Мельник И.В. *Helicobacter pylori*-инфекция и новые возможности ее эрадикации. *Илмий-Амалий Тиббиёт Журнали*. 2016;1:67-71.
  - 227) Бадритдинова МН, Орзикулова Ш. *Gastroduodenal pathology in Smirlik Key features (References)/ Ўсмирлик даврида гастродуоденал патологиянинг асосий хусусиятлари (адабиётлар шарҳи)*. *Биология и интегративная медицина* 2020;5:45-59.
- ЦИТИРАНА: 35A: Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58**(1):94-100. Цитирана от:**
- 228) Alivizda V, Mariano V, Ahmad R, Charani E, Rawson TM, Holmes AH, Castro-Sánchez E. Investigating the impact of poverty on colonization and infection with drug-resistant organisms in humans: a systematic review. *Infectious diseases of poverty*. 2018;**7**(1):76.
  - 229) Asfaw T. Prevalence and emergence of drug resistance in *Helicobacter pylori*. *Int. Res. J. Microbiol*. 2018; **7**(2):056-066.
  - 230) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. *The Turk J Gastroenterol*. 2020; **31**(3): 221.
  - 231) Mabeku, L. B. K., Bille, B. E., Zemnou, C. T., Nguefack, L. D. T., & Leundji, H. Broad spectrum resistance in *Helicobacter pylori* isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. *BMC infectious diseases*. 2019; 19(1), 1-11.
  - 232) Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in *Helicobacter pylori* diagnostics in the era of next generation sequencing. *World J Gastroenterol*. 2019; **25**(32), 4629.
- ЦИТИРАНА: 36A: Boyanova L, Stephanova-Kondratenko M, Mitov I. Anti-*Helicobacter pylori* activity of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains: preliminary report. Lett Appl Microbiol. 2009; **48** (5): 579-584. Цитирана от:**
- 233) Aiba Y, Ishikawa H, Tokunaga M, Komatsu Y. Anti-*Helicobacter pylori* activity of non-living, heat-killed form of lactobacilli including *Lactobacillus johnsonii* No. 1088. *FEMS Microbiol Lett*. 2017; **364**(11). doi: 10.1093/femsle/fnx102.
  - 234) Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. *J Clin Pathol*. 2016;**69**(3):187-203.
  - 235) Garault P, Quere G, Bourdet-Sicard R, Megraud F, inventors; Compagnie Gervais Danone, assignee. Strain of *L. bulgaricus* capable of inhibiting the adhesion of *H. pylori* strains to epithelial cells. United States patent US 9,272,007. 2016 Mar 1.
  - 236) Kanani, B., Khosrowshahi, A., Khaledabad, M. A., & Pourahmad, R. Probiotic Yogurt Formulated with Nettle (*Urtica Dioica*) Extract, a Compound with Dual Functionalities: Bifidobacterium Growth Promoter and *Helicobacter Pylori* Growth Inhibitor. *Biomedical Journal*. 2018; 10(1).
  - 237) Köberl, M., Erschen, S., Etemadi, M., White, R. A., El-Arabi, T. F., & Berg, G. Deciphering the microbiome shift during fermentation of medicinal plants. *Scientific reports*. 2019; 9(1), 1-11.
  - 238) Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY. Brief report: *Lactobacillus bulgaricus* GLB 44 (Proiotic™) plus esomeprazole for *Helicobacter pylori* eradication: A pilot study. *Helicobacter*. 2018;**23**(2):e12476.
  - 239) Petkov, K., Karsch, M., & Petkov, P. 2018 U.S. Patent No. 9,930,905. Washington, DC: U.S. Patent and Trademark Office.

- 240) Sampath, G., Shyu, D. J., Rameshkumar, N., Krishnan, M., & Kayalvizhi, N. In vitro anti-*Helicobacter pylori* and anti-gastric cancer activities of *Acacia nilotica* aqueous leaf extract and its validation using in silico molecular docking approach. *Materials Today: Proceedings*. 2020.
- 241) Saracino, I. M., Pavoni, M., Saccomanno, L., Fiorini, G., Pesci, V., Foschi, C., ... & Vaira, B. Antimicrobial efficacy of five probiotic strains against *Helicobacter pylori*. *Antibiotics*. 2020; 9(5), 244.
- 242) Zheng PX, Fang HY, Yang HB, Tien NY, Wang MC, Wu JJ. *Lactobacillus pentosus* strain LPS16 produces lactic acid, inhibiting multidrug-resistant *Helicobacter pylori*. *Journal of Microbiology, Immunology and Infection*. 2016;**49**(2):168-74.
- 243) 佩吉, et al. *Helicobacter pylori* Strains can be suppressed to adhere to the Xin Deshi lactobacillus subspecies bulgaricus bacterial strain of epithelial cell. 2016.
- 244) 佩吉, et al. *Helicobacter pylori* Strains can be suppressed to adhere to the Xin Deshi lactobacillus subspecies bulgaricus bacterial strain of epithelial cell. 2016.
- 245) Гапо, П., Кер, Г., Бурде-Сикар, Р., & Метро, Ф. Штамм *L. bulgaricus*, способный ингибировать адгезию штаммов *H. pylori* к эпителиальным клеткам. RU 2584600 С2, Россия, 2016
- ЦИТИРАНА: 37А: Boyanova L. Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. *J. Med. Microbiol.* 2009; **58** (Pt 7): 930-935. Цитирана от:**
- 246) Arévalo A, Otero WA, Trespalacios AA. *Helicobacter pylori*: resistencia múltiple en pacientes de Bogotá-Colombia. *Biomédica*. 2019;39:125-134.
- 247) Bachir M, Allem R, Tifrit A, Medjekane M, Drici AE, Diaf M, Douidi KT. Primary antibiotic resistance and its relationship with *cagA* and *vacA* genes in *Helicobacter pylori* isolates from Algerian patients. *Brazilian Journal of Microbiology*. 2018; **49**(3):544-51.
- 248) Bedoya-Gómez JJ, Alvarez-Aldana A, Moncayo-Ortiz JJ, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the Antimicrobial Resistance Rates of *Helicobacter pylori* Ten Years Later in the Western Central Region, Colombia. *Dig Dis*. 2020; **38**(3):196-203.
- 249) Bilgiler C, Stadlmann A, Makrithatis A, Thannesberger J, Kastner MT, Knoflach P, Steiner P, Schöninger-Hekele M, Högenauer C, Blesl A, Datz, C. Prospective, multicenter clinical study on inter-and intra-patient genetic variability for antimicrobial resistance of *Helicobacter pylori*. *Clin Microbiol Infect*. 2017. pii: S1198-743X(17)30349-X. doi: 10.1016/j.cmi.2017.06.025.
- 250) Bolor-Erdene M, Namdag B, Yamaoka Y, Jav S. Antibiotic resistance of *Helicobacter pylori* in Mongolia. *The Journal of Infection in Developing Countries*. 2017;**11**(11):887-894.
- 251) Cerqueira RM, Correia MR, Vilar H, Manso MC. How effective is the quadruple concomitant *Helicobacter pylori* eradication therapy for obese patients undergoing gastric bypass surgery? *Obes Surg*. 2016; **26**(6):1163-1166.
- 252) Farzi, N., Yadegar, A., Sadeghi, A., Asadzadeh Aghdaei, H., Marian Smith, S., Raymond, J., ... & Zali, M. R. High prevalence of antibiotic resistance in Iranian *Helicobacter pylori* isolates: importance of functional and mutational analysis of resistance genes and virulence genotyping. *Journal of clinical medicine*. 2019; 8(11), 2004.
- 253) Moulaei, H., Namakin, K., Namaei, M. H., & Azarkar, Z. The Effect of Red Rose Extract on *Helicobacter Pylori* Eradication: A Randomized Controlled Clinical Trial. *International Journal of Pediatrics*. 2019; 7(12), 10473-10480.
- 254) Rizvanov, A. A., Haertlé, T., Bogomolnaya, L., & Talebi Bezmin Abadi, A. *Helicobacter pylori* and its antibiotic heteroresistance: A neglected issue in published guidelines. *Frontiers in microbiology*. 2019; 10, 1796.
- 255) Safavi M, Sabourian R, Forumadi A. Treatment of *Helicobacter pylori* infection: Current and future insights. *World J Clin Cases*. 2016; **4**(1):5-19.
- 256) Vianna, J.S., Ramis, I.B., Ramos, D.F., Von Groll, A., da Silva, P.E. Drug resistance in *Helicobacter pylori* | [A resistência de *Helicobacter pylori* aos antimicrobianos] *Arquivos de Gastroenterologia*. 2016; **53**(4):215-223.
- 257) Yousefi-Avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic resistance of *Helicobacter pylori* in Iranian children: a systematic review and meta-analysis. *Microbial Drug Resist*. 2018; **24**(7):980-986.
- 258) Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in *Pichia pastoris* and its functional analysis against antibiotic-resistant *Helicobacter pylori*. *Applied microbiology and biotechnology*. 2018;**102**(11):4817-27.
- 259) Сорокман ТВ, Сокольник СВ, Попелюк ОМ, Макарова ОВ, Швигар ЛВ. Ефективність різних схем ерадикаційної терапії в дітей, хворих на хелікобактер-асоційовану патологію верхніх відділів шлунково-кишкового тракту. *ScienceRise*. 2016; **2**(3 (19)):58-64.
- 260) Чумак, Ю. В., Лобань, Г. А., Фаустова, М. О., Ананьєва, М. М., & Войнаш, В. А. Мікробіологічні аспекти формування резистентності *H. Pylori* до антимікробних препаратів. Актуальні проблеми сучасної медицини: Вісник української медичної стоматологічної академії. 2019; 19(2 (66)).
- ЦИТИРАНА: 38А: Boyanova L, Markovska R, Yordanov D, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I. High prevalence of virulent *Helicobacter pylori* strains in symptomatic Bulgarian patients. *Diagn Microbiol Infect Dis*. 2009; **64**(4): 374-380. Цитирана от:**
- 261) Gutef EH. Prevalence of *Helicobacter pylori* infection with peptic ulcer diseases in Iraqi patients. *European Journal of Pharmaceutical and Medical Research*. 2016; **3**(4): 479-482.
- 262) Padra, M., Adamczyk, B., Flahou, B., (...), Karlsson, N.G., Lindén, S.K. *Helicobacter suis* infection alters glycosylation and decreases the pathogen growth inhibiting effect and binding avidity of gastric mucins. *Mucosal Immunology* 2019; 12(3): 784-794.
- 263) Yanovich, O., Doroshko, M., Titov, L. *Helicobacter pylori* genotypes among Belarus patients with gastroduodenal disorders and their association with clinical outcome. *Acta Microbiologica et Immunologica Hungarica*. 2019; 66(3):399-411.

- 264) Adrych K. Czy każdy chory z zakażeniem *Helicobacter pylori* powinien być leczony? Aktualne stanowisko. Gastroenterologia Kliniczna. Postępy i Standardy. 2018; 10(1): 23-31.
- 265) Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant *Helicobacter pylori* infection: current perspective in Iran. J Chemother. 2020; 32(6): 273-285.
- 266) Bari Z, Fakheri H, Taghvaei T, Yaghoobi M. A Comparison between 10-day and 12-day concomitant regimens for *Helicobacter pylori* eradication: A randomized clinical trial. Middle East Journal of Digestive Diseases. 2020; 12(2): 106.
- 267) Bertrant EB, Danny TNL, Serge FC, Agnes M, Roger AM, Roger KJ, Brigitte KML. Evolution of susceptibilities of *Helicobacter pylori* strains circulating in cameroon to usual antibiotics: a three-year study. International Journal of Gastroenterology. 2020; 4(2): 63.
- 268) Bolor-Erdene M, Namdag B, Yamaoka Y, Jav S. Antibiotic resistance of *Helicobacter pylori* in Mongolia. The Journal of Infection in Developing Countries. 2017;11(11):887-894.
- 269) Bui D, Brown HE, Harris RB, Oren E. Serologic evidence for fecal-oral transmission of *Helicobacter pylori*. Am J Trop Med Hyg. 2016; 94(1):82-88.
- 270) Castro Espinosa J. Aproximación metodológica al consumo ambulatorio de antibióticos. 2018; <https://repository.usc.edu.co/handle/20.500.12421/381>
- 271) Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin containing triple therapy and rifabutin with bismuth containing quadrupletherapy for third-line treatment of *Helicobacter pylori* infection: Two pilot studies. Helicobacter. 2016; 21(5):375-381.
- 272) Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of *Helicobacter pylori* infection: an in vitro and in vivo study. J Antimicrob Chemother. 2019; 74(4): 1069-1077.
- 273) Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of *Helicobacter pylori* infection: Two pilot studies. Helicobacter. 2019; 24(5): e12606.
- 274) Contreras M, Benejat L, Mujica H, Peña J, García-Amado MA, Michelangeli F, Lehours P. Real-time PCR detection of a 16S rRNA single mutation of *Helicobacter pylori* isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts. J Med Microbiol. 2019; 68(9): 1287-1291.
- 275) Da Hyun Jung JH, Jeong SJ, Park SY, Kang IM, Lee KH, Song YG. Peptide nucleic acid probe-based analysis as a new detection method for clarithromycin resistance in *Helicobacter pylori*. Gut and liver. 2018;12(6):641.
- 276) Di Giulio M, Di Campli E, Di Bartolomeo S, Cataldi V, Marzio L, Grossi L, Ciccaglione AF, Nostro A, Cellini L. In vitro antimicrobial susceptibility of *Helicobacter pylori* to nine antibiotics currently used in Central Italy. Scand J Gastroenterol. 2016; 51(3):263-269.
- 277) Diab M, El-Shenawy A, El-Ghannam M, Salem D, Abdelnasser M, Shaheen M, Abdel-Hady M, El-Sherbini E, Saber M. Detection of antimicrobial resistance genes of *Helicobacter pylori* strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients. Egyptian Journal of Medical Human Genetics. 2018;19(4):417-23.
- 278) Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, ... & Shehab-Eldeen SA. Molecular diagnosis of *Helicobacter pylori* antibiotic resistance in the Taif region, Saudi Arabia. Microbiology and immunology. 2019; 63(6): 199-205.
- 279) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020; 31(3): 221.
- 280) Fakheri H, Bakhshi Z, Bari Z, Alhoosei S. Effects of clarithromycin-containing quadruple therapy on *Helicobacter pylori* eradication after nitroimidazole-containing quadruple therapy failure. Middle East J Dig Dis. 2016; 8(1):51-56.
- 281) Fakheri H, Firoozi MS, Bari Z. Eradication of *Helicobacter pylori* in Iran: A Review. Middle East Journal of Digestive Diseases (MEJDD). 2018;10(1):5-17.
- 282) Fan C, Zhao C, Jiang H, (...), Zhao Y, Wang L. Analysis of antibiotic resistance of *Helicobacter pylori* isolates in Changchun area. 2019. Chinese Journal of Gastroenterology 2019; 24(3): 169-172.
- 283) Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, Das R. Low prevalence of clarithromycin-resistant *Helicobacter pylori* isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016; 6: 39-43.
- 284) Haddadi MH, Negahdari B, Asadolahi R, Bazargani A. *Helicobacter pylori* antibiotic resistance and correlation with cagA motifs and homB gene. Postgraduate medicine. 2020; 132(6) : 512-520.
- 285) Hou LX, Han BX, Li S, Hong YS, Gou XJ. Clinical study on the timing of emergency gastroscopy in liver cirrhotic patients with esophageal variceal bleeding. American Journal of Biomedical Research. 2018;6(1):11-9.
- 286) Jaka H, Rhee JA, Östlundh L, Smart L, Peck R, Mueller A, Kasang C, Mshana SE. The magnitude of antibiotic resistance to *Helicobacter pylori* in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC infectious diseases. 2018;18(1):193.
- 287) Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line *Helicobacter pylori* eradication therapy. The Korean Journal of Gastroenterology. 2019;73(1):26-34.
- 288) Kim SY, Chung JW. Best *Helicobacter pylori* eradication strategy in the era of antibiotic resistance. Antibiotics. 2020; 9(8): 436.
- 289) Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, ... & Heo JJ. Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line *Helicobacter pylori* eradication therapy. The Korean Journal of Gastroenterology. 2019; 73(1): 26-34.

- 290) Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK. Comparison of new and classical point mutations associated with clarithromycin resistance in *Helicobacter pylori* strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol. 2019; **68**(4): 566-573.
- 291) Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. The efficacy of moxifloxacin-containing triple therapy after hybrid therapy failure in *Helicobacter pylori* eradication. Korean J Gastroenterol. 2017;**70**(2):72-80.
- 292) Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. The efficacy of bismuth-containing quadruple therapy after moxifloxacin-based sequential therapy failure in *Helicobacter pylori* eradication. The Korean Journal of Gastroenterology. 2018;**71**(4):196-203.
- 293) Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of *Helicobacter pylori*: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016; **16**(1):79.
- 294) Lee JY, Park KS. Optimal first-line treatment for *Helicobacter pylori* infection: recent strategies. Gastroenterol Res Pract. 2016; **2016**: Article ID 9086581
- 295) Lee SM, Kim N, Kwon YH, Nam RH, Kim JM, Park JY, Lee YS, Lee DH. rdxA, frxA, and efflux pump in metronidazole-resistant *Helicobacter pylori*: Their relation to clinical outcomes. J Gastroenterol Hepatol. 2018;**33**(3):681-8.
- 296) Lee KH, Park SY, Jeong SJ, Jung DH, Kim JH, Jeong SH, ... & Song YG. Can aminoglycosides be used as a new treatment for *Helicobacter pylori*? In vitro Activity of Recently Isolated *Helicobacter pylori*. Infection & chemotherapy. 2019; 51(1): 10.
- 297) Mahant S, Sharma AK, Gehlot V, Mukhopadhyay AK, Chhawchharia A, Dutta S, ... & Das R. Geographically distinct North-East Indian *Helicobacter pylori* strains are highly sensitive to clarithromycin but are levofloxacin resistant. Indian journal of medical microbiology. 2019; 37(3), 337-344.
- 298) Miftahussurur M, Cruz M, Subsomwong P, Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-based triple therapy is still useful as an initial treatment for *Helicobacter pylori* infection in the Dominican Republic. The American Journal of Tropical Medicine and Hygiene. 2017; **96**(5):1050-1059.
- 299) Min S, Kim N, Kwon YH, Hee R, Kim JM, Youn J, Lee YS, Lee DH. RdxA, frxA and efflux pump in metronidazole-resistant *Helicobacter pylori*: their relation to clinical outcomes. J Gastroenterol Hepatol. 2017 Jul 27. doi: 10.1111/jgh.13906.
- 300) Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, ... & Barrientos L. Prevalence of infection and antibiotic susceptibility of *Helicobacter pylori*: An evaluation in public and private health systems of Southern Chile. Pathogens. 2019; 8(4) : 226.
- 301) Park JY, Kim JG. New *Helicobacter pylori* eradication therapies. The Korean Journal of Gastroenterology. 2018;**72**(5):237-44.
- 302) Shin JE, Park KS, Nam K. Chronic functional constipation. The Korean journal of gastroenterology= Taehan Sohwagi Hakhoe chi.2019; 73(2): 92-98.
- 303) Soni KK, Kondalkar A. Formulation and evaluation of cytoprotective gastroretentive floating tablets of clarithromycin. Int. J.
- 304) Swar SO, Alzubaidy Z. M. Detection of *Helicobacter pylori* in leafy vegetables by pcr and determination of the antibacterial activity of green tea and garlic extracts against isolated bacteria. Plant Archives. 2020; 20(2): 7373-7381
- 305) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. Aliment Pharmacol Ther. 2016; **43**(4):514-533.
- 306) Vilaichone RK, Ratanachu-Ek T, Gamnarai P, Chaithongrat S, Uchida T, Yamaoka Y, Mahachai V. Extremely high prevalence of metronidazole-resistant *Helicobacter pylori* strains inmountain people (Karen and Hmong) in Thailand. Am J Trop Med Hyg. 2016; **94**(4):717-720.
- 307) Wani FA, Bashir G, Khan MA, Zargar SA, Rasool Z, Qadri Q. Antibiotic resistance in *Helicobacter pylori*: a mutational analysis from a tertiary care hospital in Kashmir, India. Indian journal of medical microbiology. 2018;**36**(2):265.
- 308) Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for *Helicobacter pylori* infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020; 25(3): e12685.

**ЦИТИРАНА: 40A: Boyanova L, Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spasova Z, Mitov I. Two-decade trends in primary *H. pylori* resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010; **67**: 319-326.**

**Цитирана от:**

- 309) Baltas N, Karaoglu SA, Tarakci C, Kolayli S. Effect of propolis in gastric disorders:inhibition studies on the growth of *Helicobacter pylori* and production of itsurease. J Enzyme Inhib Med Chem. 2016; **27**:1-5.
- 310) Egli, K., Wagner, K., Keller, P. M., Risch, L., Risch, M., & Bodmer, T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in *Helicobacter pylori*. Frontiers in cellular and infection microbiology. 2020; 10.
- 311) Gunnarsdottir AI, Gudjonsson H, Hardardottir H, Jonsdottir KD, Bjornsson ES. Antibiotic susceptibility of *Helicobacter pylori* in Iceland. Infectious Diseases. 2017; **49**(9):1-8.
- 312) Hu J, Chen L, Yang W, Li B, Sun H, Wei S, He Y, Zhao Z, Yang S, Zou Q, Chen W, Guo H, Wu C. Systematic identification of immunodominant CD4<sup>+</sup> T cell responses to HpaA in *Helicobacter pylori* infected individuals Oncotarget. 2016; **7** (34): 54380-54391.
- 313) Mori, H., Suzuki, H., Matsuzaki, J., Masaoka, T., & Kanai, T. 10-Year trends in *Helicobacter pylori* eradication rates by Sitafloxacin-based third-line rescue therapy. Digestion. 2020; 101(5), 644-650.
- 314) Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in *Helicobacter pylori* diagnostics in the era of next generation sequencing. World J Gastroenterol. 2019; **25**(32), 4629.

- 315) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. *Gastroenterology*. 2018;**155**(5):1372-82.
- 316) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther*. 2016; **43**(4):514-533.
- ЦИТИРАНА: 41А: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Association of *iceA* and *babA* genotypes in *Helicobacter pylori* strains with patient and strain characteristics. *Antonie Van Leeuwenhoek*. 2010; **98** (3):343-350. Цитирана от:**
- 317) Ansari S, Yamaoka Y. *Helicobacter pylori* BabA in adaptation for gastric colonization. *World J Gastroenterol*. 2017;**23**(23):4158-4169.
- 318) Bartpho, T. S., Wattanawongdon, W., Tongtawee, T., Paoi, C., Kangwantas, K., & Dechsukhum, C. Precancerous Gastric Lesions with *Helicobacter pylori* vacA+/babA2+/oipA+ Genotype Increase the Risk of Gastric Cancer. *BioMed research international*, 2020; 2020.
- 319) Cervantes-García, E. *Helicobacter pylori*: mecanismos de patogenicidad. *Revista Mexicana de Patología Clínica y Medicina de Laboratorio*. 2016; **63**(2), 100-109.
- 320) Chen Q, Belmonte I, Buti M, Nieto L, Garcia-Cehic D, Gregori J, Perales C, Ordeig L, Llorens M, Soria ME, Esteban R. New real-time-PCR method to identify single point mutations in hepatitis C virus. *World J Gastroenterol*. 2016; **22**(43): 9604–9612.
- 321) Chen YL, Mo XQ, Huang GR, Huang YQ, Xiao J, Zhao LJ, Wei HY, Liang Q. Gene polymorphisms of pathogenic *Helicobacter pylori* inpatients with different types of gastrointestinal diseases. *World J Gastroenterol*. 2016; **22**(44):9718-9726.
- 322) Dabiri H, Jafari F, Baghaei K, Shokrzadeh L, Abdi S, Pourhoseingholi MA, Mohammadzadeh A. Prevalence of *Helicobacter pylori* vacA, cagA, cagE, oipA, iceA, babA2 and babB genotypes in Iranian dyspeptic patients. *Microb Pathog*. 2017;**105**:226-230.
- 323) El-Shenawy A, Diab M, Shemis M, El-Ghannam M, Salem D, Abdelnasser M, Shahin M, Abdel-Hady M, El-Sherbini E, Saber M. Detection of *Helicobacter pylori* vacA, cagA and iceA1 virulence genes associated with gastric diseases in Egyptian patients. *Egyptian Journal of Medical Human Genetics*. 2017;**18**(4):365-371.
- 324) Imkamp, F., Lauener, F. N., Pohl, D., Lehours, P., Vale, F. F., Jehanne, Q., ... & Wagner, K. Rapid characterization of virulence determinants in *Helicobacter pylori* isolated from non-atrophic gastritis patients by next-generation sequencing. *Journal of clinical medicine*. 2019; **8**(7), 1030.
- 325) Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of *H. pylori* in Turkey: a systematic review. *Helicobacter*. 2016;**21**(4):251-260.
- 326) Korona-Glowniak, I., Cichoz-Lach, H., Siwiec, R., Andrzejczuk, S., Glowniak, A., Matras, P., & Malm, A. Antibiotic resistance and genotypes of *Helicobacter pylori* Strains in Patients with Gastroduodenal disease in Southeast Poland. *Journal of clinical medicine*. 2019; **8**(7), 1071.
- 327) Neumoina, N. V., Efimov, E. I., Perfilova, K. M., Shutova, I. V., Neumoina, M. V., Troshina, T. A., ... & Semaka, M. A. Genetic variants of *H. pylori* in different forms of chronic gastritis. *Opera Medica et Physiologica*, 2020; **7**(3).
- 328) Sohrabi M, Khashei R, Alizadeh M, Asl MK, Nejati MA, Dara M, Bazargani A. Low Rate of babA2 genotype among Iranian *Helicobacter pylori* clinical isolates. *Journal of clinical and diagnostic research: JCDR*. 2017;**11**(7):DC32.
- 329) Šterbenc A, Jarc E, Poljak M, Homan M. *Helicobacter pylori* virulence genes. *World J Gastroenterol*. 2019; **25**(33), 4870.
- 330) Šterbenc A, Lunar MM, Homan M, Luzar B, Zidar N, Poljak M. Prevalence of the *Helicobacter pylori* babA2 gene in children mainly depends on the PCR primer set used. *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2020; 2020.
- 331) Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C. Role of NLRP3 inflammasome in inflammatory bowel diseases. *World J Gastroenterol*. 2019; **25**(33): 4796.
- 332) Zhang SH, Xie Y, Li BM, Liu DS, Wan SH, Luo LJ, ... & Zhu X. Prevalence of *Helicobacter pylori* cagA, vacA, and iceA genotypes in children with gastroduodenal diseases. *Zhongguo dang dai er ke za zhi= Chinese journal of contemporary pediatrics*. 2016; **18**(7), 618-624.
- ЦИТИРАНА: 41Б: Zhelezova, G., L. Boyanova. Stool antigen test for diagnosis of *Helicobacter pylori* infection. *Probl Infec Parasit Dis* 2006; **34** (2): 16-18. Цитирана от:**
- 333) Best, L.M.J., Takwoingi, Y., Siddique, S., (...), Yaghoobi, M., Gurusamy, K.S. Non-invasive diagnostic tests for *Helicobacter pylori* infection. *Cochrane Database of Systematic Reviews*. 2018(3),CD012080
- 334) Gurusamy, K. S., Yaghoobi, M., & Davidson, B. R. Non-invasive diagnostic tests for *Helicobacter pylori* infection. *Cochrane Database of Systematic Reviews*. 2016; (2).
- ЦИТИРАНА: 42А: Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I. Trends in antibiotic resistance in *Prevotella* species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. *Anaerobe*. 2010; **16**(5): 489-492. Цитирана от:**
- 335) Alauzet C, Lozniewski A, Marchandin H. Metronidazole resistance and nim genes in anaerobes: a review. *Anaerobe*. 2019; **55**:40-53.
- 336) Bostwick DG, Woody J, Hunt C, Budd W. Antimicrobial resistance genes and modelling of treatment failure in bacterial vaginosis: Clinical study of 289 symptomatic women. *J. Med. Microbiol*. 2016; **65**(5): 377-286.
- 337) Carey DE, Zitomer DH, Hristova KR, Kappell AD, McNamara PJ. Triclocarban influences antibiotic resistance and alters anaerobic digester microbial community structure. *Environ Sci Technol*. 2016; **50**(1):126-134.
- 338) Engberg, J., Larsen, T., & Edlund, C. Antibiotikabehandling och dess konsekvenser. *Tandläkartidningen* 2019, **4**.
- 339) Heim N, Faron A, Wiedemeyer V, Reich R, Martini M. Microbiology and antibiotic sensitivity of head and neck space infections of odontogenic origin. Differences in inpatient and outpatient management. *Journal of Cranio-Maxillo-Facial Surgery*. 2017;**45**(10):1731-1735. <http://www.shjyxx.com/EN/10.3969/j.issn.1673-8640.2015.09.021#>

- 340) Katoumas, K., Anterriotis, D., Fyrgiola, M., (...), Triantafylou, D., Dimopoulos, I. Epidemiological analysis of management of severe odontogenic infections before referral to the emergency department. *Journal of Cranio-Maxillofacial Surgery*. 2019; 47(8): 1292-1299.
- 341) Liang, Z., Zhang, Y., He, T., (...), Li, G., An, T. The formation mechanism of antibiotic-resistance genes associated with bacterial communities during biological decomposition of household garbage. *Journal of Hazardous Materials*. 2020; 398,122973.
- 342) Lloreda Rey, L. P. Efecto antibacteriano de una nanoemulsión de ftalocianina de aluminio clorada sobre periodontopatógenos relevantes en el paciente diabético tipo 2: Estudio in vitro. 2019
- 343) Samantaray, S., Biswas, R., & Sasidharan, G. M. Intracranial abscess due to *Prevotella bivia*: First case report from India. *Anaerobe*. 2020; 65, 102249.
- 344) Stojković, D., Kostić, M., Smiljković, M., Aleksić, M., Vasiljević, P., Nikolić, M., & Soković, M.. Linking antimicrobial potential of natural products derived from aquatic organisms and microbes involved in Alzheimer's disease-a review. *Current medicinal chemistry*. 2020; 27(26), 4372-4391.
- 345) Tent, P. A., Juncar, R. I., Onisor, F., Bran, S., Harangus, A., & Juncar, M. The pathogenic microbial flora and its antibiotic susceptibility pattern in odontogenic infections. *Drug metabolism reviews*. 2019; 51(3), 340-355.
- 346) Toprak NU, Veloo AC, Urban E, Wybo I, Justesen US, Jean-Pierre H, Morris T, Akgul O, Kulekci G, Soyletir G, Nagy E. A multicenter survey of antimicrobial susceptibility of *Prevotella* species as determined by Etest methodology. *Anaerobe*. 2018;**52**:9-15.
- 347) Toprak, N. U., Akgul, O., Söki, J., Soyletir, G., Nagy, E., Leitner, E., ... & Morris, T. Detection of beta-lactamase production in clinical *Prevotella* species by MALDI-TOF MS method. *Anaerobe*. 2020; 65, 102240.
- 348) Ülger Toprak, N. İstanbul'da İki Merkeze ait *Prevotella* Türlerinin Gradyent Test Yöntemiyle Belirlenen Antimikrobiyal İlaç Duyarlılığı. *Mikrobiyol Bul*, 2020; 54(2), 246-256.
- 349) Захарова ИН, Сугян НГ, Шаммас К, Антониадес А, Николау Э, Камилари Е, Титарев СИ, Сергеев АА, Мнафки НА. Влияние антибактериальной терапии на состояние желудочно-кишечного тракта у детей. *Медицинский совет*. 2017(19). <https://cyberleninka.ru/article/n/vliyanie-antibakterialnoy-terapii-na-sostoyanie-zheludочно-kishechnogo-trakta-u-detey>

**ЦИТИРАНА: 43А:** Medeiros JA, Gonçalves TM, **Boyanova L**, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of *Helicobacter pylori* eradication by triple therapy plus *Lactobacillus acidophilus* compared to triple therapy alone. *Eur J Clin Microbiol Infect Dis*. 2011; **30** (4):555-559. **Цитирана от:**

- 350) Ameen AM, Abdulridha MK, Najeeb AA. Comparative effectiveness of probiotics timing regimen in *Helicobacter pylori*-induced peptic ulcer disease patients. *Journal of Pharmaceutical Sciences and Research*. 2019;**11**(1):75-83.
- 351) Bagirova M, Allahverdiyev AM, Abamor ES, Aliyeva H, Unal G, Tanalp TD. An overview of challenges to eradication of *Helicobacter pylori* infection and future prospects. *Eur Rev Med Pharmacol Sci*. 2017; **21**(9):2199-2219.
- 352) Hwang YJ, Kim N, Yun CY, Kwon MG, Baek SM, Kwon YJ, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia: a long-term prospective clinical study. *The Korean Journal of Helicobacter and Upper Gastrointestinal Research*. 2018;**18**(3):186-97.
- 353) Lau CSM., Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of *Helicobacter pylori*: A meta-analysis. *Infection and Drug Resistance* 2016; **9**:275-289.
- 354) Lee C-Y, Shih H-C, Yu M-C, (...), Kuan Y-H, Lin C-C. Evaluation of the potential inhibitory activity of a combination of *L. acidophilus*, *L. rhamnosus* and *L. sporogenes* on *Helicobacter pylori*: A randomized double-blind placebo-controlled clinical trial. *Chinese Journal of Integrative Medicine*. 2017; **23**(3):176-182.
- 355) Lu C, Sang J, He H, Wan X, Lin Y, Li L, Li Y, Yu C. Probiotic supplementation does not improve eradication rate of *Helicobacter pylori* infection compared to placebo based on standard therapy: a meta-analysis. *Sci Rep*. 2016; **6**:23522.
- 356) Oh JH. *Helicobacter pylori* and Gastric Microbiota. *Korean J Helicobacter Up Gastrointest Res*. 2016; **16**(2):59-67.
- 357) Shahraki T, Shahraki M, Shahri ES, Mohammadi M. No significant impact of *Lactobacillus reuteri* on eradication of *Helicobacter pylori* in children (double-blind randomized clinical trial). *Iranian Red Crescent Medical Journal*. 2017; **19**(3) e42101.
- 358) Shi, X., Zhang, J., Mo, L., Shi, J., Qin, M., & Huang, X. Efficacy and safety of probiotics in eradicating *Helicobacter pylori*: A network meta-analysis. *Medicine*. 2019; 98(15).
- 359) Talebi Bezmin Abadi A. *Helicobacter pylori* treatment: New perspectives using current experience. *J Glob Antimicrob Resist*. 2017; **8**:123-130.
- 360) Vitali Čepo, D., Prusac, M., Velkovski Škopić, O., & Tatarević, A. Preporuke o primjeni probiotika u ljekarničkoj praksi. *Medicus*. 2020; 29(1 Hapatologija danas), 115-134.
- 361) Yu, M., Zhang, R., Ni, P., Chen, S., & Duan, G. Efficacy of *Lactobacillus*-supplemented triple therapy for *H. pylori* eradication: A meta-analysis of randomized controlled trials. *PloS one*. 2019; 14(10), e0223309.
- 362) Zhang, M., Zhang, C., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of *H. pylori* and incidence of therapy-associated side effects. *Microbial Pathogenesis*. 2020; 147, 104403.
- 363) Zhu XY, Liu F. Probiotics as an adjuvant treatment in *Helicobacter pylori* eradication therapy. *J Dig Dis*. 2017; **18**(4):195-202.
- 364) Плотникова, Е. Ю., & Захарова, Ю. Место пробиотиков в антихеликобактерной терапии. Эффективная фармакотерапия. 2020; 16(15), 40-47.

**ЦИТИРАНА: 44А:** **Boyanova L**, Yordanov D, Gergova G, Markovska R, Mitov I. Benefits of *Helicobacter pylori cagE* genotyping in addition to *cagA* genotyping. A Bulgarian study. *Antonie Van Leeuwenhoek*. 2011; **100**(4):529-35.DOI: 10.1007/s10482-011-9608-8. **Цитирана от:**



- 365) Brkić DV, Katičić M, Bedenić B, Stanko AP, Plečko V. Detection of virulence gene belonging to *cag* pathogenicity island in *Helicobacter pylori* isolates after multiple unsuccessful eradication therapy in Northwest Croatia. *Periodicum Biologorum*. 2016; **118** (1):45-52.
- 366) Peña J, Rojas H, Reyes N, Fernández-Delgado M, García-Amado MA, Michelangeli F, Contreras M. Multiple *cag* genotypes of *Helicobacter pylori* isolates colonize the oesophagus in individual hosts in a Venezuelan population. *J Med Microbiol*. 2017; **66**(2):226-235.
- ЦИТИРАНА: 45А: Boyanova L.** Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. *Future Microbiol*. 2011; **6** (8): 843-846. **Цитирана от:**
- 367) Afsar MNA, Jhinu ZN, Bhuiyan MAI, Islam Z, Siddiqua TJ. *Helicobacter pylori* infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis. *BMJ open gastroenterology*. 2020; **7**(1): e000490.
- 368) Asi DH, Farivar TN, Rahmani B, Hajmanoochehri F, Razavi ANE, Jahanbin B, Dodaran MS, Peymani A.. The role of transferrin receptor in the *Helicobacter pylori* pathogenesis; L-ferritin as a novel marker for intestinal metaplasia. *Microbial pathogenesis*. 2019; 126:157-164.
- 369) Campuzano-Maya, G. La anemia como manifestación de la infección por *Helicobacter pylori*. *Medicina & Laboratorio*, 2020; 20(03-04), 111-134.
- 370) Hamed Asl, D., Naserpour Farivar, T., Rahmani, B., (...), Soleimani Dodaran, M., Peymani, A. The role of transferrin receptor in the *Helicobacter pylori* pathogenesis; L-ferritin as a novel marker for intestinal metaplasia. *Microbial Pathogenesis* 2019; 126:157-164.
- 371) Hartl, K., & Sigal, M. Microbe-driven genotoxicity in gastrointestinal carcinogenesis. *International journal of molecular sciences*. 2020; 21(20), 7439.
- 372) Jee, S. R. *Helicobacter pylori* and Hematologic Diseases. *The Korean Journal of Helicobacter and Upper Gastrointestinal Research*. 2020; 20(1), 11-20.
- 373) Kaminski ZJ, Relich I, Konieczna I, Kaca W, Kolesinska B. Cross-Reactivity of polyclonal antibodies against *Canavalia ensiformis* (Jack Bean) urease and *Helicobacter pylori* urease subunit A fragments. *Chemistry & biodiversity*. 2018; **15**(1):e1700444.
- 374) Kell DB, Pretorius E. No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. *Biological Reviews*. 2018;**93**(3):1518-57.
- 375) Tsay FW, Hsu PI. *H. pylori* infection and extra-gastrointestinal diseases. *Journal of biomedical science*. 2018;**25**(1):65.
- 376) Ulasoglu C, Temiz HE, Sağlam ZA. The Relation of Cytotoxin-Associated Gene-A Seropositivity with Vitamin B12 Deficiency in *Helicobacter pylori*-Positive Patients. *BioMed research international*. 2019, 2019.
- 377) Voropaev EV. Molecular and genetic factors for realization of the pathogenic potential of *helicobacter pylori*: personified techniques for assessment of manifestations, laboratory diagnosis and prognosis. *Проблемы здоровья и экологии*. 2018; 55(1): 16-20.
- 378) Ворopaев ЕВ. Молекулярно-генетические факторы реализации патогенного потенциала *Helicobacter pylori*: персонифицированные технологии оценки проявлений, лабораторной диагностики и прогноза. *Проблемы здоровья и экологии*. 2018(1 (55)).
- 379) Ворopaев ЕВ, Осипкина ОВ, Баранов ОЮ, Зятьков АА, Бонда НА, Платошкин ЭН, Ворopaева АВ, Беляковский ВН, Ачинович СЛ, Шафорост АС, Зайцева ВИ. Анализ канцерогенного потенциала *Helicobacter pylori* на основании определения степени фосфорилирования CagA-белка бактерии. *Проблемы здоровья и экологии*. 2018(4 (58)).
- ЦИТИРАНА: 46А: Markovska R, Boyanova L, Yordanov D, Gergova G, Mitov I.** *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. *Diagn Microbiol Infect Dis*. 2011; **71**(4):335-340. **Цитирана от:**
- 380) Al-Maleki AR, Loke MF, Lui SY, Ramli NS, Khosravi Y, Ng CG, Venkatraman G, Goh KL, Ho B, Vadivelu J. *Helicobacter pylori* Outer Inflammatory Protein A (OipA) suppresses apoptosis of AGS gastric cells in vitro. *Cellular microbiology*. 2017 Dec 1.
- 381) Al-Essa SHF, Al-Ghazawi GJ, Wahab ADA. A comparative study of diagnosis methods of *Helicobacter pylori* in patients with gastroenteritis in Basrah province. *Biochem. Cell. Arch*. 2020; **20**(1):957-962.
- 382) Braga LL, Batista MH, de Azevedo OG, da Silva Costa KC, Gomes AD, Rocha GA, Queiroz DM. oip A “on” status of *Helicobacter pylori* is associated with gastric cancer in North-Eastern Brazil. *BMC cancer*. 2019;**19**(1):48.
- 383) El Khadir M, Alaoui Boukhris S, Benajah DA, El Rhazi K, Ibrahimi SA, El Abkari M, Harmouch T, Nejari C, Mahmoud M, Benlemlih M, Bennani B. VacA and CagA status as biomarker of two opposite end outcomes of *Helicobacter pylori* infection (gastric cancer and duodenal ulcer) in a Moroccan population. *PLoS One*. 2017; 12(1):e0170616.
- 384) El-Sayed, M. S., Musa, N., Eltabbakh, M., Abdelhamid, D. H., Mostafa, S. M. I., Salah, M. M., ... & Hassan, R. A. Detection of *Helicobacter pylori oipA* and *dupA* genes among dyspeptic patients with chronic gastritis. *Alexandria Journal of Medicine*. 2020; 56(1), 105-110.
- 385) El-Shenawy A, Diab M, Shemis M, El-Ghannam M, Salem D, Abdelnasser M, Shahin M, Abdel-Hady M, El-Sherbini E, Saber M. Detection of *Helicobacter pylori vacA*, *cagA* and *iceA1* virulence genes associated with gastric diseases in Egyptian patients. *Egyptian Journal of Medical Human Genetics*. 2017; **18**(4):365-371.
- 386) Farzi N, Yadegar A, Aghdaei HA, Yamaoka Y, Zali MR. Genetic diversity and functional analysis of *oipA* gene in association with other virulence factors among *Helicobacter pylori* isolates from Iranian patients with different gastric diseases. *Infection, Genetics and Evolution*. 2018;**60**:26-34.
- 387) Liu X, He B, Cho WC, Pan Y, Chen J, Ying H, Wang F, Lin K, Peng H, Wang S. A systematic review on the association between the *Helicobacter pylori vacA* i genotype and gastric disease. *FEBS Openbio*. 2016; **6**(5):409-417.
- 388) Mostafa Abd El-Hamid, M., Ahmed, A. E. A., & Zakaria Abu Amer, M. A novel three drug regimen (moxifloxacin–omeprazole–nitazoxanide) in comparison to traditional triple therapy for treatment and eradication of naïve and resistant *H. pylori* infection in dyspeptic patients. *Al-Azhar Medical Journal*. 2020; 49(3), 1163-1172.

- 389) Matsuo Y, Kido Y, Yamaoka Y. *Helicobacter pylori* outer membrane protein-related pathogenesis. Toxins (Basel). 2017; **9**(3):101.
- 390) Ranjbar R, Khamesipour F, Jonaidi-Jafari N, Rahimi E. *Helicobacter pylori* in bottled mineral water: genotyping and antimicrobial resistance properties. BMC Microbiol. 2016; **16**:40.
- 391) Sohrabi M, Khashei R, Alizadeh M, Asl MK, Nejati MA, Dara M, Bazargani A. Low Rate of *babA2* genotype among Iranian *Helicobacter pylori* clinical isolates. J Clin Diagn Res. 2017;**11**(7):DC32-DC36.
- 392) Šterbenc A, Jarc E, Poljak M, Homan M. *Helicobacter pylori* virulence genes. World J Gastroenterol. 2019; **25**(33): 4870.
- 393) Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C. Role of NLRP3 inflammasome in inflammatory bowel diseases. World J Gastroenterol. 2019; **25**(33): 4796.
- 394) Whitmire JM, Merrell DS. *Helicobacter pylori* genetic polymorphisms in gastric disease development. *Helicobacter pylori* in Human Diseases. 2019: 173-194.

**ЦИТИРАНА: 47A: Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012; 10(4):407-409. Цитирана от:**

- 395) Ameen AM, Abdulridha MK, Najeeb AA. Comparative effectiveness of probiotics timing regimen in *helicobacter pylori*-induced peptic ulcer disease patients. Journal of Pharmaceutical Sciences and Research. 2019;**11**(1):75-83.
- 396) Bendini S. Can you take probiotics and antibiotics at the same time? Probiotics Gazette. 2018: <https://www.probioticsgazette.com/can-take-probiotics-antibiotics-time/>
- 397) Fleet M, Rahman PK. Probiotics and their health benefits. Microbial Functional Foods and Nutraceuticals. 2017; 267-279.
- 398) Guridi CB, Serena AR, Cabrera SG, Fernández IA, Hernández CR, Vivanco BM, ... & Nieto-Magro C. Clinical evaluation of the synbiotic Prodefen Plus® in the prevention of the antibiotic-associated diarrhoea in subjects requiring antibiotic treatment. Beneficial Microbes. 2020; **11**(6), 535-545.
- 399) Hanson L, VandeVusse L, Jermé M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: asystematic review. J Midwifery Womens Health. 2016;**61**(3):339-355.
- 400) Javaloyas M. Infecció per *Clostridium difficile*. Circular Farmaceutica. 2012; **70**(3):30-34.
- 401) Jimeno, M. E. Microbiota, probióticos, prebióticos y simbióticos en pediatría. Boletín de la Sociedad de Pediatría de Aragón, La Rioja y Soria. 2016; 46(3), 77-83.
- 402) Ju, A., Duan, A., Zhang, Y., Qin, Y., Xue, L., Ma, X., ... & Yang, S. Effects Of Orally Administered Recombinant Lactobacillus Casei Expressing HN Protein On Early Growth Performance, Intestinal Health And Protection Against NDV Challenge In Chickens. 2020.
- 403) Lendrum JE, Seebach B, Klein B, Liu S. Sleep and the gut microbiome: antibiotic-induced depletion of the gut microbiota reduces nocturnal sleep in mice. bioRxiv. 2017:199075.
- 404) Osita EC, Philip BD, Harrison GT, Sylvester NC, Okechukwu EC. Effects of *Lactobacillus* spp. isolated from the sap of palm tree *Elaeis guineensis* (palm wine) on cellular and innate immunity. African Journal of Microbiology Research. 2019;**13**(2):33-9.
- 405) Pts, W. P., Codes, W. P., Points, M., & Voucher, B. M. D. Home/Articles/Gastroenterology/Restoring Gut Health with Hexbio® In the Course of Antibiotics. Urology, 2019.
- 406) Rowles HL. How are probiotics affected by antibiotics. Ann Clin Lab Res. 2017;**5**(2):163.
- 407) Rowles HL. Increasing antibiotic therapy compliance through concurrent probiotic consumption. International Journal of Probiotics & Prebiotics. 2017;**12**(2):83-88.
- 408) Rowles, H. L. Probiotics Slow the Growth of Pathogenic Bacteria. International Journal of Probiotics & Prebiotics. 2019; 14, 28-32.
- 409) Shi, X., Zhang, J., Mo, L., Shi, J., Qin, M., & Huang, X. Efficacy and safety of probiotics in eradicating *Helicobacter pylori*: A network meta-analysis. Medicine. 2019; 98(15).
- 410) Zhang W, Guo H, Cao C, Li L, Kwok LY, Zhang H, Sun Z. Adaptation of *Lactobacillus casei* zhang to gentamycin involves an alkaline shock protein. Front Microbiol. 2017;**8**:2316.

**ЦИТИРАНА: 48A: Boyanova L, Ilieva J, Gergova G, Davidkov L, Spasova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012; 61(Pt 1):85-93. Цитирана от:**

- 411) Bayati, S., Amirmozafari, N., Alebouyeh, M., Farzi, N., Ebrahimi Daryani, N., & Zali, M. R. Antibiotic resistance among *Helicobacter pylori* strains isolated from patients with histopathological changes of the gastric tissue towards metronidazole, clarithromycin, and ciprofloxacin. Archives of Clinical Infectious Diseases. 2019; 14(1).
- 412) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020; **31**(3): 221-233.
- 413) Krzyżek P, Pawełka D, Iwańczak B, Kempński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościński G. High primary antibiotic resistance of *Helicobacter pylori* strains isolated from pediatric and adult patients in Poland during 2016-2018. Antibiotics (Basel). 2020;**9**(5):228.
- 414) Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, ... & Seto WK. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line *Helicobacter pylori* therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother. 2020; **75**(11), 3391-3394.
- 415) Maysaa El Sayed Zaki, Walaa Othman, Mahmoud Abdelwahab Ali, Ahmed Shehta. Fluoroquinolone-resistant *Helicobacter pylori* strains isolated from one Egyptian University Hospital: Molecular Aspects. Journal of Microbiology and Antimicrobial Agents. 2016; **2**(1). <http://jmaa.co.uk/ojs-2.4.7-1/index.php/JMAA/article/view/41>
- 416) Morilla, A. M., Álvarez-Argüelles, M. E., Duque, J. M., Armesto, E., Villar, H., & Melón, S. Primary antimicrobial resistance rates and prevalence of *Helicobacter pylori* infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología (English Edition). 2019; 42(8), 476-485.

- 417) Paul B, Adimoolam S, Qureshi Mj, Ismail Ne. A review of *Helicobacter pylori* infection diseases, antibiotic resistance and diagnosis. Asian J Pharm Clin Res. 2018;**11**(12):566-71.
- 418) Wang, D., Guo, Q., Yuan, Y., & Gong, Y. The antibiotic resistance of *Helicobacter pylori* to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC microbiology. 2019; 19(1), 1-10.
- 419) Williams, K., Colquhoun, A., Munday, R., & Goodman, K. J. Antibiotic dispensation rates among participants in community-driven health research projects in Arctic Canada. BMC public health. 2019; 19(1), 1-8.
- 420) Zaki MES, Othman W, Ali Ma, Shehta A. Fluoroquinolone-resistant *Helicobacter pylori* strains isolated from one Egyptian university hospital: molecular aspects. Journal of Microbiology and Antimicrobial Agents. 2016;**2**(1). <http://jmaa.co.uk/ojs-2.4.7-1/index.php/JMAA/article/view/41>
- 421) Андреев ДН, Маев ИВ, Кучерявый ЮА. Оценка влияния сопутствующих анамнестических и клинических факторов на эффективность и безопасность антихеликобактерной терапии. Архивъ внутренней медицины. 2016; **1**(27): <http://cyberleninka.ru/article/n/otsenka-vliyaniya-soputstvuyuschih-anamnesticheskikh-i-klinicheskikh-faktorov-na-effektivnost-i-bezopasnost-antihelikobakternoy>
- 422) Маев ИВ, Андреев ДН. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;**89**(8):5-12.
- 423) Шульгина, Е. М.; Караулова, Л. В.; Симонова, Ж. Г. Оценка вероятности инфицированности *Helicobacter pylori* у больных с гастродуоденальной патологией в зависимости от факторов риска с использованием модели логит-регрессии. Вятский медицинский вестник, 2019, 3 (63).

**ЦИТИРАНА: 50А: Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of *Helicobacter pylori vacA* intermediate region genotyping—a Bulgarian study, Diagn Microbiol Infect Dis 2012; **74**(3):253-257. Цитирана от:**

- 424) Aftab H, Miftahussurur M, Subsomwong P, Ahmed F, Khan AA, Matsumoto T, Suzuki R, Yamaoka Y. Two populations of less-virulent *Helicobacter pylori* genotypes in Bangladesh. PloS one. 2017;**12**(8):e0182947.
- 425) Alderete, A. D., Caballero, R. L., Sarmiento, O. F., Márquez, R. F., Bernal, M. E. F., & Cordero, M. A. Correlation between the presence of pathogenicity factors of *Helicobacter pylori* and digestive diseases in patients with digestive symptoms. 2012-2016. Panorama Cuba y Salud. 2018; 13(2), 40-47.
- 426) Bakhti, S. Z., Latifi-Navid, S., & Zahri, S. Unique constellations of five polymorphic sites of *Helicobacter pylori vacA* and *cagA* status associated with risk of gastric cancer. Infection, Genetics and Evolution. 2020; 79, 104167.
- 427) El Khadir M, Alaoui Boukhris S, Benajah DA, El Rhazi K, Ibrahimi SA, El Abkari M, Harmouch T, Nejari C, Mahmoud M, Benlemlih M, Bennani B. VacA and CagA status as biomarker of two opposite end outcomes of *Helicobacter pylori* infection (gastric cancer and duodenal ulcer) in a Moroccan population. PLoS One. 2017; **12**(1):e0170616.
- 428) Keikha M, Ali-Hassanzadeh M, Karbalaeei M. Association of *Helicobacter pylori vacA* genotypes and peptic ulcer in Iranian population: a systematic review and meta-analysis. BMC gastroenterology. 2020; **20**(1): 1-11.
- 429) Liu X, He B, Cho WC, Pan Y, Chen J, Ying H, Wang F, Lin K, Peng H, Wang S. A systematic review on the association between the *Helicobacter pylori vacA* i genotype and gastric disease. FEBS Openbio. 2016; **6**(5):409–417.
- 430) Miernyk KM, Bruden D, Rudolph KM, Hurlburt DA, Sacco F, McMahon BJ, Bruce MG. Presence of *cagPAI* genes and characterization of *vacA* s, i and m regions in *Helicobacter pylori* isolated from Alaskans and their association with clinical pathologies. J Med Microbiol. 2020; **69**(2): 218-227.
- 431) Miftahussurur, M., Yamaoka, Y., & Graham, D. Y. *Helicobacter pylori* as an oncogenic pathogen, revisited. Expert reviews in molecular medicine. 2017; 19, e4.
- 432) Paredes-Osses E, Sáez K, Sanhueza E, Hebel S, González C, Briceño C, Cancino AG. Association between *cagA*, *vacAi*, and *dupA* genes of *Helicobacter pylori* and gastroduodenal pathologies in Chilean patients. Folia Microbiol (Praha). 2017; **62**(5):437-444.
- 433) Trang T, Thanh Binh T, Yamaoka Y. Relationship between *vacA* types and development of gastroduodenal diseases. Toxins (Basel). 2016; **8**(6). pii: E182. doi:10.3390/toxins8060182
- 434) Whitmire JM, Merrell DS. *Helicobacter pylori* genetic polymorphisms in gastric disease development. *Helicobacter pylori* in Human Diseases. 2019;173-194.

**ЦИТИРАНА: 51А: Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients. Rising concerns. Expert Rev. Anti Infect. Ther. 2013; **11** (4): 411-420. Цитирана от:**

- 435) Arenas I, Ibarra MA, Santana FL, Villegas E, Hancock RE, Corzo G. In vitro and in vivo antibiotic capacity of two host defense peptides. Antimicrob Agents Chemother. 2020; **64**(7).
- 436) Bhandari K, Zamora JA. *Actinomyces naeslundii* bacteremia in an elderly woman with type 2 diabetes mellitus. Infectious Diseases in Clinical Practice. 2017;**25**(6):e23.
- 437) Critchley JA, Restrepo BI, Ronacher K, Kapur A, Bremer AA, Schlesinger LS, Basaraba R, Kornfeld H, van Crevel R. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: Part 1: Epidemiology and clinical management. Chest. 2017; **152**(1):165-173.
- 438) De A, Pasquantonio G, Cerroni L, Petrelli D, Lauro D, Longhi M, Vitali LA. Genotypic and phenotypic heterogeneity in *Streptococcus mutans* isolates from diabetic patients in Rome, Italy. Springerplus. 2016; **5**(1):1794.
- 439) Fejfarová V, Jirkovská A, Dubský M, Game F, Vydláková J, Sekerková A, Franeková J, Kučerová M, Stríž I, Petkov V, Bém R, Wosková V, Němcová A, Skibová J. An alteration of lymphocytes subpopulations and immunoglobulins levels in patients with diabetic foot ulcers infected particularly by resistant pathogens. J Diabetes Res. 2016; **2016**:2356870.
- 440) Grint D, Alisjhabana B, Ugarte-Gil C, Riza AL, Walzl G, Pearson F, Ruslami R, Moore DA, Ioana M, McAllister S, Ronacher K. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bulletin of the World Health Organization. 2018;**96**(11):738.
- 441) Hadi SA. An update on antibiotic resistance and DFUs. Podiatry today. 2016; **29**(3): <http://www.podiatrytoday.com/update-antibiotic-resistance-and-dfus>

- 442) Haghighi, M., Kariman, H., & Sistanizad, M. Evaluating Association between Glycosylated Hemoglobin and the Spectrum and Antibiotic Resistance of Uropathogens: A Cross Sectional Study. *Journal of Pharmaceutical Care*. 2019; 67-71.
  - 443) He, K., Hemmila, M. R., Cain-Nielsen, A. H., Machado-Aranda, D. A., Frydrych, L. M., & Delano, M. J. Complications and resource utilization in trauma patients with diabetes. *PloS one*. 2019; 14(8), e0221414.
  - 444) Heimbuck, A. M., Priddy-Arrington, T. R., Padgett, M. L., Llamas, C. B., Barnett, H. H., Bunnell, B. A., & Caldorera-Moore, M. E. Development of responsive chitosan–Genipin hydrogels for the treatment of wounds. *ACS Applied Bio Materials*, 2019; 2(7), 2879-2888.
  - 445) Korbel L, Easterling RS, Punja N, Spencer JD. The burden of common infections in children and adolescents with diabetes mellitus: A Pediatric Health Information System study. *Pediatric diabetes*. 2018;**19**(3):512-9.
  - 446) Kurup, R., & Ansari, A. A. A study to identify bacteriological profile and other risk factors among diabetic and non-diabetic foot ulcer patients in a Guyanese hospital setting. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019;; 13(3), 1871-1876.
  - 447) Lipsky BA, Aragón-Sánchez J, Diggle M, Embil J, Kono S, Lavery L, Senneville É, Urbančič-Rovan V, Van Asten S; International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. *Diabetes Metab Res Rev*. 2016; **32 Suppl 1**:45-74.
  - 448) Lubis VA, Katar Y, Bahar E. Identifikasi bakteri infeksi saluran pernafasan bawah non tuberkulosis (Non TB) dan pola resistensinya pada penderita diabetes melitus di RSUP M. Djamil. *Jurnal Kesehatan Andalas*. 2016; **5**(3):692-696.
  - 449) Mahbub, S., Akter, S., Akter, P., Hoque, M. A., Rub, M. A., Kumar, D., ... & Džudžević-Čančar, H. Effects of temperature and polyols on the ciprofloxacin hydrochloride-mediated micellization of sodium dodecyl sulfate. *RSC Advances*. 2020; 10(25), 14531-14541.
  - 450) Markakis K, Faris AR, Sharaf H, Faris B, Rees S, Bowling FL. Local Antibiotic Delivery Systems: Current and Future Applications for Diabetic Foot Infections. *The International Journal of Lower Extremity Wounds*. 2018;**17**(1):14-21.
  - 451) Martins IJ. Antibiotic resistance involves antimicrobial inactivation in global communities. *SAJ Pharma Pharmacol*. 2017;**2**:102.
  - 452) Martins IJ. Diabetes and Clinical Studies. *J Diab Clin Stud*. 2018; **2**(1):1-3.
  - 453) Navarro-Flores, E., Pérez-Ros, P., Martínez-Arnau, F. M., Julián-Rochina, I., & Cauli, O. Neuro-psychiatric alterations in patients with diabetic foot syndrome. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*. 2019; 18(8), 598-608.
  - 454) Opara JK, Onwuliri FC, Agumah NB, Njoku OM, Onwuliri EA. Evaluation antibacterial effects of *Garcinia Kola* and *Vernonia Amygdalina* on *Staphylococcus aureus* isolated from residents of Abuja. *Nigeria. World Journal of Pharmaceutical Research*. 2017; **6**(15):95-104.
  - 455) Opara JK, Onwuliri FC, Agumah NB, Njoku OM, Onwuliri EA. Incidence of multidrug resistant (MDR) *Staphylococcus aureus* isolated from urban population and private health clinics in the federal capital territory; Abuja, Nigeria. *Ijppr.Human*, 2017; **10**(4): 1-14
  - 456) Pontes, D. G., Silva, I. T. D. C. E., Fernandes, J. J., Monteiro, A. D. F. G., Gomes, P. H. D. S., Ferreira, M. G. M., ... & Cavalcante, L. P. Perfil microbiológico e de resistência bacteriana no pé diabético infectado. *Revista do Colégio Brasileiro de Cirurgiões*. 2020; 47.
  - 457) Pragash DS, Girija S, Sekar U, Rayapu V, Sheriff DS. Uropathogens and diabetes mellitus-a perspective. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*. 2017; **16**(5): 29-32.
  - 458) Qu Z, Yu J, Ma K, Chen Y. Characteristics of bacterial infection in patients with diabetic foot and its relationship with degree of vascular lesions in lower extremities. *Biomedical Research*. 2018;**28**(22):10181-10185.
  - 459) Rajana VM. Immune dysfunction in diabetes mellitus (DM). *Int J Health Sci Res*. 2017; **7**(12):256-275.
  - 460) Sanchez-Jimenez R, Ceron E, Bernal-Alcántara D, Castillejos-López M, Gonzalez-Trujano E, Negrete-García MC, Alvarado-Vasquez N. Association between IL-15 and insulin plasmatic concentrations in patients with pulmonary tuberculosis and type 2 diabetes. *Tuberculosis*. 2018;**111**:114-20.
  - 461) Sekhar S, Unnikrishnan MK, Rodrigues GS, Vyas N, Mukhopadhyay C. Antimicrobial susceptibility pattern of aerobes in diabetic foot ulcers in a South-Indian tertiary care hospital. *The Foot*. 2018;**37**:95-100.
  - 462) Sowmya AV, Jayalakshmi G, Agatha D. Community acquired pneumonia-current scenario among immunocompromised patients in a tertiary care hospital. *International Journal of Bioassays*. 2016; **5**(01):4715-4719.
  - 463) Waked, R., Jaafar, D., Chedid, M., Saliba, G., Haddad, E., & Choucair, J. Impact of the inpatient infectious disease consultations at a tertiary care university hospital. *The International Arabic Journal of Antimicrobial Agents*. 2020; 10(2).
  - 464) Xie, M., Yu, J., Li, L., Jia, R., Song, X., Wang, Y., & Fan, X. Nomogram for Preoperative Estimation of Orbit Invasion Risk in Periocular Squamous Cell Carcinoma. *Frontiers in oncology*. 2020; 10, 564.
  - 465) Земляной, А. Б., Зеленина, Т. А., & Салухов, В. В. Параллели особенностей инфекций синдрома диабетической стопы на стационарном и амбулаторном этапах лечения. *Вестник Национального медико-хирургического Центра им. НИ Пирогова*. 2020; 15(4).
- ЦИТИРАНА: 53A: Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. *Diagn Microbiol Infect Dis* 2013; **77** (4): 287-288. Цитирана от:**
- 466) Ansari SA, Khan TA, Kazmi SU. Association of oral *Helicobacter pylori* with gastric complications. *Life sciences*. 2018;**205**:125-30.
  - 467) Lou, X.-J., Shen, L.-N., Chen, J., Li, L. Correlation of oral *Helicobacter pylori* infection with gastric *Helicobacter pylori* infection: Implications for eradication. *World Chinese Journal of Digestology*. 2016; **24**(18): 2918-2922.
  - 468) Yacoubi A, Hassn MS, Almogbel E, Makhrelouf L, Bouziane D, Saleh AM. The Relationship of *Helicobacter pylori* and Dental Plaques with Gastric Dyspepsia. *Ibnosina Journal of Medicine and Biomedical Sciences*. 2017; **9**(1):12-16.
  - 469) Yee JK. *Helicobacter pylori* colonization of the oral cavity: A milestone discovery. *World J Gastroenterol*. 2016; **22**(2):641-648.

**ЦИТИРАНА: 54A:** Markovska R, Schneider I, Stoeva T, Bojkova K, **Boyanova L**, Bauernfeind A, Mitov I. First identification of KPC-2 and VIM-1 producing *Klebsiella pneumoniae* in Bulgaria. *Diagn Microbiol Infect Dis*. 2013;**77**(3):252-253. **Цитирана от:**

- 470) Sabtcheva S, Ivanov IN, Todorova B, Simeonov Y, Dobрева E, Ivanova K, Velinov T, Kantardjiev T. Detection and characterization of OXA-48-producing *Klebsiella pneumoniae* originated in Bulgaria. *J Chemother*. 2016; **28**(5):450-453.
- 471) Thomson GK, Snyder JW, McElheny CL, Thomson KS, Doi Y. Coproduction of KPC-18 and VIM-1 carbapenemases by *Enterobacter cloacae*: implications for newer  $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations. *J Clin Microbiol*. 2016; **54**(3):791-794.
- 472) Todorova B, Sabtcheva S, Ivanov IN, Lesseva M, Chalashkanov T, Ioneva M, Bachvarova A, Dobрева E, Kantardjiev T. First clinical cases of NDM-1-producing *Klebsiella pneumoniae* from two hospitals in Bulgaria. *J Infect Chemother*. 2016; **22**(12): 837-840.
- 473) Trudić A, Jelesić Z, Mihajlović-Ukropina M, Medić D, Zivlak B, Gusman V, Đilas, M. Carbapenemase production in hospital isolates of multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli* in Serbia. *Vojnosanitetski pregled*, 2017;**74**(8):715-21.

**ЦИТИРАНА: 54B:** Adrian G. McNicholl AG, Tepes B, Gasbarrini A, Aisa AP, Vaira D, Bordin DS, Lerang F, Castro-Fernandez M, Bujanda L, Leja M, Vujasinovic M, Rokkas T, Kupcinskas L, Veijola L, Shvets O, Buzás GM, Machado JC, **Boyanova L**, ..., Megraud F, O'Morain CA, Gisbert JP. Tu1328 Pan-European Registry on *H. pylori* Management (HP-EuReg): Interim Analysis of First- and Second-Line Treatments. *Gastroenterology*. 2016; 150 (4 Supplement 1): Page S875. **Цитирана от:**

- 474) Cosme A, Torrente Iranzo S, Montes Ros M, Fernández-Reyes Silvestre M, Alonso Galán H, Lizasoain J, Bujanda L. *Helicobacter pylori* antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies. *Helicobacter*. 2019 Feb 1:e12557.
- 475) Ramírez FB, Núñez CG, Mas MT, Jiménez NR, Caballero FL. Criterios para la erradicación de *Helicobacter pylori*. *FMC: Formación Médica Continuada en Atención Primaria*. 2018;**25**(1):43-53.
- 476) Сафина ДД, Абдулхаков СР, Абдулхаков РА. Эрадикационная терапия *Helicobacter pylori*: настоящее и будущее. *Экспериментальная и клиническая гастроэнтерология*. 2016(11):84-93.

**ЦИТИРАНА: 55A: Boyanova L.** Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. *World J Microbiol Biotechnol*. 2014; **30** (5):1633-1637. **Цитирана от:**

- 477) Krynicka P, Ochmanek R, Strojewska P, Brzeska M, Frydrych A. Wpływ składników pokarmowych na leczenie *Helicobacter pylori*. *Nauki Przyrodnicze i Medyczne: Najnowsze doniesienia dotyczące nauk medycznych i biotechnologicznych*.:50-68.
- 478) Lee SM, Park SY, Kim MJ, Cho EA, Jun CH, Park CH, Kim HS, Choi SK, Rew JS. Key lime (*Citrus aurantifolia*) inhibits the growth of triple drug resistant *Helicobacter pylori*. *Gut Pathog*. 2018;**10**(1):16.
- 479) Sarnowska M, Gawron-Gzella A. Rooibos (*Aspalathus linearis* (Burm. f.) R. Dahlgren) – substancje biologicznie aktywne i działanie farmakologiczne [Rooibos (*Aspalathus linearis* (Burm. f.) R. Dahlgren) – biological active substances and pharmacological activity]. *Borgis - Postępy Fitoterapii*. 2016; 3:189-199. <http://www.czytelniamedyczna.pl/5803,rooibos-aspalathus-linearis-burm-f-r-dahlgren-substancje-biologicznie-aktywne-i.html>
- 480) Venegas, A., Touma, J. H., Bravo, J., & Perez-Perez, G. Progress in use of natural products and their active components against *Helicobacter pylori*. *Advances in Microbiology*. 2016; **6**(14):1091.
- 481) Zea D, Bayona M. Actividad antimicrobiana de productos naturales contra *Helicobacter pylori*. *Revista Venezolana de Salud Pública*. 2017;**5**(2):19-26.

**ЦИТИРАНА: 56A: Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I.** *Helicobacter pylori* susceptibility to fosfomicin, rifampin and five usual antibiotics for *H. pylori* eradication. *Diagn Microbiol Infect Dis* 2014; **79**:358–361. **Цитирана от:**

- 482) Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in *Helicobacter pylori* infection. *World J Gastroenterol*. 2017; **23**(16):2854-2869.
- 483) Bedoya-Gómez IJ, Alvarez-Aldana A., Moncayo-Ortiz JJ, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the antimicrobial resistance rates of *Helicobacter pylori* ten years later in the Western Central Region, Colombia. *Dig Dis*. 2020; **38**(3), 196-203.
- 484) Elmesky, M. M., Deghady, A. A., Ellakany, A. S., & Saad, N. A. Comparison Between Triple Therapy Versus Salvage Therapy in the Treatment of *Helicobacter Pylori* Infection in Some Egyptian Patients. *Alexandria journal*. 2016; **XXI**:
- 485) Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomicin. *Clin. Microbiol. Rev*. 2016; **29**(2):321-347.
- 486) Goudarzi M, Heidary M, Azad M, Fazeli M, Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in *Helicobacter pylori* isolates from patients. *Gastroenterol Hepatol Bed Bench*. 2016; **9**(Suppl1):S47-S52.
- 487) Güven, B., Gülerman, F., & Kaçmaz, B. *Helicobacter pylori* resistance to clarithromycin and fluoroquinolones in a pediatric population in Turkey: A cross-sectional study. *Helicobacter*. 2019; **24**(3), e12581.
- 488) Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J. Molecular characterization of *Helicobacter pylori* resistance to rifamycins. *Helicobacter*. 2018;**23**(1). doi: 10.1111/hel.12451
- 489) Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of *H. pylori* in Turkey: A systematic review. *Helicobacter*. 2016; **21**(4):251-260.
- 490) Naik DG. *Helicobacter pylori* mediated gastritis, peptic ulcer and gastric cancer. *International Journal of Biochemistry and Biomolecules*. 2016; **1**(1-2):36-42.
- 491) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. *Gastroenterology*. 2018;**155**(5):1372-82.
- 492) Silvan, J. M., Gutiérrez-Docio, A., Moreno-Fernandez, S., Alarcón-Cavero, T., Prodanov, M., & Martinez-Rodriguez, A. J. Procyanidin-rich extract from grape seeds as a putative tool against *Helicobacter pylori*. *Foods*. 2020; **9**(10), 1370.
- 493) Talebi Bezmin Abadi A. *Helicobacter pylori* treatment: New perspectives using current experience. *J Glob Antimicrob Resist*. 2017;**8**:123-130.

- 494) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther.* 2016; **43**(4):514-533.
  - 495) Zollner-Schwetz I, Leitner E, Plieschnegger W, Semlitsch G, Stepan V, Reiter L, Reich G, Mörtz E, Pavék J, Parsché P, Betterklier C, Atzmüller D, Krause R, Högenauer C. Primary resistance of *Helicobacter pylori* is still low in Southern Austria. *Int J Med Microbiol.* 2016; **306**(4):206-211.
  - 496) Ахметова, Д. Г., Балтабекова, А. Ж., & Шустов, А. В. Устойчивость к антибиотикам *Helicobacter pylori*: обзор эпидемиологических тенденций и проблемы терапии. *Русский медицинский журнал. Медицинское обозрение.* 2018; 2(7-1), 13-18.
- ЦИТИРАНА: 57А: Boyanova L, Sabov R, Kolarov R, Mitov I. Chronic odontogenic osteomyelitis and facial actinomycosis of six-month duration. JMM Case Reports. 2014 DOI 10.1099/jmmcr.0.000729 Цитирана от:**
- 497) Thukral R, Shrivastav K, Mathur V, Barodiya A, Shrivastav S. Actinomyces: a deceptive infection of oral cavity. *Journal of the Korean Association of Oral and Maxillofacial Surgeons.* 2017; **43**(4):282-285.
- ЦИТИРАНА: 58А: Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015, 31: 4-10. Цитирана от:**
- 498) Abdu, A. R., Egbagba, J., & Fente, B. G. Identification and antimicrobial susceptibility profile of bacterial pathogens isolated from wound infections in a tertiary hospital, Bayelsa South southern, Nigeria. *Trop J Path Micro.* 2019; 5(12), 966-975.
  - 499) Al-Hamdoni, S. A. S., & Al-Rawi, A. M. M. Assessment the Effect of Some Reagents on the Planktonic Cells and Biofilms of Red Complex Periodontal Pathogens. *International Journal of Sciences: Basic and Applied Research (IJSBAR).* 2020; 51(2): 1-13
  - 500) Akhi MT, Ghotaslou R, Alizadeh N, Yekani M, Beheshtirouy S, Asgharzadeh M, Pirzadeh T, Memar MY. *nim* gene-independent metronidazole-resistant *Bacteroides fragilis* in surgical site infections. *GMS hygiene and infection control.* 2017; **12**:13-.
  - 501) Albrecht, J., Barbaric, J., & Nast, A. Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors. *The British journal of dermatology,* 2019; **180**(5), 1262-1263.
  - 502) Andersen JM, Shoup M, Robinson C, Britton R, Olsen KE, Barrangou R. CRISPR diversity and in *Clostridium difficile*. *Genome Biol Evol.* 2016; **8**(9):2841-2855.
  - 503) Badr, M. T., Blümel, B., Baumgartner, S., Komp, J., & Häcker, G. Antimicrobial Susceptibility Patterns and Wild-Type MIC Distributions of Anaerobic Bacteria at a German University Hospital: A Five-Year Retrospective Study (2015–2019). *Antibiotics.* 2020; 9(11), 823.
  - 504) Cherkaoui A, Fischer A, Azam N, Riat A, Schrenzel J. A comparison of Sensititre™ Anaerobe MIC plate with ATB ANA® test for the routine susceptibility testing of common anaerobe pathogens. *European Journal of Clinical Microbiology & Infectious Diseases.* 2018; **37**(12):2279-84.
  - 505) Cobo, F., Rodríguez-Granger, J., Pérez-Zapata, I., Sampedro, A., Aliaga, L., & Navarro-Marí, J. M. Antimicrobial susceptibility and clinical findings of significant anaerobic bacteria in southern Spain. *Anaerobe.* 2019; 59, 49-53.
  - 506) Cooley L, Teng J. Anaerobic resistance: should we be worried?. *Current opinion in infectious diseases.* 2019; 32(6), 523-530.
  - 507) Dahlen G, Preus HR. Low antibiotic resistance among anaerobic Gram-negative bacteria in periodontitis 5 years following metronidazole therapy. *Anaerobe.* 2017; **43**:94-98.
  - 508) de Sá Almeida, J. S., de Oliveira Marre, A. T., Teixeira, F. L., Boente, R. F., Domingues, R. M., de Paula, G. R., & Lobo, L. A. Lactoferrin and lactoferricin B reduce adhesion and biofilm formation in the intestinal symbionts *Bacteroides fragilis* and *Bacteroides thetaiotaomicron*. *Anaerobe.* 2020; 64, 102232.
  - 509) Dellinger EP. Cephalosporin plus metronidazole for surgical prophylaxis. *Surgical infections.* 2018; **19**(4):359-61.
  - 510) Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. *J Antimicrob Chemother.* 2018; **73**(2):265-279.
  - 511) Dumont Y, Michon AL, Laurens C, Bonzon L, Godreuil S, Jean-Pierre H. Rôle du laboratoire de biologie médicale dans le diagnostic microbiologique des bactéries anaérobies. *Revue Francophone des Laboratoires.* 2018; **2018**(505):40-7.
  - 512) El Badawy NE, El shabrawy RM, Ghonaim RA, Allam Z. Identification and detection of antibiotic susceptibility of the most common anerobes causing infection in surgical hospital, Faculty of Medicine Zagazig University, Egypt. *African Journal of Clinical and Experimental Microbiology.* 2016; **17**(2): 140-150.
  - 513) Gajdács M, Spengler G, Urbán E. Identification and antimicrobial susceptibility testing of anaerobic bacteria: Rubik's cube of clinical microbiology?. *Antibiotics.* 2017; **6**(4):25.
  - 514) Gajdács, M., Terhes, G., & Urbán, E. Az anaerob baktériumok által okozott véráramfertőzések gyakorisága 2005–2009 és 2013–2017 között egy egyetemi központban. Retrospektív összehasonlító vizsgálat. *Orvosi Hetilap.* 2020; 161(19), 797-803.
  - 515) García-Bayona L, Comstock LE. Streamlined genetic manipulation of diverse *Bacteroides* and *Parabacteroides* isolates from the human gut microbiota. *MBio.* 2019] 10(4).
  - 516) Gilarranz-Luengo R, Chamizo-López FJ, Horcajada-Herrera I, Bordes-Benítez A. Trends in antimicrobial susceptibility among anaerobes in Gran Canaria: Analysis of 15-years data. *Enferm Infecc Microbiol Clin.* 2016; **34**(3):210-211.
  - 517) Gil-Tomás JJ, Jover-García J, Colomina-Rodríguez J. Vigilancia de la sensibilidad antibiótica de anaerobios gramnegativos: RedMiVa 2010-2016. *Enfermedades Infecciosas y Microbiología Clínica.* 2018; **36**(3):200-1.
  - 518) Gustafson CT, Boakye-Agyeman F, Brinkman CL, Reid JM, Patel R, Bajzer Z, Dadsetan M, Yaszemski MJ. Controlled delivery of vancomycin via charged hydrogels. *PLoS One.* 2016; **11**(1):e0146401.
  - 519) Haidar YM, Tripathi PB, Tjoa T, Walia S, Zhang L, Chen Y, Nguyen DV, Mahboubi H, Armstrong WB, Goddard JA. Antibiotic prophylaxis in clean-contaminated head and neck cases with microvascular free flap reconstruction: A systematic review and meta-analysis. *Head & neck.* 2018; **40**(2):417-27.
  - 520) Hansen KCM, Schwensen SAF, Henriksen DP, Justesen US, Sydenham TV. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal samples from patients receiving broad-spectrum antibiotics. *Anaerobe.* 2017; **47**:79-85.

- 521) Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI. Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology. *Anaerobe*. 2016; **42**:27-30.
- 522) Ho PL, Yau CY, Ho LY, Lai EL, Liu MC, Tse CW, Chow KH. Antimicrobial susceptibility of *Bacteroides fragilis* group organisms in Hong Kong by the tentative EUCAST disc diffusion method. *Anaerobe*. 2017; **47**:51-56.
- 523) Hwang, S., Jo, M., Hong, J. E., Park, C. O., Lee, C. G., Yun, M., & Rhee, K. J. Zerumbone suppresses enterotoxigenic *Bacteroides fragilis* infection-induced colonic inflammation through inhibition of NF- $\kappa$ B. *International journal of molecular sciences*. 2019; **20**(18), 4560.
- 524) Ishak, N., Wahab, Z. A., Nordin, S. A., & Ibrahim, R. Susceptibility patterns of anaerobes isolated from clinical specimens in tertiary Hospital, Malaysia. *The Malaysian Journal of Pathology*. 2020; **42**(2), 245-252.
- 525) Jayasimhan D, Wu L, Huggan P. Fusobacterial liver abscess: a case report and review of the literature. *BMC Infect Dis*. 2017;**17**(1):440.
- 526) Jeverica S, Kolenc U, Mueller-Premru M, Papst L. Evaluation of the routine antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015. *Anaerobe*. 2017; **47**:64-69.
- 527) József S. The clinically important anaerobic, human pathogenic *Bacteroides* species and their antibiotic resistance levels in Central and Southeast Europe. *Bulletin of Medical Sciences*. 2018;**91**(1):19-25.
- 528) Kierzkowska M, Majewska A, Sawicka-Grzelak A, Młynarczyk A, Chmura A, Kwiatkowski A, Durlik M, Paczek L, Młynarczyk G. Antibiotic resistance profiles of strictly anaerobic Gram-negative *Bacteroides* spp. and *Parabacteroides* spp. bacilli isolated from infected inpatients on surgical wards. *J Glob Antimicrob Resist*. 2016; **7**:128-129. .
- 529) Kierzkowska M, Majewska A, Szymanek-Majchrzak K, Sawicka-Grzelak A, Młynarczyk A, Młynarczyk G. In vitro effect of clindamycin against *Bacteroides* and *Parabacteroides* isolates in Poland. *J Glob Antimicrob Resist*. 2017:128.
- 530) Kierzkowska, M., Majewska, A., Szymanek-Majchrzak, K., Sawicka-Grzelak, A., Młynarczyk, A., & Młynarczyk, G. Oporność typu MLSB u klinicznych izolatów *Bacteroides* i *Parabacteroides* MLSB resistance in clinical isolates of *Bacteroides* and *Parabacteroides*. *Organ narodowego instytutu zdrowia publicznego*, 49. Med. Dośw. Mikrobiol., 2018, 70: 49 - 56
- 531) Kierzkowska M, Majewska A, Młynarczyk G. Trends and impact in antimicrobial resistance among *Bacteroides* and *Parabacteroides* species in 2007–2012 compared to 2013–2017. *Microbial Drug Resist*. 2020; **26**(12):1452-1457.
- 532) Kim YA. The importance of the early and appropriate treatment of anaerobic bacteremia patients. *Infect Chemother*. 2016; **48**(2):143-144.
- 533) Kim, M., Kim, H. S., Song, Y. J., Lee, E., Song, K. H., Choe, P. G., ... & Kim, H. B. Redundant combinations of antianaerobic antimicrobials: Impact of pharmacist-based prospective audit and feedback and prescription characteristics. *European Journal of Clinical Microbiology & Infectious Diseases*. 2020; **39**(1), 75-83.
- 534) Kierzkowska, M., Majewska, A., Szymanek-Majchrzak, K., Sawicka-Grzelak, A., Młynarczyk, A., & Młynarczyk, G. The presence of antibiotic resistance genes and bft genes as well as antibiotic susceptibility testing of *Bacteroides fragilis* strains isolated from inpatients of the Infant Jesus Teaching Hospital, Warsaw during 2007–2012. *Anaerobe*. 2019; **56**, 109-115.
- 535) Litterio MR, Cejas D, Gutkind G, Radice M. Identification of CfiA coding genes in *Bacteroides fragilis* isolates recovered in Argentina. Inconsistencies in CfiA organization and nomenclature. *Anaerobe*. 2017;**48**:257-261.
- 536) Man MY, Shum HP, Wu A, Lee RA, Yan WW. A case of severe empyema with acute respiratory distress syndrome caused by *Slackia exigua* requiring veno-venous extracorporeal membrane oxygenation. *Anaerobe*. 2017; **48**:7-11.
- 537) Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, Chang PK, O'Neill PJ, Mollen KP, Huston JM, Diaz JJ Jr, Prince JM. The Surgical Infection Society Revised Guidelines on the management of intra-abdominal infection. *Surg Infect (Larchmt)*. 2017;**18**(1):1-76.
- 538) Memar, M. Y., Yekani, M., Aghazadeh, M., & Baghi, H. B. Antibiotic Treatment of Anaerobic Infections: Uncharted Land in Iran. *Iranian journal of public health*. 2019; **48**(11), 2103-2104.
- 539) Merchan C, Parajuli S, Siegfried J, Scipione MR, Dubrovskaya Y, Rahimian J. Multidrug-resistant *Bacteroides fragilis* bacteremia in a US resident: an emerging challenge. *Case Reports in Infectious Diseases*. 2016, Article ID 3607125, doi:10.1155/2016/3607125
- 540) Niestępski S, Harnisz M, Korzeniewska E, Aguilera-Arreola MG, Contreras-Rodríguez A, Filipkowska Z, Osińska A. The emergence of antimicrobial resistance in environmental strains of the *Bacteroides fragilis* group. *Environment international*. 2019;**124**:408-19.
- 541) Peeters B, Magerman K, Waumans L, Cartuyvels R. Laboratory survey and literature review of anaerobic bacteriology: foundations of aclinically orientated and evidence-based workup for anaerobic cultures. *Diagn Microbiol Infect Dis*. 2016; **86** (1):15-22.
- 542) Petersen MW, Perner A, Bahador M, Sjövall F, Möller MH. Empirical metronidazole for patients with severe bacterial infection: protocol for a systematic review. *Acta Anaesthesiologica Scandinavica*. 2018;**62**(5):724-30.
- 543) Rams TE, Sautter JD, van Winkelhoff AJ. Antibiotic resistance of human periodontal pathogen *Parvimonas micra* over 10 years. *Antibiotics*. 2020; **9**(10), 709.
- 544) Rodloff AC, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European collection of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST) 2010–2016. *Anaerobe*. 2018;**51**:78-88.
- 545) Sárvári KP, Sóki J, Kristóf K, Juhász E, Miszti C, Latkóczy K, Melegh SZ, Urbán E. A multicentre survey of the antibiotic susceptibility of clinical *Bacteroides* species from Hungary. *Infectious Diseases*. 2018 ; **50**(5):372-80.
- 546) Sayın E. Türkiye'deki Bir Üniversite Eğitim ve Araştırma Hastanesinde Elde Edilen Toksik Clostridioides difficile İzolatlarına Antimikrobiyallerin İn Vitro Etkisi. *Mikrobiyol Bul*. 2020; **54**(3), 368-377.
- 547) Schwensen SA, Henriksen DP, Justesen US, Sydenham TV. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal samples from patients receiving broad-spectrum antibiotics. *Anaerobe*. 2017;**47**:79-85.



- 548) Shafquat Y, Jabeen K, Farooqi J, Mehmood K, Irfan S, Hasan R, Zafar A. Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan. *Antimicrobial Resistance & Infection Control*. 2019; **8**(1), 1-7.
- 549) Sóki J, Székely E. A klinikailag fontos humán patogén anaerob *Bacteroides* fajok és antibiotikumérzékenységi szintjeik Közép-és Délkelet-Európában. *Bulletin of medical sciences/orvostudományi értesítő*. 2018; **91**(1), 19-25.
- 550) Steininger C, Willinger B. Resistance patterns in clinical isolates of pathogenic *Actinomyces* species. *J Antimicrob Chemother*. 2016; **71**(2):422-427.
- 551) Sydenham TV, Jensen BH, Petersen AM, Krogfelt KA, Justesen US. Antimicrobial resistance in the *Bacteroides fragilis* group in faecal microbiota from healthy Danish children. *Int J Antimicrob Agents*. 2017; **49**(5):573-578.
- 552) Tan TY, Ng LS, Kwang LL, Rao S, Eng LC. Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital. *Anaerobe*. 2017; **43**:69-74.
- 553) Teng JC, Dreyer L. Antimicrobial susceptibility patterns of anaerobic bacteria in Victoria, Australia. *bioRxiv*. 2018 Jan 1:308023.
- 554) Terheyden H. Komplexe Augmentationen. *Der MKG-Chirurg*. 2016; **9**: 35. doi:10.1007/s12285-015-0035-0
- 555) Toprak NU, Alida V, Urban E, Wybo I, Justesen US, Jean-Pierre H, Morris T, Akgul O, Kulekci G, Soyletir G, Nagy E. Performance of mass spectrometric identification of clinical *Prevotella* species using the VITEK MS system: A prospective multi-center study. *Anaerobe*. 2018; **54**:205-209.
- 556) Toprak NU, Veloo AC, Urban E, Wybo I, Justesen US, Jean-Pierre H, Morris T, Akgul O, Kulekci G, Soyletir G, Nagy E. A multicenter survey of antimicrobial susceptibility of *Prevotella* species as determined by Etest methodology. *Anaerobe*. 2018;**52**:9-15.
- 557) Tunckanat, F., Sancak, B., Altun, B., Dursun, E., & Akdogan-Kittana, F. N.. Investigation of Antibiotic Susceptibilities of Anaerobic Bacteria Isolated From Patients With Chronic Periodontitis/Kronik Periodontitli Hastalardan Izole Edilen Anaerop Bakterilerin Antibiyotik Duyarlılık Durumlarının Arastirilmesi. *KLIMIK Journal*. 2019; 32(3), 240-245.
- 558) Ugarte-Torres A, Gillrie MR, Griener TP, Church DL. *Eggerthella lenta* bloodstream infections are associated with increased mortality following empiric piperacillin-tazobactam (TZP) monotherapy: A population-based cohort study. *Clinical Infectious Diseases*. 2018; **67**(2):221-8.
- 559) Ülger Toprak N. İstanbul'da İki Merkeze ait Prevotella Türlerinin Gradiyent Test Yöntemiyle Belirlenen Antimikrobiyal İlaç Duyarlılığı. *Mikrobiyol Bul*, 2020; 54(2), 246-256.
- 560) Večeřová R, Panáček A, Kolář M. Effect of silver nanoparticles on anaerobic bacteria | [Účinek nanočástic stříbra na anaerobní bakterie]. *Klinická Mikrobiologie a Infekční Lekarství*. 2017; **23**(1):17-20.
- 561) Veloo ACM, Tokman HB, Jean-Pierre H, Dumont Y, Jeverica S, Lienhard R, ... & ESGAI study group. Antimicrobial susceptibility profiles of anaerobic bacteria, isolated from human clinical specimens, within different European and surrounding countries. A joint ESGAI study. *Anaerobe*. 2020; **61**, 102111.
- 562) Zhang J, Liang H, Zheng Y, Wang D, Xia J, Peng W, Cheng K, Wang L, Liu Y, Peng W, Li Q. Photodynamic therapy versus systemic antibiotic for the treatment of periodontitis in a rat model. *Journal of periodontology*. 2019 Jan 11.
- 563) Zhang X, Bai Y, Zhang L, Draz MS, Ruan Z, Zhu Y. Antimicrobial susceptibility and clonality of vaginally derived multidrug-resistant *Mobiluncus* isolates in China. *Antimicrob Agents Chemother*. 2020; **64**(8).
- 564) Zhang CY, Li MH, Guo MQ. A phase conversion headspace technique for the determination of anti-anaerobic activity of drug candidate based on the metabolic acidity change in culture medium. *Journal of Chromatography A*. 2020; 1621: 461024.
- 565) Zhao-Fleming H, Dissanaike S, Rumbaugh K. Are anaerobes a major, underappreciated cause of necrotizing infections? *Anaerobe*. 2017; **45**:65-70.
- 566) Zhou XJ, Gong LJ, Li J, Liu QC, Zhu DS. Intestinal flora changes in a mouse model of transverse aortic constriction. *Medical Journal of Chinese People's Liberation Army*. 2016; **41**(10):808-812.

**ЦИТИРАНА: 59А: Boyanova L.** Susceptibility of anaerobes to fusidic acid and fosfomycin. *Int J Antimicrob Agents*. 2015; **45**(5):560-561. **Цитирана от:**

- 567) Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D. Activity of fosfomycin when tested against US contemporary bacterial isolates. *Diagn Microbiol Infect Dis*. 2019;**93**(2):143-6.
- 568) Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D. Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against gram-negative bacterial strains by using time-kill curves. *Antimicrob Agents Chemother*. 2019; **63**(5).
- 569) Grabein B, Graninger W, Baño JR, Dinh A, Liesenfeld DB. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. *Clin Microbiol Infect*. 2017; **23**(6):363-372.
- 570) Williams PC, Waichungo J, Gordon NC, Sharland M, Murunga S, Kamau A, Berkley JA. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria. *J Med Microbiol*. 2019; **68**(5): 711.

**ЦИТИРАНА: 60А: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I.** Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. *Diagn Microbiol Infect Dis* 2015; **82**(1):85-86. **Цитирана от:**

- 571) Abdel-Latif MM, Abouzied MM. Molecular mechanisms of natural honey against *H. pylori* infection via suppression of NF-κB and AP-1 activation in gastric epithelial cells. *Arch Med Res*. 2016; **47**(5):340-348.
- 572) Aleixo MLM, Galbiati C, Lemos LMS. Produtos naturais anti - *Helicobacter pylori*: revisão. *Revista Ibero-Americana de Ciências Ambientais*. 2018;9(1). <http://www.sustenere.co/index.php/rica/article/view/CBPC2179-6858.2018.001.0005/1049>
- 573) Coşarcă S, Tanase C, Muntean DL. Therapeutic aspects of catechin and its derivatives—an update. *Acta Biologica Marisiensis*. 2019; **2**(1): 21-29. <https://abmj.ro/wp-content/uploads/2019/07/26685124-Acta-Biologica-Marisiensis-Therapeutic-Aspects-of-Catechin-and-Its-Derivatives-%E2%80%93-An-Update.pdf>
- 574) Debraekeleer A, Remaut H. Future perspective for potential *Helicobacter pylori* eradication therapies. *Future Microbiology*. 2018;**13**(06):671-87.

- 575) Ebrahimpour S, Esmaeili H, Ghadimi R. Food bioactive components, a possible adjuvant for *H. pylori* eradication. *Caspian J Intern Med* 2017; **8**(2): 130-131.
- 576) Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, ... & Arslan M. Sociodemographic characteristics and clinical risk factors of *Helicobacter pylori* infection and antibiotic resistance in the Eastern Black Sea region of Turkey. *The Turkish Journal of Gastroenterology*, 2020; **31**(3): 221.
- 577) Hołubiuk Ł, Imiela J. Diet and *Helicobacter pylori* infection. *Przegląd gastroenterologiczny*. 2016; **11**(3):150.
- 578) Hroncová Z, Konopásková K, Volšátová T, Killer J. Quantification of Firmicutes, Actinobacteria, and Gammaproteobacteria from Bohemian Honey. *Scientia Agriculturae Bohemica*. 2018;**49**(3):192-200.
- 579) Kolaylı S , Baltas N , Sahin H, Karaoglu S. Evaluation of anti-*Helicobacter pylori* activity and urease inhibition by some Turkish authentic honeys. *Journal of Food Science and Engineering* 2017;**7**: 67-73.
- 580) Naveed M, BiBi J, Kamboh AA, Suheryani I, Kakar I, Fazlani SA, FangFang X, Yunjuan L, Kakar MU, El-Hack ME, Noreldin AE. Pharmacological values and therapeutic properties of black tea (*Camellia sinensis*): A comprehensive overview. *Biomedicine & Pharmacotherapy*. 2018;**100**:521-31.
- 581) Özturan A, Bilici S, Sargin Zg, Karakan T. *Helicobacter pylori* enfeksiyonu olan bireylerde tedavi öncesi ve sonrası beslenme durumlarının değerlendirilmesi üzerine bir araştırma. *Gazi Sağlık Bilimleri Dergisi*. 2017;**2**(2):20-31.
- 582) Puścion-Jakubik A, Borawska MH, Socha K. Modern methods for assessing the quality of bee honey and botanical origin identification. *Foods*. 2020; **9**(8): 1028.
- 583) Puścion-Jakubik A, Socha K, Borawska MH. Comparative study of labelled bee honey from Poland and the result of the melissopalynological analysis. *Journal of Apicultural Research*. 2020; **59**(5), 928-938.
- 584) Quraisiah A, Fazalda A, Alfizah H, Azlina MFN. In vitro Study of Anti-*Helicobacter pylori* Activity of Honey: A systematic review. *Sains Malaysiana*. 2020; **49**(2): 411-420.
- 585) Rezaeimanesh N, Farzi N, Pirmanesh S, Emami S, Yadegar A. Management of multi-drug resistant *Helicobacter pylori* infection by supplementary, complementary and alternative medicine; a review. *Gastroenterology and Hepatology from bed to bench*. 2017;**10**(Suppl1):S8.
- 586) Samanta S. Potential bioactive components and health promotional benefits of tea (*Camellia sinensis*). *Journal of the American College of Nutrition*. 2020; 1-29.
- 587) Serafim C, Araruna ME, Júnior EA, Diniz M, Hiruma-Lima C, Batista L. A Review of the role of flavonoids in peptic ulcer (2010–2020). *Molecules*. 2020; **25**(22), 5431.
- 588) Venegas A, Touma JH, Bravo J, Perez-Perez G. Progress in use of natural products and their active components against *Helicobacter pylori*. *Advances in Microbiology*. 2016; **6**(14):1091-1129.
- ЦИТИРАНА: 61A: Boyanova L, Kolarov R, Mateva L, Markovska R, Mitov I. Actinomycosis- a frequently forgotten disease. Future Microbiol. 2015; 10(4): 613–628. Цитирана от:**
- 589) Ahmadi A, Salem MM, Safdarian M, Ilkhani S, Hamidian R, Cheraghipour M, Daneshvar A, Izadi F. Management of Laryngocutaneous Fistula following Chondroradionecrosis of the Larynx in a Patient with Laryngeal Actinomycosis. *Iranian Journal of Otorhinolaryngology*. 2017;**29**(3):154.
- 590) Aini RI, Ratunanda SS, Wijana W, Permana AD, Mahdiani S. Aktinomikosis di tonsil lingualis dan supraglotis sebagai manifestasi klinis pertama pada pasien imunokompromais. *Oto Rhino Laryngologica Indonesiana*. 2017;**47**(1):81-88.
- 591) Alsohime F, Assiri RA, Al-Shahrani F, Bakeet H, Elhazmi M, Somily AM. Premature labor and neonatal sepsis caused by *Actinomyces neuui*. *Journal of infection and public health*. 2018; **12**(2), 282-284.  
<https://www.sciencedirect.com/science/article/pii/S1876034118300376>
- 592) Azadi, D., Motallebirad, T., Ghaffari, K., Shokri, D., & Rezaei, F. Species Diversity, Molecular Characterization, and Antimicrobial Susceptibility of Opportunistic Actinomycetes Isolated from Immunocompromised and Healthy Patients of Markazi Province of Iran. *Infection and drug resistance*. 2020; **13**, 1.
- 593) Bacharewicz-Szczerbicka, J., Serwin, A. B., Kozłowska, D., & Flisiak, I. Case Report/Opis Przypadku. *Dermatol Rev/Przegl Dermatol* 2019, 106, 522–528.
- 594) Bacharewicz-Szczerbicka, J., Serwin, A. B., Kozłowska, D., & Flisiak, I. Metastasis of laryngeal cancer or cervical actinomycosis-the importance of early differential diagnosis. *Dermatology Review/Przegląd Dermatologiczny*. 2019; **106**(5).
- 595) Balis, E., Kakavas, S., Kompogiorgas, S., Kotsifas, K., & Boulbasakos, G. Presentation of pulmonary tuberculosis and actinomycosis co-infection as a lung mass: a literature review and unique case report. *Monaldi Archives for Chest Disease*. 2019; **89**(3).
- 596) Bonifaz, A., Buitrón-García, R., Ramírez-Galván, A., & Tirado-Sánchez, A. Actinomyces-like Organisms on Intrauterine Devices from Asymptomatic Users. *International Journal of TROPICAL DISEASE & Health*. 2017; 1-3.
- 597) Bortoluzzi, P., Nazzaro, G., Giacalone, S., & Veraldi, S. Cervicofacial actinomycosis: a report of 14 patients observed at the Dermatology Unit of the University of Milan, Italy. *International journal of dermatology*. 2020; **59**(10), 1222-1225.
- 598) Carrara, J., Hervy, B., Dabi, Y., Illac, C., Haddad, B., Skalli, D., ... & Vaysse, C. Added-value of endometrial biopsy in the diagnostic and therapeutic strategy for pelvic actinomycosis. *Journal of clinical medicine*. 2020; **9**(3), 821.
- 599) Crisafulli, E., Bernardinello, N., Alfieri, V., Pellegrino, F., Lazzari, C., Gnetti, L., & Chetta, A. A pulmonary infection by *Actinomyces odontolyticus* and *Veillonella atypica* in an immunocompetent patient with dental caries. *Respirology case reports*. 2019; **7**(9), e00493.
- 600) Dagher, R., Riaz, T., Tande, A. J., Osmon, D. R., Jagtiani, A., Steckelberg, J. M., ... & Berbari, E. F. Prosthetic Joint Infection due to Actinomycet species: A case series and review of literature. *Journal of bone and joint infection*. 2019; **4**(4), 174-180.
- 601) de Oca, G. M., Simón-Díaz, P., Torres-Haro, J., Macías-Jiménez, J. B., Araiza, J., & Bonifaz, A. Actinomycosis cérvico-facial tratada con amoxicilina-clavulanato. *Dermatología Revista Mexicana*. 2016; **60**(6), 526-530.
- 602) Ding X, Sun G, Fei G, Zhou X, Zhou L, Wang R. Pulmonary actinomycosis diagnosed by transbronchoscopic lung biopsy: A case report and literature review. *Experimental and therapeutic medicine*. 2018;**16**(3):2554-8.

- 603) Dioguardi, M., Crincoli, V., Laino, L., Alovise, M., Sovereto, D., Lo Muzio, L., & Troiano, G. Prevalence of Bacteria of Genus *Actinomyces* in Persistent Extraradicular Lesions—Systematic Review. *Journal of clinical medicine*. 2020; **9**(2), 457.
- 604) Doğan, B. İ., Ceyda, A. N. A. R., Sertogullarından, B., & Turan, O. COVID-19 Pandemi Döneminde Multiple Nodüllerle Gelen Hastada Nadir Görülen Bir Enfeksiyon Etkeni: Aktinomikoz Odontoliticos. *İzmir Göğüs Hastanesi Dergisi* 2020; **34**(3):129-34
- 605) Elzein, F., Kharraz, R., Arab, N., Alotaibi, F., Almohaya, A., & Almutairy, A. A case series of actinomycosis from a single tertiary care center in Saudi Arabia. *IDCases*. 2019; **15**, e00521.
- 606) e Monteiro, E. V., Gaspar, J., Paiva, C., Correia, R., Valente, V., Coelho, A., & Lamas, N. J. Abdominal Actinomycosis misdiagnosed as liposarcoma. *Autopsy & case reports*. 2020; **10**(1).
- 607) Gajdacs, M., Urbán, E., & Terhes, G. Microbiological and clinical aspects of cervicofacial actinomyces infections: an overview. *Dentistry journal*. 2019; **7**(3), 85.
- 608) Gajdacs, M., & Urbán, E. The Pathogenic Role of *Actinomyces* spp. and Related Organisms in Genitourinary Infections: Discoveries in the New, Modern Diagnostic Era. *Antibiotics*. 2020; **9**(8), 524.
- 609) García-García A, Coronel-Martínez J, Cantú-de Leon D, del Socorro Romero-Figueroa M, Caballero-Pantoja YE, Manzanares-Leal GL, Rodríguez-Morales M, Sandoval-Trujillo H, Ramírez-Durán N. Detection of *Actinomyces* spp. in cervical exudates from women with cervical intraepithelial neoplasia or cervical cancer. *J Med Microbiol*. 2017; **66**(6):706-712.
- 610) Gaspar, J., Paiva, C., Correia, R., Valente, V., Coelho, A., & Lamas, N. J. Abdominal Actinomycosis misdiagnosed as liposarcoma. *Autopsy and Case Reports*. 2020; **10**(1).
- 611) Gupta, N., Aggarwal, A., Ramteke, P., & Soneja, M. Mandibular osteomyelitis due to *Actinomyces* spp. *BMJ case reports*. 2020; **13**(5).
- 612) Granier, S., Zarrouk, V., Mauillon, J., Hammel, P. Granier, S., Zarrouk, V., Mauillon, J., Hammel, P. Gastrointestinal actinomycosis | [Actinomycose digestive] Hepato-Gastro et Oncologie Digestive. 2018; **25**(1), pp. 21-29
- 613) Hartert, M., Wolf, M., Ferber, J., & Huertgen, M. Thoracoabdominal actinomycosis—Chameleon through kaleidoscope. *Respiratory Medicine Case Reports*. 2020; **31**: 101281.
- 614) Jabi, R., Ramdani, H., Elmir, S., Elmejati, F., Serji, B., El Harroudi, T., & Bouziane, M. Pseudotumoral actinomycosis mimicking malignant colic disease: A case report and literature review. *Visceral Medicine*. 2020; **36**(4), 333-337.
- 615) Knežević, S., Slavuljica, I., Cekinović Grbeša, Đ., Gorup, L., Škrobonja, I., Poljak, I., ... & Trošelj Vukić, B. Aktinomikoza temporalne kosti, aktinomikotični meningitis i limfadenitis vrata-prikaz bolesnice. *Infektološki glasnik*. 2018; **38**(3), 81-85.
- 616) Łanowy, P., Ślusarz, K., Pyka, W., Dzindzio, J., Bichalski, M., Blaszkowska, M., ... & Jaroszewicz, J. Actinomycosis-forgotten disease as a diagnostic challenge. *Journal of Education, Health and Sport*. 2019; **9**(5), 256-264.
- 617) Lee, S. Z., Syed, M. T., & Kumar, P. Actinomycosis or malignancy: A diagnostic dilemma. *Int J Case Rep Images*. 2019; **10**, 101055Z01SL2019.
- 618) López-Casillas N, Cuevas-González A. Actinomicosis primaria de pared abdominal: presentación de un caso con fistula enterocutánea y revisión de la bibliografía Primary actinomycosis of the abdominal wall: presentation of a case with enterocutaneous fistula. *Rev Hispanoam Hernia*. 2018;**6**(1):45-49
- 619) Loth-Bouketal A, Graziani J, Fakhry N. Actinomicosis cervicofacial. *EMC-Otorrinolaringología*. 2017;**46**(3):1-5.
- 620) Lynch T, Gregson D, Church DL. Species-level identification of *Actinomyces* isolates causing invasive infections: multiyear comparison of Vitek MS (Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry) to partial sequencing of the 16S rRNA gene. *J Clin Microbiol*. 2016; **54**(3):712-717.
- 621) Manterola, C., Grande, L., & Otzen, T. Actinomicosis de Pared Abdominal con Infiltración Hepática Simulando una Neoplasia Maligna. Reporte de un Caso. *International Journal of Morphology*. 2019; **37**(3), 1033-1037.
- 622) Millet, A., Bachelet, A., & Croguennec, M. Actinomycose pelvienne. *Annales françaises de médecine d'urgence*. 2020; **10**(1), 41-42.
- 623) Montes de Oca G, Simón-Díaz P, Torres-Haro J, (...), Araiza J, Bonifaz A. Cervicofacial actinomycosis treated with amoxicillin/clavulanate | [Actinomicosis cérvico-facial tratada con amoxicilina-clavulanato]. *Dermatologia Revista Mexicana*. 2016; **60** (6): 526-530. <http://www.medigraphic.com/pdfs/derrevmex/rmd-2016/rmd166k.pdf>
- 624) Mousavi SA, Mojahed M, Shahcheraghi SH. Actinomycosis of hand: a case report. *Reviews in Medical Microbiology*: 2016; **27**(3):85–86.
- 625) Nahum A, Filice G, Malhotra A. A Complicated thread: abdominal actinomycosis in a young woman with Crohn disease. *Case Reports in Gastroenterology*. 2017;**11**(2):377-381.
- 626) Nakahira ES, Maximiano LF, Lima FR, Ussami EY. Abdominal and pelvic actinomycosis due to longstanding intrauterine device: a slow and devastating infection. *Autops Case Rep*. 2017;**7**(1):43-47.
- 627) Ocampo-Verdeja AE, Damián-Zapién A, Gallegos-Fernández AA, Soto-Ortiz JA, Mayorga J. Actinomycosis: 11-years clinical-epidemiological study. *Dermatología Revista Mexicana*. 2018;**62**(1):3-10.
- 628) Oikonomidis, P., Fousekis, F., Kotsaftis, P., Pilios, I., Dimas, D., & Giannoulis, G. A case of pulmonary actinomycosis presented with endobronchial involvement. *Respiratory medicine case reports*. 2019; **28**, 100930.
- 629) Palmitessa, V., Cuppone, R., Monno, R., Fumarola, L., & Lippolis, A. A case report of esophageal actinomycosis in an immunocompetent patient and review of the literature. *New Microbiol*. 2019; **42**(1), 55-60.
- 630) Puspitasari, T., Ratunanda, S. S., Poerwana, R. A., & Wijana, W. Penatalaksanaan Aktinomikosis Oroservikofasial dengan Berbagai Faktor Risiko. *Jurnal Sistem Kesehatan*. 2020; **5**(4).
- 631) Regino, C. A., Navarro, K., García, A., Bacca, J., & Uribe, N. Abdominopelvic actinomycosis mimicking a malignant ovarian neoplasia: case report and review of literature. *Cureus*. 2020; **12**(12).
- 632) Rojas, S. A., Ortega, J. G. O., Quintanilla, M. P., & Cabrejos, R. D. I. Abdominal actinomycosis: differential diagnosis of ovarian malignant tumor. *Anales Médicos de la Asociación Médica del Centro Médico ABC*. 2019; **64**(2), 144-148.

- 633) Rousseau C, Piroth L, Pernin V, Cassuto E, Etienne I, Jeribi A, Kamar N, Pouteil-Noble C, Mousson C. Actinomycosis: An infrequent disease in renal transplant recipients?. *Transplant Infectious Disease*. 2018;**20**(6):e12970.
- 634) Sandoval-Mallma, E., & Caballero-Silva, J. Actinomicosis diseminada en un paciente inmunocompetente: Reporte de caso. *Horizonte Médico (Lima)*. 2019; **19**(3), 89-95.
- 635) Sawtelle AL, Chappell NP, Miller CR. *Actinomyces*-related tubo-ovarian abscess in a poorly controlled type II diabetic with a copper intrauterine device. *Military Medicine*. 2017;**182** (3), e1874-e1876.
- 636) Scheifer C, Bor C, Debray MP, Chanson N, Chauveheid MP, Gombert B, Papo T, Sacré K. A 27-Year-Old Man With Multiple Cavitory Lung Lesions. *Chest*. 2018; **155**(2): e43- e46.
- 637) Sousa DE, Wilson TM, Machado M, Pereira AA, Costa GR, Dutra V, Castro MB. Pulmonary actinomycosis in a free-living black-tufted marmoset (*Callithrix penicillata*). *Primates*. 2019 Jan 12:1-5. <https://link.springer.com/article/10.1007/s10329-018-00713-w>
- 638) Stájer, A., Ibrahim, B., Gajdács, M., Urbán, E., & Baráth, Z. Diagnosis and management of cervicofacial actinomycosis: lessons from two distinct clinical cases. *Antibiotics*. 2020; **9**(4), 139.
- 639) Stájer, A., Ibrahim, B., Gajdács, M., Baráth, Z., & Urbán, E. A cervicofaciális actinomycosisok jellemzői és korszerű diagnosztikája: összefoglaló az irodalmi adatok alapján. *Fogorvosi Szemle*. 2020; **113**(3), 96-104.
- 640) Sugrue, I., O'Connor, P. M., Hill, C., Stanton, C., & Ross, R. P. *Actinomyces* produces defensin-like bacteriocins (actifensins) with a highly degenerate structure and broad antimicrobial activity. *Journal of bacteriology*. 2020; **202**(4).
- 641) Wang, L., Zhang, H., Di Wu, M. F., Yang, P., Hu, X., Tattevin, P., ... & Qiu, C. Pulmonary lesions associated with sputum culture-positive actinomycetes: Report of one case. *Annals of translational medicine*. 2019; **7**(23).
- 642) Zayed, Y., Osterholzer, D., Armstrong, E., Azher, Q., & Bachuwa, G. Pulmonary actinomycosis and tracheal squamous cell carcinoma: A rare simultaneous presentation of both in a single patient. *Respiratory medicine case reports*. 2019; **27**, 100855.
- 643) Zhang M, Zhang XY, Chen YB. Primary pulmonary actinomycosis: a retrospective analysis of 145 cases in mainland China. *The International Journal of Tuberculosis and Lung Disease*. 2017; **21**(7):825-831.
- 644) Zhang AN, Guss D, Mohanty SR. Esophageal stricture caused by *Actinomyces* in a patient with no apparent predisposing factors. *Case reports in gastrointestinal medicine*. 2019; 2019. Article ID 7182976

**ЦИТИРАНА: 62А:** Kotsilkov K, Popova C, **Boyanova L**, Setchanova L , Mitov I. Comparison of culture method and real-time PCR for detection of putative periodontopathogenic bacteria in deep periodontal pockets. *Biotechnol. Biotechnol. Equip.* 2015; **DOI:** 10.1080/13102818.2015.1058188 [http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c\\_ntmko](http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c_ntmko) **Цитирана от:**

- 645) AL-Bdery, A. S. J., & Al-Yasseen, A. K. Genotypic and phenotypic detection of some virulence factors among *Porphyromonas gingivalis* related with periodontitis in Al-Najaf Al-Ashraf city, Iraq. *Plant Archives*. 2018; **18**(2), 2345-2353.
- 646) Al-Hamdoni, S. A. S., & Al-Rawi, A. M. M. Assessment the Effect of Some Reagents on the Planktonic Cells and Biofilms of Red Complex Periodontal Pathogens. *International Journal of Sciences: Basic and Applied Research (IJSBAR)*. 2020; **51**(2): 1-13.
- 647) Couper L, Swei A. Tick Microbiome Characterization by Next-Generation 16S rRNA Amplicon Sequencing. *JoVE (Journal of Visualized Experiments)*. 2018; **25**(138):e58239.
- 648) Hasriati, E., Anggani, H. S., Purbiati, M., & Bachtiar, E. W. Antibacterial effect of 0.2% chlorhexidine and 1% chitosan mouthwash on bacteria during orthodontic miniscrew use. *International Journal of Applied Pharmaceutics*. 2020; 8-12.
- 649) Jassim AL-Bdery AS, Al-Yasseen AK. Genotypic and phenotypic detection of some virulence factors among *Porphyromonas gingivalis* related with periodontitis in Al-Najaf al-Ashraf city, Iraq *Plant Archives*. 2018; **18**(2): 2345-2353.
- 650) Li, L. F., Wei, R., Liu, H. B., Jiang, B. G., Cui, X. M., Wei, W., ... & Hu, Y. L. Characterization of Microbial Communities in *Ixodes persulcatus* (Ixodida: Ixodidae), a Veterinary and Medical Important Tick Species in Northeastern China. *Journal of medical entomology*. 2020; **57**(4), 1270-1276.
- 651) Marín, M. J., Ambrosio, N., O'Connor, A., Herrera, D., Sanz, M., & Figuero, E. Validation of a multiplex qPCR assay for detection and quantification of *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis* and *Tannerella forsythia* in subgingival plaque samples. A comparison with anaerobic culture. *Archives of oral biology*. 2019; **102**, 199-204.
- 652) Nastych, O., Goncharuk-Khomyn, M., Foros, A., Cavalcanti, A., Yavuz, I., & Tsaryk, V. Usporedba parametara bakterijskog opterećenja u subgingivalnom plaku kod parodontitisa i periimplantitisa metodom RT-PCR. *Acta stomatologica Croatica*. 2020; **54**(1), 32-43.
- 653) Ng E, Byun R, Spahr A, Divnic-Resnik T. The efficacy of air polishing devices in supportive periodontal therapy: A systematic review and meta-analysis. *Quintessence International*. 2018;**49**(6):453-467.
- 654) Nwaokorie, F. O., & Ayanbadejo, P. O. Detection of Six Periodontopathogens in the Subgingival Plaque of Patients with Chronic Periodontitis in Lagos, Nigeria. *Nigerian Journal of Dental Research*. 2020; **5**(2), 145-154.
- 655) Pahumunto, N., Sophatha, B., Piwat, S., & Teanpaisan, R. Increasing salivary IgA and reducing *Streptococcus mutans* by probiotic *Lactobacillus paracasei* SD1: a double-blind, randomized, controlled study. *Journal of dental sciences*. 2019; **14**(2), 178-184.
- 656) Pawlaczyk-Kamieńska, T., Śniatała, R., Batura-Gabryel, H., Borysewicz-Lewicka, M., & Cofta, S. Periodontal status and subgingival biofilms in cystic fibrosis adults. *Polish journal of microbiology*. 2019; **68**(3), 377.
- 657) Shahi S, Vahed SZ, Fathi N, Sharifi S. Polymerase chain reaction (PCR)-based methods: Promising molecular tools in dentistry. *International journal of biological macromolecules*. 2018; **117**(1):983-992.
- 658) Tomás I, Regueira-Iglesias A, López M, Arias-Bujanda N, Novoa L, Balsa-Castro C, Tomás M. Quantification by qPCR of Pathobionts in Chronic Periodontitis: Development of Predictive Models of Disease Severity at Site-Specific Level. *Frontiers in microbiology*. 2017;**8**:1443.

- 659) Vakhitov D, Tuomisto S, Martiskainen M, Korhonen J, Pessi T, Salenius JP, Suominen V, Lehtimäki T, Karhunen PJ, Oksala N. Bacterial signatures in thrombus aspirates of patients with lower limb arterial and venous thrombosis. *Journal of vascular surgery*. 2017 Aug 26.
- 660) Zang X, Tang H, Jiao X, Huang J. Can a visual loop-mediated isothermal amplification assay stand out in different detection methods when monitoring *Campylobacter jejuni* from diverse sources of samples? *Food Control*. 2017; **75**: 220-227.
- ЦИТИРАНА: 63A:** Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. *APMIS*. 2015;**123**(10):887-94. **Цитирана от:**
- 661) Berglund, B., Hoang, N. T. B., Tärnberg, M., Le, N. K., Nilsson, M., Khu, D. T. K., ... & Hanberger, H. Molecular and phenotypic characterization of clinical isolates belonging to a KPC-2-producing strain of ST15 *Klebsiella pneumoniae* from a Vietnamese pediatric hospital. *Antimicrobial Resistance & Infection Control*. 2019; **8**(1), 1-8.
- 662) Chi, X., Berglund, B., Zou, H., Zheng, B., Börjesson, S., Ji, X., ... & Nilsson, L. E. Characterization of clinically relevant strains of extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* occurring in environmental sources in a rural area of China by using whole-genome sequencing. *Frontiers in microbiology*. 2019; **10**, 211.
- 663) Ferrari, C., Corbella, M., Gaiarsa, S., Comandatore, F., Scaltriti, E., Bandi, C., ... & Sasser, D. Multiple *Klebsiella pneumoniae* KPC clones contribute to an extended hospital outbreak. *Frontiers in microbiology*. 2019; **10**, 2767.
- 664) Flores C, Bianco K, de Filippis I, Clementino MM, & Romão CMC. Genetic relatedness of NDM-producing *Klebsiella pneumoniae* co-occurring VIM, KPC, and OXA-48 enzymes from surveillance cultures from an Intensive care unit. *Microbial Drug Resist.* 2020; **26**(10), 1219-1226.
- 665) Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant *Enterobacteriaceae*: a strategic road map for infection control. *Infect Control Hosp Epidemiol*. 2017; **38**(5):580-594.
- 666) Jones-Dias D, Manageiro V, Ferreira E, Barreiro P, Vieira L, Moura IB, Caniça M. Architecture of Class 1, 2, and 3 integrons from Gram negative bacteria recovered among fruits and vegetables. *Front Microbiol*. 2016;**7**:1400.
- 667) Kittinger C, Lipp M, Folli B, Kirschner A, Baumert R, Galler H, Grisold AJ, Luxner J, Weissenbacher M, Farnleitner AH, Zarfel G. Enterobacteriaceae isolated from the river Danube: antibiotic resistances, with a focus on the presence of ESBL and carbapenemases. *PLoS One*. 2016;**11**(11):e0165820.
- 668) Ku YH, Chuang YC, Chen CC, Lee MF, Yang YC, Tang HJ, Yu WL. *Klebsiella pneumoniae* isolates from meningitis: epidemiology, virulence and antibiotic resistance. *Scientific reports*. 2017;**7**(1):6634.
- 669) Lagacé-Wiens PR, Adam HJ, Poutanen S, Baxter MR, Denisuk AJ, Golden AR, ... & Zhanel GG. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007–16. *J Antimicrob Chemother*. 2019; **74**(Suppl 4), iv22-iv31.
- 670) Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing *Klebsiella pneumoniae*: epidemiology, genetic context, treatment options, and detection methods. *Front Microbiol*. 2016;**7**:895.
- 671) Lomonaco S, Crawford MA, Lascols C, Timme RE, Anderson K, Hodge DR, Fisher DJ, Pillai SP, Morse SA, Khan E, Hughes MA. Resistome of carbapenem- and colistin-resistant *Klebsiella pneumoniae* clinical isolates. *PloS one*. 2018;**13**(6):e0198526.
- 672) Loucif L, Kassah-Laouar A, Saidi M, Messala A, Chelaghma W, Rolain JM. Outbreak of OXA-48-producing *Klebsiella pneumoniae* involving a sequence type 101 clone in Batna university hospital, Algeria. *Antimicrob Agents Chemother*. 2016;**60**(12):7494-7497.
- 673) Machuca J, Lopez-Cerero L, Fernandez-Cuenca F, Mora-Navas L, Mediavilla-Gradolph C, López-Rodríguez I, Pascual Á. OXA-48-like-producing *Klebsiella pneumoniae* in southern Spain in 2014–2015. *Antimicrob Agents Chemother*. 2019; **63**(1):e01396-18.
- 674) Martins WM, Nicolas MF, Yu Y, Li M, Dantas P, Sands K, ... & Andrey DO. Clinical and Molecular Description of a high-copy IncQ1 KPC-2 plasmid harbored by the international ST15 *Klebsiella pneumoniae* Clone. *Msphere*. 2020; **5**(5).
- 675) Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Evolution and epidemiology of multidrug-resistant *Klebsiella pneumoniae* in the United Kingdom and Ireland. *MBio*. 2017;**8**(1). pii: e01976-16.
- 676) Oteo J, Pérez-Vázquez M, Bautista V, Ortega A, Zamarrón P, Saez D, Fernández-Romero S, Lara N, Ramiro R, Aracil B, Campos J; Spanish Antibiotic Resistance Surveillance Program Collaborating Group. The spread of KPC-producing *Enterobacteriaceae* in Spain: WGS analysis of the emerging high-risk clones of *Klebsiella pneumoniae* ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. *J Antimicrob Chemother*. 2016;**71**(12):3392-3399.
- 677) Su S, Zhang J, Zhao Y, Yu L, Wang Y, Wang Y, ... & Zhang X. Outbreak of KPC-2 carbapenem-resistant *Klebsiella pneumoniae* ST76 and carbapenem-resistant K2 hypervirulent *Klebsiella pneumoniae* ST375 strains in Northeast China: molecular and virulent characteristics. *BMC Infectious Diseases*. 2020; **20**(1): 1-14.
- 678) Sui W, Zhou H, Du P, Wang L, Qin T, Wang M, Ren H, Huang Y, Hou J, Chen C, Lu X. Whole genome sequence revealed the fine transmission map of carbapenem-resistant *Klebsiella pneumoniae* isolates within a nosocomial outbreak. *Antimicrobial Resistance & Infection Control*. 2018;**7**(1):70.
- 679) Tekeli A, Dolapci İ, Evren E, Oguzman E, Karahan ZC. Characterization of *Klebsiella pneumoniae* coproducing KPC and NDM-1 Carbapenemases from Turkey. *Microbial Drug Resist.* 2020; **26**(2), 118-125.
- 680) Tokajian S, Moghnieh R, Salloum T, Arabaghian H, Alousi S, Moussa J, Abboud E, Youssef S, Husni R. Extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* in wastewaters and refugee camp in Lebanon. *Future microbiology*. 2018;**13**(1):81-95.
- 681) Xiao SZ, Wang S, Wu WM, Zhao SY, Gu FF, Ni YX, Guo XK, Qu JM, Han LZ. The resistance phenotype and molecular epidemiology of *Klebsiella pneumoniae* in bloodstream infections in Shanghai, China, 2012-2015. *Front Microbiol*. 2017; **8**:250.
- 682) Yousfi H, Hadjadj L, Dandachi I, Lalaoui R, Merah A, Amoura K, ... & Rolain JM. Colistin- and carbapenem-resistant *Klebsiella pneumoniae* clinical isolates: Algeria. *Microbial Drug Resist.* 2019; **25**(2): 258-263.

**ЦИТИРАНА: 65A: Boyanova L, Evstatiev I, Gergova G, Yaneva P, Mitov I. Linezolid susceptibility in *Helicobacter pylori*, including strains with multidrug resistance. Int J Antimicrob Agents. 2015;46(6):703-706. Цитирана от:**

- 683) Arévalo A, Otero WA, Trespalacios AA. *Helicobacter pylori*: resistencia múltiple en pacientes de Bogotá-Colombia. Biomédica. 2019;39.
- 684) Bayati S, Alebouyeh M, Amirmozafari N, Ebrahimi Daryani N, Talebi M, Zali MR. Histological changes in refractory *Helicobacter pylori* infection and its relationship with increased levels of resistance to antibiotics and therapeutic regimens: one-year follow-up. APMIS. 2020; 128(1), 25-34.
- 685) Goudarzi M, Heidary M, Azad M, Fazeli M, Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in *Helicobacter pylori* isolates from patients. Gastroenterol Hepatol Bed Bench. 2016;9(Suppl1):S47-S52.
- 686) Goudarzi M, Seyedjavadi SS, Fazeli M, Roshani M, Azad M, Heidary M, Navidinia M, Goudarzi H. Identification of a novel cassette array in integron-bearing *Helicobacter pylori* strains isolated from Iranian Patients. Asian Pac J Cancer Pr. 2016; 17:3309-3315.
- 687) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-82.
- 688) Shi J, Jiang Y, Zhao Y. Promising in vitro and in vivo inhibition of multidrug-resistant *Helicobacter pylori* by linezolid and novel oxazolidinone analogues. J Glob Antimicrob Resist. 2016;7:106-109.
- 689) Tang Q, Zhao Y, Xu B, Gong P, Wang D. An Update on the Structure of Oxazolidinone Analogs and a Comparison with Linezolid in terms of in vitro and intracellular efficacy against clinically relevant bacterial species. Japanese journal of infectious diseases. 2017;70(6):678-681.
- 690) Zhang S, Huang J, Xie X, He Y, Mo F, Luo Z. Quercetin from *Polygonum capitatum* protects against gastric inflammation and apoptosis associated with *Helicobacter pylori* infection by affecting the levels of p38MAPK, BCL-2 and BAX. Molecules. 2017;22(5):744. doi: 10.3390/molecules22050744.

**ЦИТИРАНА: 66A: Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;48(1):56-62. Цитирана от:**

- 691) Alarcón T, Urruzuno P, Martínez MJ, Domingo D, Llorca L, Correa A, López-Brea M. Antimicrobial susceptibility of 6 antimicrobial agents in *Helicobacter pylori* clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enferm Infecc Microbiol Clin. 2017; 35(5):278-282..
- 692) Alba C, Blanco A, Alarcón T. Antibiotic resistance in *Helicobacter pylori*. Current opinion in infectious diseases. 2017; 30(5):489-497.
- 693) Alhammad MA, Hadir EK, Hamed Y. Clarithromycin resistance and genetic pattern Of *Helicobacter pylori* in a group of patients with peptic ulcer disease in Alexandria, Egypt. International Journal of Scientific & Technology Research. 2019; 8:3-5.
- 694) Bedoya-Gómez IJ, Alvarez-Aldana A, Moncayo-Ortiz JJ, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the antimicrobial resistance rates of *Helicobacter pylori* ten years later in the Western central region, Colombia. Digestive Diseases. 2020; 38(3): 196-203.
- 695) Biernat MM, Bińkowska A, Łaczmański Ł, Biernat P, Krzyżek P, Gościński G. Phenotypic and genotypic analysis of resistant *Helicobacter pylori* strains isolated from children with gastrointestinal diseases. Diagnostics. 2020; 10(10): 759.
- 696) Byambajav TO, Bira N, Chojamts G, Davaadorj D, Gantuya B, Sarantuya T, ... & Oyuntsetseg K. Initial trials with susceptibility-based and empiric anti-*H. pylori* therapies in Mongolia. Frontiers in pharmacology. 2019; 10: 394.
- 697) Dang NQH, Ha TMT, Nguyen ST, Le ND K, Nguyen TMT, Nguyen TH, Pham TTH. High rates of clarithromycin and levofloxacin resistance of *Helicobacter pylori* in patients with chronic gastritis in the south east area of Vietnam. J Glob Antimicrob Resist. 2020; 22:620-624.
- 698) Dekhlich N, Ivanchik N, Kozlov R, Alimov A, Steshits A, Kirsov P, Pandav K. Dynamics of antimicrobial resistance of *Helicobacter pylori* isolates in the Smolensk region of Russian Federation. Helicobacter. 2018;23(6):e12545.
- 699) Famouri F, Emadoleslami MS, Riahi R, Saneian H, Nasri P. The sensitivity of *H. pylori* in gastric tissue samples of children and adolescents to various antibiotics in center of Iran. International Journal of Pediatrics. 2018;6(12):8685-96.
- 700) García G, Betancourt E, Corrales R. Analisis de resonancia de plasmon superficial en *Helicobacter pylori*. Investigación clínica. 2020; 61(1): 525-530.
- 701) Gudra, D., Pupola, D., Skenders, G., Leja, M., Radovica-Spalvina, I., Gorskis, H., ... & Fridmanis, D. Lack of significant differences between gastrointestinal tract microbial population structure of *Helicobacter pylori*-infected subjects before and 2 years after a single eradication event. Helicobacter. 2020; 25(5), e12748.
- 702) Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for *Helicobacter pylori* eradication treatment. PloS one. 2018;13(1):e0189888.
- 703) Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of *Helicobacter pylori* infection-the MaastrichtV/Florence Consensus Report. Gut. 2017; 66(1):6-30.
- 704) Mihai, C., Mihai, B. M., Dranga, M., Cardoneanu, A., & Prelipcean, C. C. Lactobacillus reuteri—an alternative in the first-line of *Helicobacter pylori* eradication. Farmacia. 2019; 67(5), 871-876.
- 705) Ni, C., & Jiang, D. Three-Dimensional Numerical Simulation of Particle Focusing and Separation in Viscoelastic Fluids. Micromachines. 2020; 11(10), 908.
- 706) Talebi Bezmin Abadi A. *Helicobacter pylori* treatment: New perspectives using current experience. J Glob Antimicrob Resist. 2017;8:123-130.
- 707) Xu, G., Shi, Y., Zhang, X., (...), Zhang, N., Li, Z. Correlation Analysis of Pathways and Operons of *Helicobacter pylori* Resistance Genes Using Bibliometrics. Clinical Laboratory. 2019; 65(5): 673-683.

- 708) Yang, L., Zhang, J., Xu, J., Wei, X., Yang, J., Liu, Y., ... & Gai, Z. *Helicobacter pylori* infection aggravates dysbiosis of gut microbiome in children with gastritis. *Frontiers in cellular and infection microbiology*. 2019; 9, 375.
- 709) Дехнич НН, Иванчик НВ, Козлов РС, Алимов АВ, Стешиц АС, Кирсов ПП. Распространенность антимикробной резистентности *Helicobacter pylori* в Смоленской области в 2015-2017 гг. *Вестник Смоленской государственной медицинской академии*. 2018; **17**(1).
- 710) Дехнич НН, Иванчик НВ, Козлов РС, Алимов АВ, Стешиц АС, Кирсов ПП. Антибиотикорезистентность *Helicobacter pylori* в Смоленске. *КМАХ*, 2018; **20**(1):42-48.
- ЦИТИРАНА: 67А: Boyanova L, Markovska R, Yordanov D, Gergova G, Mitov I. Clarithromycin resistance mutations in *Helicobacter pylori* in association with virulence factors and antibiotic susceptibility of the strains. *Microb Drug Resist*. 2016; **22**(3):227-232. Цитирана от:**
- 711) Akramovich AA, Akbarovna DD, Utkurovna TS. Study of mutations in the 23 s rRNA gene are associated with clarithromycin resistance in *H. pylori*. *European science review*. 2018; №. 9-10-1.
- 712) Alba C, Blanco A, Alarcón T. Antibiotic resistance in *Helicobacter pylori*. *Current opinion in infectious diseases*. 2017; **30**(5):489-497.
- 713) Baroni MR, Bucci P, Giani RN, Giusti A, Tedeschi FA, Salvatierra E, Barbaglia Y, Jimenez F, Zalazar FE. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in *Helicobacter pylori*. *Revista Argentina de microbiologia*. 2018; **50**(4):359-64.
- 714) Bastia F. Method for determining *Helicobacter pylori*. 2016 . <https://patents.google.com/patent/WO2017134627A1/fi>
- 715) Brennan DE, Dowd C, O'Morain C, McNamara D, Smith SM. Can bacterial virulence factors predict antibiotic resistant *Helicobacter pylori* infection? *World J Gastroenterol*. 2018; **24**(9):971.
- 716) Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line *Helicobacter pylori* eradication: A comparative, open trial. *World J Gastroenterol*. 2019; **25**(46): 6743.
- 717) Eed EM, Hawash YA, Khalifa AS, (...), Ismail KA, Shehab-Eldeen SA. Molecular diagnosis of *Helicobacter pylori* antibiotic resistance in the Taif region, Saudi Arabia. *Microbiology and Immunology*. 2019; 63(6): 199-205.
- 718) Gong Y, Yuan Y. Resistance mechanisms of *Helicobacter pylori* and its dual target precise therapy. *Crit Rev Microbiol*. 2018; **44**(3):371-92.
- 719) Haddadi, M. H., Negahdari, B., Asadolahi, R., & Bazargani, A. *Helicobacter pylori* antibiotic resistance and correlation with cagA motifs and homB gene. *Postgraduate medicine*. 2020; 132(6), 512-520.
- 720) Hanafiah, A., Binmaeil, H., Ali, R. A. R., Rose, I. M., & Lopes, B. S. Molecular characterization and prevalence of antibiotic resistance in *Helicobacter pylori* isolates in Kuala Lumpur, Malaysia. *Infection and drug resistance*. 2019; 12, 3051.
- 721) Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among *H. pylori* infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. *BMC infectious diseases*. 2019; 19(1), 1-7.
- 722) Kalach N, Bontems P, Raymond J. *Helicobacter pylori* infection in children. *Helicobacter*. 2017; **22**(S1).
- 723) Khashei R, Dara M, Bazargani A, Bagheri Lankarani K, Taghavi A, Moeini M, Dehghani B, Sohrabi M. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian *Helicobacter pylori* clinical isolates. *APMIS*. 2016; **124**(9):787-793.
- 724) Kim, S. Y., Park, J. M., Lim, C. H., Lee, H. A., Shin, G. Y., Choe, Y., ... & Choi, M. G. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for *Helicobacter pylori*. *Gut and Liver*. 2020.
- 725) Kwon YH, Jeon SW, Nam SY, Lee HS, Park J. H. Efficacy of tailored therapy for *Helicobacter pylori* eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. *Helicobacter*. 2019; 24(4): e12585.
- 726) Matta AJ, Zambrano DC, Pazos AJ. Punctual mutations in 23S rRNA gene of clarithromycin-resistant *Helicobacter pylori* in Colombian populations. *World J Gastroenterol*. 2018; **24**(14):1531.
- 727) Ranjbar R, Farsani FY, Dehkordi FS. Phenotypic analysis of antibiotic resistance and genotypic study of the *vacA*, *cagA*, *iceA*, *oipA* and *babA* genotypes of the *Helicobacter pylori* strains isolated from raw milk. *Antimicrobial Resistance & Infection Control*. 2018; **7**(1):115.
- 728) Wang D, Li Q, Gong Y, Yuan Y. The association between *vacA* or *cagA* status and eradication outcome of *Helicobacter pylori* infection: A meta-analysis. *PLoS One*. 2017; **12**(5):e0177455.
- 729) Zerbetto De Palma G, Mendiondo N, Wonaga A, Viola L, Ibarra D, Campitelli E, Salim N, Corti R, Goldman C, Catalano M. Occurrence of mutations in the antimicrobial target genes related to levofloxacin, clarithromycin, and amoxicillin resistance in *Helicobacter pylori* isolates from Buenos Aires city. *Microb Drug Resist*. 2017; **23**(3):351-358.
- ЦИТИРАНА: 68А: Boyanova L, Ilieva J, Gergova G, Mitov I. Levofloxacin susceptibility testing against *Helicobacter pylori*: evaluation of a modified disk diffusion method compared to E test. *Diagn Microbiol Infect Dis*. 2016; **84**(1):55-56. Цитирана от:**
- 730) Alba C, Blanco A, Alarcón T. Antibiotic resistance in *Helicobacter pylori*. *Current opinion in infectious diseases*. 2017; **30**(5):489-97.
- 731) Ganta D, Chavez J, Lopez A. Disposable Chronoamperometric Sensor Coated with Silver Nanowires for Detecting Levofloxacin. *Analytical Letters*. 2020; **53**(12), 1992-2001.
- 732) Liu C, Xie D, Liu P, Xie S, Wang S, Cheng F, Zhang M, Wang L. Voltammetric determination of levofloxacin using silver nanoparticles deposited on a thin nickel oxide porous film. *Microchimica Acta*. 2019; **186**(1):21.
- 733) Parra-Sepúlveda C, Merino JS, Sáez-Carrillo K, González C, García-Cancino A. Antibiotic resistance surveillance of *Helicobacter pylori* at the Biobío region (Chile) in a decade. *Arquivos de gastroenterologia*. 2019; **56**(4), 361-366.
- 734) Yahya, E., & Abdulsamad, M. A. In-vitro Antibacterial Activity of Carbopol-Essential Oils hydrogels. *Journal of Applied Science & Process Engineering*. 2020; **7**(2), 564-571.



**ЦИТИРАНА:69A: Boyanova L**, Evstatiev I, Yordanov D, Markovska R, Mitov I. Three unsuccessful treatments of *Helicobacter pylori* infection by a highly virulent strain with quadruple antibiotic resistance. *Folia Microbiol (Praha)*. 2016; **61**(4):307-310. **Цитирана от:**

- 735) González A, Fillat MF, Lanas Á. Transcriptional regulators: valuable targets for novel antibacterial strategies. *Future medicinal chemistry*. 2018;**10**(5):541-60.
- 736) González A, Salillas S, Velázquez-Campoy A, Angarica VE, Fillat MF, Sancho J, Lanas Á. Identifying potential novel drugs against *Helicobacter pylori* by targeting the essential response regulator HsrA. *Scientific reports*. 2019; **9**(1): 1-13.
- 737) Moghadam MT, Chegini Z, Norouzi A, Dosari AS, Shariati A. Three-decade failure to eradication of refractory *Helicobacter pylori* infection and recent efforts to eradicate the infection. *Curr Pharm Biotechnol*. 2020 Aug 6.
- 738) Rezaei S, Abadi ATB, Mobarez AM. Metronidazole-resistant *Helicobacter pylori* isolates without *rdxA* mutations obtained from Iranian dyspeptic patients. *New microbes and new infections*. 2020; **34**:100636.

**ЦИТИРАНА 70A: Boyanova L**, Markovska R, Mitov I. Review article: virulence arsenal of the most pathogenic species among the Gram positive anaerobic cocci, *Finegoldia magna*. *Anaerobe*. 2016;**42**:145-151. **Цитирана от:**

- 739) Alsubaie S, Dolgum S, Binkhamis K, Alweijri I, Bugshan A, Alzamil F. *Finegoldia magna* causing intramedullary thoracic spinal cord abscess in an infant. *Anaerobe*. 2019; **56**, 57-60.
- 740) Brüggemann H, Jensen A, Nazipi S, Aslan H, Meyer RL, Poehlein A, Brzuszkiewicz E, Al-Zeer MA, Brinkmann V, Söderquist B. Pan-genome analysis of the genus *Finegoldia* identifies two distinct clades, strain-specific heterogeneity, and putative virulence factors. *Scientific reports*. 2018;**8**(1):266.
- 741) Chien S, Gorman D, Koutsogiannidis CP, Ravishankar R, Kamath G, Zamvar V. The novel use of oral antibiotic monotherapy in prosthetic valve endocarditis caused by *Finegoldia magna*: a case study. *Journal of cardiothoracic surgery*. 2019; **14**(1), 1-5.
- 742) Corvec S, Seiler E, Wang L, Moreno MG, Trampuz A. Characterization of medical relevant anaerobic microorganisms by isothermal microcalorimetry. *Anaerobe*. 2020; **66**: 102282.
- 743) Dahal N, Nowitzke J, Eis A, Popa I. Binding-induced stabilization measured on the same molecular protein substrate using single-molecule magnetic tweezers and heterocovalent attachments. *The Journal of Physical Chemistry B*, 2020; **124**(16), 3283-3290.
- 744) De Donder L, Uyttebroek O, Van Cleven S, Berrevoet F. A subcutaneous infection mimicking necrotizing fasciitis due to *Butyrivibrio fibrisolens*. *Acta Chirurgica Belgica*. 2020; **120**(6), 425-428.
- 745) Dehkordi SH, Osorio G. Case of pacemaker pocket infection caused by *Finegoldia magna*. *Anaerobe*. 2017;**47**:135-136.
- 746) González Ruiz L, Flores-Terry MÁ, Franco-Muñoz M, García-Arpa M. A common skin infection due to a rare microorganism | [Una infección cutánea frecuente por un germen poco común]. *Piel*, 2018; **34**(5)
- 747) Guérin, F., Lachaal, S., Auzou, M., Le Brun, C., Barraud, O., Decousser, J. W., ... & Cattoir, V. Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in *Finegoldia magna* clinical isolates. *Anaerobe*. 2020; **64**, 102220.
- 748) Söderquist B, Björklund S, Hellmark B, Jensen A, Brüggemann H. *Finegoldia magna* isolated from orthopedic joint implant-associated infections. *Journal of clinical microbiology*. 2017;**55**(11):3283-3291.
- 749) Szymczak, Z., Michalski, P., Dudek, J., Plusa, T., Baranowski, P., Burczy, M., & Burczy, J. A. C. E. K. *Finegoldia magna* the cause of hip revision surgery-a two case report. *Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego*. 2019; **47**(279), 99-102.

**ЦИТИРАНА 72A: Markovska R**, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Kaneva R, Mitev V, Mitov I. Isolation of *Escherichia coli* ST131 producing KPC-2 in Bulgaria. *Infect Dis (Lond)*. 2017; **49**(5): 429-431. **Цитирана от:**

- 750) Du X, Huang J, Wang D, Zhu Y, Lv H, Li X. Whole genome sequence of an *Escherichia coli* ST131 strain isolated from a patient with bloodstream infection in China co-harboring *bla*KPC-2, *bla*CTX-M-3, *bla*CTX-M-14, *qnrS1*, *aac*(3)-IIa and *aac*(6')-Ib-cr genes. *J Glob Antimicrob Resist* 2020; **22**: 700-702.
- 751) Yair Y, Gophna U. Pandemic bacteremic *Escherichia coli* strains: Evolution and emergence of drug-resistant pathogens. *Current Topics in Microbiology and Immunology*. 2018; **416**: 163-180.

**ЦИТИРАНА 73A: Boyanova L**. Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. *Anaerobe*. 2017; **44**:13-19. **Цитирана от:**

- 752) AbdElnabi NMM, Omran NF, Ali AA, Omara FA. Modelling a smart non-invasive adrenaline sensor. *International Journal of Sensor Networks* 2020; **32**(2): 96-106.
- 753) Anderson CJ, Kendall MM. *Salmonella enterica* serovar *Typhimurium* strategies for host adaptation. *Frontiers in microbiology*. 2017;**8**:1983.
- 754) Alauzet C, Cunat L, Wack M, Lanfumey L, Legrand-Frossi C, Lozniewski A, Agrinier N, Cailliez-Grimal C, Fripiat JP. Impact of a model used to simulate chronic socio-environmental stressors encountered during spaceflight on murine intestinal microbiota. *International Journal of Molecular Sciences*. 2020; **21**(21):7863.
- 755) Beitollahi H, Dourandish Z, Tajik S, Ganjali MR, Norouzi P, Faridbod F. Application of graphite screen printed electrode modified with dysprosium tungstate nanoparticles in voltammetric determination of epinephrine in the presence of acetylcholine. *Journal of Rare Earths*. 2018; **36**(7):750-7.
- 756) Beitollahi H, Tajik S, Aflatoonian MR, Makarem A. NiFe<sub>2</sub>O<sub>4</sub> nanoparticles modified screen printed electrode for simultaneous determination of serotonin and norepinephrine. *Analytical and Bioanalytical Electrochemistry*. 2018; **10**(11): 1399-1413.
- 757) Borrel V, Thomas P, Catovic C, Racine PJ, Konto-Ghiorgi Y, Lefevre L, Duclairoir-Poc C, Zouboulis CC, Feuilloley MG. Acne and stress: impact of catecholamines on *Cutibacterium acnes*. *Frontiers in medicine*. 2019;**6**:155.
- 758) Cambrone M, Nilly F, Mesguida O, Boukerb AM, Racine PJ, Baccouri O, Borrel V, Martel J, Fécamp F, Knowlton R, Zimmermann K. Influence of catecholamines (epinephrine/norepinephrine) on biofilm formation and adhesion in pathogenic and probiotic strains of *Enterococcus faecalis*. *Frontiers in microbiology*. 2020;**11**:1501.

- 759) Chekabab SM, Rehman MA, Yin X, Carrillo C, Mondor M, Diarra MS. Growth of *Salmonella enterica* Serovars *Typhimurium* and *Enteritidis* in iron-poor media and in meat: Role of catecholate and hydroxamate siderophore transporters. *Journal of food protection*. 2019;**82**(4):548-60.
  - 760) Danilova ND, Solovyeva TV, Mart'yanov SV, Zhurina MV, Gannesen AV. Stimulatory effect of epinephrine on biofilms of *Micrococcus luteus* C01. *Microbiology*. 2020;**89**(4):493-497.
  - 761) de Lima PO, Nani BD, Almeida B, (...), Franz-Montan M, Cogo-Müller K. Stress-related salivary proteins affect the production of volatile sulfur compounds by oral bacteria. *Oral Diseases*. 2018; **24**(7):1358-1366.
  - 762) Dubar M, Frippiat JP, Remen T, Boufenzar A, Alauzet C, Baumann C, Gibot S, Bisson C. Comparison of sTREM-1 and associated periodontal and bacterial factors before/after periodontal therapy, and impact of psychosocial factors. *Journal of Clinical Periodontology*. 2020; **47**(9):1064-78.
  - 763) Hampelska K, Jaworska MM, Babalska ZŁ, Karpiński TM. The role of oral microbiota in intra-oral halitosis. *Journal of Clinical Medicine*. 2020; **9**(8):2484.
  - 764) Hampl R, Bičková M, Stárka L. Gut microbiome and brain | [Střevní mikrobiota a mozek] *Diabetologie Metabolismus Endokrinologie Vyziva* 2019; **22**(1): 43-48.
  - 765) Harrold D, Saunders R, Bailey J. Dietary putrescine supplementation reduces faecal abundance of *Clostridium perfringens* and markers of inflammation in captive azure-winged magpies. *Journal of Zoo and Aquarium Research*. 2020;**8**(2):114-23.
  - 766) Horn N, Bhunia AK Food-associated stress primes foodborne pathogens for the gastrointestinal phase of infection. *Frontiers in Microbiology*. 2018; **9**(AUG),1962.
  - 767) Huang X, Le W, Chen Q, Chen J, Zhu Y, Shi D, Chen B, Cui Z. Suppression of the innate cancer-killing activity in human granulocytes by stress reaction as a possible mechanism for affecting cancer development. *Stress*. 2020;**23**(1):87-96.
  - 768) Jumina J, Harizal H. Dermatologic toxicities and biological activities of chromium. intrace metals in the environment-new approaches and recent advances 2019 Dec 3. IntechOpen.
  - 769) chandra HD, M, Kumara Swamy, BE. Development of electrochemical sensor for adrenaline at poly (allura red) modified carbon paste electrode: A voltammetric study *Chemical Data Collections* 2020; **28**:100447
  - 770) Memmert S, Damanaki A, Nogueira AV, Nokhbehshaim M, Götz W, Cirelli JA, Rath-Deschner B, Jäger A, Deschner J. Regulation of tyrosine hydroxylase in periodontal fibroblasts and tissues by obesity-associated stimuli. *Cell and tissue research*. 2018 Oct 25:1-0.
  - 771) Purnamasari KD, Rohita T, Zen DN, Ningrum WM. The effect of deep breathing exercises on menstrual pain perception in adolescents with primary dysmenorrhea. *Pertanika Journal of Science and Technology*. 2020; **28**(2), pp. 649-657
  - 772) Safaei M, Beitollahi H, Shishehbore MR. Synthesis and characterization of NiFe<sub>2</sub>O<sub>4</sub> nanoparticles using the hydrothermal method as magnetic catalysts for electrochemical detection of norepinephrine in the presence of folic acid. *Journal of the Chinese Chemical Society*. 2019;**66**(12):1597-603.
  - 773) Sarkodie EK, Zhou S, Baidoo SA, Chu W. Influences of stress hormones on microbial infections. *Microbial pathogenesis*. 2019;**131**:270-6.
  - 774) Sviridova AA, Kabaeva AR, Rogovskii VS, (...), Melnikov MV, Boyko AN. Norepinephrine and intestinal microbiome in the early stages of demyelination: Clinical-immunological parallels. *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*. 2019; **119**(10): 28-34.
  - 775) Swamy BK. Development of electrochemical sensor for adrenaline at poly (allura red) modified carbon paste electrode: A voltammetric study. *Chemical Data Collections*. 2020;**28**:100447.
  - 776) Van Riet, N., & Luycx, B. Novel way of promoting and maintaining gut health in pro-athletes. Whitepaper 4Gold [https://4gold.eu/wp-content/uploads/2019/08/whitepaper-gut-health\\_4gold.pdf](https://4gold.eu/wp-content/uploads/2019/08/whitepaper-gut-health_4gold.pdf)
  - 777) Volgers C, Savelkoul PH, Stassen FR. Gram-negative bacterial membrane vesicle release in response to the host-environment: different threats, same trick?. *Crit Rev Microbiol*. 2017; **24**:1-6. DOI: 10.1080/1040841X.2017.1353949
  - 778) Wang F, Tang Y. The Role of monoamine system in core affects and basic emotions. *Arch Neurol & Neurosci*. 2019; **3**(1):. ANN.MS.ID.000553. <https://irispublishers.com/ann/fulltext/the-role-of-monoamine-system-in-core-affects-and-basic-emotions.ID.000553.php>
  - 779) Werbner M, Barshesht Y, Werbner N, Zigdon M, Averbuch I, Ziv O, Brant B, Elliott E, Gelberg S, Titelbaum M, Koren O. Social-stress-responsive microbiota induces stimulation of self-reactive effector T helper cells. *Msystems*. 2019;**4**(4).
  - 780) Zschocke AK. Микробиом: Worauf Sie bei Ihren Patienten achten sollten. *Osteopathische Medizin*. 2017; **18** (2): 36–39.
  - 781) Горобец CM, Романенко ИГ, Бобкова СА, Джерелей АА, Крючков ДЮ, Горобец ОВ. Факторы риска развития галитоза (обзор). *Крымский терапевтический журнал*. 2017;**3**:13-18
  - 782) Свиридова АА, Кабаева АР, Роговский ВС, Кожиева МХ, Мельников МВ, Бойко АН. Норадреналин и микробиом кишечника на ранних стадиях демиелинизирующего процесса: клиничко-иммунологические параллели. *Журнал неврологии и психиатрии им. СС Корсакова. Спецвыпуски*. 2019;**119**(10):28-34.
- ЦИТИРАНА:74А:** Yordanov D, **Boyanova L**, Markovska RD, Ilieva J, Andreev N, Gergova G, Mitov IG. Influence of dietary factors on *Helicobacter pylori* and CagA seroprevalence in Bulgaria. *Gastroenterol Res Pract*. 2017;**2017**: Article ID 9212143, doi:10.1155/2017/9212143 <https://www.hindawi.com/journals/grp/2017/9212143/> **Цитирана от:**
- 783) El Kady, H. Screening for *Helicobacter pylori* Infection among Asymptomatic University Students in Alexandria, Egypt, Using Non Invasive Laboratory Techniques. *Int. J. Curr. Microbiol. App. Sci*. 2018; 20187(6), 2136-2155.
  - 784) Li Z, Ying X, Shan F, Ji J. The association of garlic with *Helicobacter pylori* infection and gastric cancer risk: A systematic review and meta-analysis. *Helicobacter*. 2018; **23**(5):e12532.
  - 785) Mentis, A. F. A., Boziki, M., Grigoriadis, N., & Papavassiliou, A. G. *Helicobacter pylori* infection and gastric cancer biology: tempering a double-edged sword. *Cellular and Molecular Life Sciences*. 2019; 76(13), 2477-2486.
  - 786) Monno, R., De Laurentiis, V., Trerotoli, P., Roselli, A. M., Ierardi, E., & Portincasa, P. *Helicobacter pylori* infection: association with dietary habits and socioeconomic conditions. *Clinics and research in hepatology and gastroenterology*. 2019; 43(5), 603-607.

- 787) Shalapour, S., & Karin, M. Cruel to be kind: epithelial, microbial, and immune cell interactions in gastrointestinal cancers. *Annual review of immunology*. 2020; 38, 649-671.
- 788) Sjomina O, Pavlova J, Niv Y, Leja M. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 2018; 23:e12514.
- 789) Zamani M, Ebrahimitabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of *Helicobacter pylori* infection. *Aliment Pharmacol Ther*. 2018; 47(7):868-876.
- ЦИТИРАНА: 75A. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. *Diagn Microbiol Infect Dis*. 2017; 88(3): 264-267.**
- 790) Deyi VYM, Burette A, Ntounda R, Elkilic O, Cadranet S, Bontems P, Hallin M. Update of primary *Helicobacter pylori* resistance to antimicrobials in Brussels, Belgium. *Diagn Microbiol Infect Dis*. 2019; 95(4): 114875.
- 791) Pateria P, Chin M, Goodheart R, McCullough C, Raby E, Robinson JO, Ingram PR. Increasing secondary resistance to fluoroquinolones amongst *Helicobacter pylori* in Western Australia. *Tasman Medical Journal*. 2020; 2(1): 15-19.
- 792) Yan T-L, Gao J-G, Wang J-H, (...), Lu C, Xu C-F. Current status of *Helicobacter pylori* eradication and risk factors for eradication failure. *World J Gastroenterol*. 2020; 26(32): 4846-4856.
- 793) Zendehdel, A., & Roham, M. Role of *Helicobacter pylori* infection in the manifestation of old age-related diseases. *Molecular genetics & genomic medicine*. 2020; 8(4), e1157.
- ЦИТИРАНА: 76A. Markovska R, Stoeva T, Boyanova L, Stankova P, Pencheva D, Keuleyan E, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Kaneva R, Mitov I. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing *K. pneumoniae* isolates. *Diagn Microbiol Infect Dis*. 2017; 89(4):310-313.**
- 794) Domokos J, Damjanova I, Kristof K, Ligeti B, Kocsis B, Szabo D. Multiple benefits of plasmid-mediated quinolone resistance determinants in *Klebsiella pneumoniae* ST11 high-risk clone and recently emerging ST307 clone. *Frontiers in microbiology*. 2019; 10, 157.
- 795) Horváth M, Kovács T, Koderivalappil S, Ábrahám H, Rákhely G, Schneider G. Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant *Klebsiella pneumoniae* isolates. *Scientific reports*. 2020; 10(1), 1-11.
- 796) Marianna, H., Tamás, K., Sarshad, K., Hajnalka, Á., Gábor, R., & Schneider, G. Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant *Klebsiella pneumoniae* isolates. *Scientific Reports (Nature Publisher Group)*. 2020; 10(1).
- 797) Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, ... & Pitout JDD. *Klebsiella pneumoniae* ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. *J Antimicrob Chemother*. 2020; 75(4), 896-902.
- 798) Wang Y, Luo C, Du P, Hu J, Zhao X, Mo D, ... & Zhou H. Genomic epidemiology of an outbreak of *Klebsiella pneumoniae* ST471 producing extended-spectrum  $\beta$ -Lactamases in a neonatal intensive care unit. *Infection and drug resistance*. 2020; 13, 1081.
- ЦИТИРАНА: 77A: Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. *Lett Appl Microbiol*. 2017; 65(6):469-474. doi: 10.1111/lam.12807**
- 799) Andreev, D.N., Maev, I.V., Samsonov, A.A. The importance of probiotics in optimizing the efficacy and safety of *Helicobacter pylori* infection eradication therapy *Meditinskiy Sovet* 2020(5):. 9-16.
- 800) Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. *Helicobacter pylori* in human health and disease: Mechanisms for local gastric and systemic effects. *World J Gastroenterol*. 2018; 24(28): 3071-3089.
- 801) Bruno G, Rocco G, Zaccari P, (...), Mascellino MT, Severi C. *Helicobacter pylori* infection and gastric dysbiosis: Can probiotics administration be useful to treat this condition? *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2018; 2018,6237239.
- 802) Ezequiel S, Zaily L, Ángela F. Estudio Micrográfico de Electrones en Indígenas *Lactobacillus delbrueckii* subsp. *fagos* de *Bulgaricus*. *Acta Microscopica* . 2020; 29(4):1927-1934.
- 803) Ji J, Yang H. Using probiotics as supplementation for *Helicobacter pylori* antibiotic therapy. *International journal of molecular sciences*, 2020, 21.3: 1136.
- 804) Layus BI.; Gerez CL.; Rodriguez AV. Antibacterial activity of *Lactobacillus plantarum* CRL 759 against methicillin-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Arabian Journal for Science and Engineering*, 2020, 45.6: 4503-4510.
- 805) Le VM, Asyakina LK, Velichkovitch NS, Kozlova OV, Milentyeva IS, Pozdnyakova AV, Prosekov AY. Screening and characterization of the antagonistic properties of microorganisms isolated from natural sources. *Open Access Maced J Med Sci [Internet]*. 2020;8 (A):195-202. Available from: <https://oamjms.eu/index.php/mjms/article/view/3573>
- 806) O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of *Helicobacter pylori* infection in 2018. *Helicobacter*. 2018; 23,e12519.
- 807) Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY. Brief report: *Lactobacillus bulgaricus* GLB44 (Proviotic™) plus esomeprazole for *Helicobacter pylori* eradication: A pilot study. *Helicobacter*. 2018; 23(2),e12476.
- 808) Pero, Raffaella, et al. A novel view of human *Helicobacter pylori* infections: Interplay between microbiota and beta-defensins. *Biomolecules*, 2019, 9.6: 237.
- 809) Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. *Helicobacter pylori* treatment in the post-antibiotics era—searching for new drug targets. *Applied Microbiology and Biotechnology*, 2020, 1-15.
- 810) Shehata HR; Chandler RA, Newmaster SG. Draft genome sequences of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains CBC-LB69 and CBC-LB8, isolated from homemade dairy foods in Bulgaria. *Microbiology Resource Announcements*, 2020, 9.45.

- 811) Velikova P, Petrov K, Lozanov V, Tsvetanova F, Stoyanov A, Wu Z, Liu Z, Petrova P. Microbial diversity and health-promoting properties of the traditional Bulgarian yogurt. *Biotechnology & Biotechnological Equipment*. 2018 May 1:1-3.
- ЦИТИРАНА: 79А: Markovska R, Boyanova L, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori* *cag* pathogenicity island (*cagPAI*) integrity and significance of its individual genes. *Infect Genet Evol*. 2018;**59**: 167-171..**
- 812) Ansari S, Yamaoka Y. *Helicobacter pylori* virulence factors exploiting gastric colonization and its pathogenicity. *Toxins*. 2019; **11**(11): 677.
- 813) Ansari S, Yamaoka Y. *Helicobacter pylori* virulence factor cytotoxin-associated gene A (*cagA*)-mediated gastric pathogenicity. *International Journal of Molecular Sciences*. 2020; **21**(19): 7430.
- 814) dos Santos Pereira E, Albuquerque LM, de Queiroz Balbino V, da Silva Junior WJ, Burbano RMR, Gomes JPP, Rabenhorst SHB. *Helicobacter pylori* *cagE*, *cagG*, and *cagM* can be a prognostic marker for intestinal and diffuse gastric cancer. *Infection. Genetics and Evolution*. 2020; **84**:104477.
- 815) Haddadi MH, Negahdari B, Asadolahi R, Bazargani A. *Helicobacter pylori* antibiotic resistance and correlation with *cagA* motifs and *homb* gene. *Postgraduate medicine*. 2020; **132**(6): 512-520.
- 816) Yanovich O, Doroshko M, Titov L. *Helicobacter pylori* genotypes among Belarus patients with gastroduodenal disorders and their association with clinical outcome. *Acta microbiologica et immunologica Hungarica*. 2019; **66**(3): 399-411.
- 817) Сорокман ТВ, Попелюк НА, Колесник ДИ. Инфекция *Helicobacter pylori*: современный взгляд на факторы вирулентности и патогенности. *Актуальная инфектология*. 2019; **7**(4).
- ЦИТИРАНА:78А: Boyanova L. Direct Gram staining and its various benefits in the diagnosis of bacterial infections. *Postgrad Med*. 2018;**130**(1):105-110. doi: 10.1080/00325481.2018.1398049.**
- 818) Ako SE, Akum EA, Nkenfou CN, Pokam TB, Assob JCN. Fecal Gram stain morphotype and their distribution patterns in a Cameroonian cohort with and without HIV infection. *Scientific African*, 2020; **8**, e00376.
- 819) Gutiérrez-Arenas EG, Tavera-Valdez AN, Niderhauser-García A, Jaramillo-Rangel G, Ortega-Martínez MG. Optimización de la tinción de gram para su aplicación en tejidos. *Revista de Ciencias Farmacéuticas y Biomedicina* 2020; (ISSN: 2448-8380), 10.
- 820) Hassan Y, Abdullahi SA, Than LT. *Candida albicans* interdigital foot infection: A case report highlighting the importance of antifungal susceptibility testing. *Afr. J. Microbiol. Res*. 2018; **12**(36): 889-896.
- 821) Karsiyakali N, Yucetas U, Karatas A, Karabay E, Okucu E, Erkan E. Renal pelvis urine Gram stain as a traditional, but new marker in predicting postoperative fever and stone culture positivity in percutaneous nephrolithotomy: an observational, prospective, non-randomized cohort study. *World J Urol*. 2020 Jul 28. doi: 10.1007/s00345-020-03381-y.
- 822) Li H, Li L, Chi Y, Tian Q, Zhou T, Han C, ... & Zhou Y.. Development of a standardized Gram stain procedure for bacteria and inflammatory cells using an automated staining instrument. *MicrobiologyOpen*. 2020; **9**(9), e1099.
- 823) Nawijn F, Houwert RM, van Wessem KPJ, Simmermacher RKJ, Govaert GAM, van Dijk MR, de Jong MB, de Bruin IGJ, Leenen LPH, Hietbrink F. A 5-Year Evaluation of the Implementation of Triple Diagnostics for Early Detection of Severe Necrotizing Soft Tissue Disease: A Single-Center Cohort Study. *World J Surg*. 2019;**43**(8):1898-1905.
- 824) Rehman A, Ahmad S, Mateen A, Qamar H, Mubashar MA, Raza A, ... & Arshad A. Mechanistic Study of Antibacterial Properties of Chemically Synthesize Zinc Oxide Nanoparticles. *Advanced Nano Research*. 2019; **2**(1), 42-52.
- 825) Rodríguez PA, Arenas R. Hans Christian Gram y su tinción. *Dermatología Cosmética, Médica y Quirúrgica*. 2018;**16**(2):166-167.
- 826) Sharma N K, Gautam DK, Khan MR. (2020, July). Comparative Analysis on Multiplier. In 2020 11th International Conference on Computing, Communication and Networking Technologies (ICCCNT) (pp. 1-5). IEEE.
- 827) Süzük Yıldız, S. “In-House” Tween® 80 Yöntemi ile Pozitif Kan Kültürlerinden Mikroorganizmaların MALDI-TOF MS Yöntemi ile Doğrudan Tanımlanması: Deneysel ve Klinik Çalışma. *Mikrobiyol Bul*. 2020; **54**(4), 523-534.
- 828) Teixeira, P. M., Vital, W. C., Lima, A. A., Silva, N. N. T., Carneiro, C. M., de Medeiros Teixeira, L. F., & da Silva, G. N. Bacterial vaginosis: prevalence, risk profile and association with sexually transmitted infections. *Revista de Epidemiologia e Controle de Infecção*. 2020; **10**(3).
- ЦИТИРАНА:80А: Nagy E, Boyanova L, Justesen US; ESCMID Study Group of Anaerobic Infections. How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories? *Clin Microbiol Infect*. 2018;**24**(11):1139-1148. doi: 10.1016/j.cmi.2018.02.008.**
- 829) Acuña-Amador L, & Barloy-Hubler F. *Porphyromonas* spp. have an extensive host range in ill and healthy individuals and an unexpected environmental distribution: A systematic review and meta-analysis. *Anaerobe*. 2020;102280.
- 830) Al Hag, W. A., Elbadawi, H., & Hamid, M. A. Use of 16s rRNA to identify non-lactose-fermenting bacilli and molecular detection of ESBL resistance genes associated with hospital-acquired infection in Soba University Hospital, Sudan. *F1000Research*. 2020;**9**(1311):1311.
- 831) Bharath Kumar N. Halophilic Abilities of Bacteria in Selected Locations of Tamil Nadu. *International Journal of Microbiology Research*, 2019:0975-5276.
- 832) de Oliveira BFR, Cavalcanti MDA, de Oliveira Nunes S, Lobo LA, Domingues RMCP, Muricy G, Laport MS. *Paraclostridium* is the main genus of anaerobic bacteria isolated from new species of the marine sponge Plakina in the Brazilian Southeast coast. *Curr microbiol*. 2019;**76**(6):713-722.
- 833) Dubreuil L, Jehl F, Cattoen C, Bonnet R, Bru JP, Caron F, ... & Weber P. Improvement of a disk diffusion method for antibiotic susceptibility testing of anaerobic bacteria. French recommendations revisited for 2020. *Anaerobe*, 2020;**64**:102213.
- 834) Dumont Y, Michon AL, Laurens C, Bonzon L, Jean-Pierre H, Godreuil S. Rôle des bactéries anaérobies en clinique humaine. *Revue Francophone des Laboratoires*. 2018;**2018**(505):32-9.
- 835) Enault, C., Aujoulat, F., Pantel, A., (...), Lavigne, J.-P., Marchandin, H. Surgical site infection after hip replacement due to a novel *Peptoniphilus* species, provisionally named ‘*Peptoniphilus nemausus*’ sp. nov. *Anaerobe* 2020, **61**:102071
- 836) Erdélyi E, Ambrus A, Szabó L, Kiricsi Á, Nagy E, Rovó L, Bella Z. A mikrobiológiai vizsgálatok szerepe a peritonsillaris tályog kezelésében hat év anyagának retrospektív elemzése alapján. *Orvosi Hetilap*. 2020 Nov 1;**161**(44):1877-83.

- 837) Eszter, E., Andrea, A., Linda, S., (...), László, R., Zsolt, B. The role of microbiological examination in treating peritonsillar abscess based on the retrospective analysis of data from six years | [A mikrobiológiai vizsgálatok szerepe a peritonsillaris tályog kezelésében hat év anyagának retrospektív elemzése alapján] Orvosi Hetilap. 2020; **161**(44):1877-1883
- 838) Gajdács, M. Anaerobes and laboratory automation: Like oil and water? Anaerobe, 2019;**59**:112-114.
- 839) Gajdács M, Urbán E, Terhes G. Microbiological and clinical aspects of cervicofacial *actinomyces* infections: an overview. Dentistry journal, 2019;**7**(3): 85.
- 840) Gajdács M, Urbán E. Relevance of anaerobic bacteremia in adult patients: A never-ending story?. European Journal of Microbiology and Immunology. 2020;
- 841) Gajdács M, Urbán E. The Pathogenic Role of *Actinomyces* spp. and Related Organisms in Genitourinary Infections: Discoveries in the New, Modern Diagnostic Era. Antibiotics, 2020; **9**(8):524.
- 842) Jeverica S, Sóki J, Premru MM, Nagy E, Papst L. High prevalence of division II (*cfiA* positive) isolates among blood stream *Bacteroides fragilis* in Slovenia as determined by MALDI-TOF MS. Anaerobe. 2019 Feb 1.
- 843) Kierzkowska M, Majewska A, Młynarczyk G. Five years prospective survey of antibiotic resistance in *Bacteroides* and *Parabacteroides* isolated from inpatients of clinical hospital in Warsaw, Poland Pięcioletnie prospektywne badanie oporności na antybiotyki bakterii z rodzajów *Bacteroides* i *Parabacteroides* izolowanych od chorych. Organ Narodowego Instytutu Zdrowia Publicznego.: Med. Dośw. Mikrobiol. 2020; **72**:13-19.
- 844) Maier L, Goemans CV, Pruteanu M, Wirbel J, Kuhn M, Cacace E, ... Typas A. Dissecting the collateral damage of antibiotics on gut microbes. BioRxiv. 2020
- 845) Márió G, Gabriella T, Edit U. The incidence of bloodstream infections caused by anaerobic bacteria in a university hospital between 2005-2009 and 2013-2017: A retrospective, comparative study | [Az anaerob baktériumok által okozott véráramfertőzések gyakorisága 2005-2009 és 2013-2017 között egy egyetemi központban: Retrospektív összehasonlító vizsgálat] Orvosi Hetilap. 2020; **161**(19), pp. 797-803.
- 846) Ombelet S, Barbé B, Affolabi D, Ronat JB, Lompo P, Lunguya O, ... & Hardy L. Best practices of blood cultures in low-and middle-income countries. Frontiers in medicine, 2019;**6**: 131.
- 847) Peeters M, Ombelet S, Chung P, Tsoumanis A, Lim K, Long L, ... Jacobs J. Slow growth of *Burkholderia pseudomallei* compared to other pathogens in an adapted blood culture system in Phnom Penh, Cambodia. J Med Microbiol. 2019; **68**(8):1159-1166.
- 848) Posteraro P, De Maio F, Menchinelli G, Palucci I, Errico FM, Carbone M, ... Posteraro B. First bloodstream infection caused by *Prevotella copri* in a heart failure elderly patient with Prevotella-dominated gut microbiota: a case report. Gut pathog. 2019; **11**(1):1-6.
- 849) Rassolie A, Özenci V. Short-term culture for rapid identification of anaerobic bacteria from blood cultures. Anaerobe, 2019;**57**: 59-62.
- 850) Scherler A, Ardisson S, Moran-Gilad J, Greub G. (2019). ESCMID/ESGMD postgraduate technical workshop on diagnostic microbiology. Microbes and infection, 2019; **21**(8-9): 343-352.
- 851) Zhang, C. Y., Li, M. H., & Guo, M. Q. (2020). A phase conversion headspace technique for the determination of anti-anaerobic activity of drug candidate based on the metabolic acidity change in culture medium. Journal of Chromatography A. 2020;**1621**: 461024.
- 852) Zou J, Yang X, Zeng L, Wang X, Liu Y, Wei D, ... & Hu N. Identification and Antimicrobial Susceptibility of Clinically Isolated Anaerobic Bacteria: A Retrospectively Study in a Jiangxi Tertiary-Care Hospital. Jundishapur Journal of Microbiology, 2019;**12**(10).

**ЦИТИРАНА 85А: Boyanova L, Hadzhiyski P, Markovska R, Yaneva P, Yordanov D, Gergova G, Mitov I. Prevalence of *Helicobacter pylori* is still high among symptomatic Bulgarian children. Acta Microbiol Immunol Hung. 2019; **66**(2):255-260.**

- 853) Seo JH, Bortolin K, Jones NL. *Helicobacter pylori* infection in children. Helicobacter. 2020; **25**, e12742.
- 854) Поливанова ТВ, Каспаров ЭВ, Вшивков ВА, Перетягко ОБ, Ахметшин ТН. Распространенность гастроэзофагеальной рефлюксной болезни, гастродуоденальных эрозий и язв и их ассоциация у школьников Сибири с семейной предрасположенностью к язвенной болезни. Сибирский научный медицинский журнал. 2020; **40**(5), 113-121.

**ЦИТИРАНА 86А: Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. Infect Genet Evol. 2019; **69**:61-67. Цитирана от:**

- 855) Dziri R, Ayari I, Barguelli F, Ouzari HI, El Asli MS, Klibi N. First report of NDM and VIM coproducing *Klebsiella pneumoniae* in Tunisia and emergence of novel clones. Microbial Drug Resist. 2019; **25**(9): 1282-1286.
- 856) Foster-Nyarko, E., Alikhan, N. F., Ravi, A., Thilliez, G., Thomson, N. M., Baker, D., ... & Pallen, M. J. Genomic diversity of *Escherichia coli* isolates from non-human primates in the Gambia. Microbial genomics. 2020; **6**(9).
- 857) Ripabelli G, Sammarco ML, Salzo A, Scutellà M, Felice V, Tamburro M. New Delhi metallo- $\beta$ -lactamase (NDM-1)-producing *Klebsiella pneumoniae* of sequence type ST11: first identification in a hospital of central Italy. Lett Appl Microbiol. 2020; **71**(6): 652-659.
- 858) Zou, H., Jia, X., Liu, H., Li, S., Wu, X., & Huang, S. Emergence of NDM-5-Producing *Escherichia coli* in a Teaching Hospital in Chongqing, China: IncF-Type Plasmids May Contribute to the Prevalence of blaNDM-5. Frontiers in microbiology. 2020; **11**, 334.

**ЦИТИРАНА:90А: Boyanova L, Kalvatchev N, Yordanov D, Hadzhiyski P, Markovska R, Gergova G, Mitov I. *Clostridioides (Clostridium) difficile* carriage in asymptomatic children since 2010: a narrative review. Biotechnol Biotech Eq. 2019; **33**:1, 1228-1236, DOI: 10.1080/13102818.2019.1650666 Цитирана от:**

- 859) Khattab RA, Ahmed NA, Ragab YM, Rasmy SA. Bacteria producing antimicrobials against *Clostridium difficile* isolated from human stool. Anaerobe. 2020; 102206.

**ЦИТИРАНА:91А:** Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in *Helicobacter pylori*: current state and future directions. *Expert Rev Clin Pharmacol*. 2019;**12**(9):909-915. doi: 10.1080/17512433.2019. **Цитирана от:**

- 860) BaniHani MN, Khabour OF, Alzoubi KH, Bashir NA, Shakhathreh MAK, Sabi SH, Alrabadi N. The association between ABCB1 C1236T/C3435T SNPs and *H. pylori* infection among Jordanians. *Genes*. 2020; **11**(1): 63.
- 861) Bedoya-Gómez IJ, Alvarez-Aldana A, Moncayo-Ortiz JI, Guaca-González YM, Santacruz-Ibarra JJ, Arturo-Arias BL, ... & Beltrán-Angarita L. Surveillance of the antimicrobial resistance rates of *Helicobacter pylori* ten years later in the Western Central Region, Colombia. *Digestive Diseases*, 2020; **38**(3): 196-203.
- 862) Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, Sun Y. Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in *Helicobacter pylori* by enhancing drug efflux. *Helicobacter*. 2020; **25**(4): e12715.
- 863) Cano, A., Ettcheto, M., Espina, M., López-Machado, A., Cajal, Y., Rabanal, F., ... & Souto, E. B. State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. *Journal of Nanobiotechnology*. 2020; **18**(1), 1-24.
- 864) Di Fermo P, Di Lodovico S, Amoroso R, De Filippis B, D'Ercole S, Di Campli E, Cellini L, Di Giulio M. Searching for new tools to counteract the *Helicobacter pylori* resistance: The positive action of resveratrol derivatives. *Antibiotics*. 2020;**9**(12):891.
- 865) Isaza-Gómez E, Ángel-González MS, Ocampo-Muñoz M, Díaz-Quintero CA, Molina-Céspedes IC, Velásquez-Martínez MA, Posada-Moreno P, Salazar-Ochoa S. Controversies in surgery: Eradication of *Helicobacter pylori*. Therapy for all or according to usual indications? *Revista Colombiana de Cirugía*. 2020;**35**(4):665-674.
- 866) Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is only clarithromycin susceptibility important for the successful eradication of *Helicobacter pylori*?. *Antibiotics*. 2020;**9**(9):589.
- 867) Krzyżek P, Paluch E, Gościński G. Synergistic therapies as a promising option for the treatment of antibiotic-resistant *Helicobacter pylori*. *Antibiotics*. 2020;**9**(10):658.
- 868) Krzyżek P, Gościński G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of bacterial cellulose chemisorbed with anti-metabolites, 3-bromopyruvate or sertraline, to fight against *Helicobacter pylori* Lawn Biofilm. *International journal of molecular sciences*. 2020;**21**(24):9507.
- 869) Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The prevalence of multidrug resistance of *helicobacter pylori* and its impact on eradication in Korea from 2017 to 2019: A single-center study. *Antibiotics*. 2020;**9**(10):646.
- 870) Pellicano R, Roldán IJ, Castaño R, Navas MC. Which should be the first-line treatment for *Helicobacter pylori* in Colombia? A lesson from a recent study. *Biomédica*. 2019; **39**(4): 811-815.
- 871) Raj R, Agarwal N, Raghavan S, Chakraborti T, Poluri KM, Kumar D. Exquisite binding interaction of 18β-Glycyrrhetic acid with histone like DNA binding protein of *Helicobacter pylori*: A computational and experimental study. *International Journal of Biological Macromolecules*. 2020.
- 872) Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, Xie WR, He XX. The efficacy of washed microbiota transplantation on *Helicobacter pylori* eradication: A pilot study. *Gastroenterol Res Pract*. 2020: 8825189.
- 873) Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, ... & Xie Y. The effect of antibiotic resistance on *Helicobacter pylori* eradication efficacy: A systematic review and meta-analysis. *Helicobacter*. 2020; e12714.
- 874) Емельянов ИА. Современные подходы к повышению эффективности эрадикации *H. pylori* при высокой антибиотикорезистентности (обзор литературы). *Вестник новых медицинских технологий. Электронное издание*. 2020;**14**(5).

**ЦИТИРАНА 92А:** Boyanova L, Markovska R, Mitov I. Multidrug resistance in anaerobes. *FutureMicrobiol*. 2019; **14**(12):1055–1064.. **Цитирана от:**

- 875) Kozhakhmetova, S. S., Zholdybayeva, E. V., Mukhtarova, K. E., & Ramankulov, Y. M. Pathogenicity factors and antibiotic resistance of the *Bacteroides fragilis*. *Eurasian Journal of Applied Biotechnology*. 2020; (1), 3-13.

**ЦИТИРАНА: 101А:** Nyssen OP, Pérez-Aisa A, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Jurecic NB, Huguet JM, Alcaide N, Voynovan I, Bote JMB, Modolell I, Lasala JP, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Pinto RM, Niv Y, Kupcinskaskas L, Tonkic A, Leja M, Rokkas T, **Boyanova L**, ... *Helicobacter pylori* first-line and rescue treatments in patients allergic to penicillin: experience from the European Registry on *H. pylori* management (Hp-EuReg). *Helicobacter*. 2020;**00**:e12686. <https://doi.org/10.1111/hel.12686>. **Цитирана от:**

- 876) Zhou Y, Ye Z, Lu J, Miao S, Lu X, Sun H, ... & Huang Y. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. *Helicobacter*. 2020: e12721.

**ЦИТИРАНА: 102А:** Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskaskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, **Boyanova L**, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojević V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on *Helicobacter pylori* management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. *Gut*. 2021;**70**(1):40-54. doi: 10.1136/gutjnl-2020-321372. **Цитирана от:**

- 877) Graham DY. Transitioning of *Helicobacter pylori* therapy from trial and error to antimicrobial stewardship. *Antibiotics*. 2020;**9**(10):671.

**ЦИТИРАНА: 49Б:** Боянова Л., Панов Вл., Йорданов Д., Марковска Р., Марина М., Гергова Г., Иванова К., Панайотов Ст., Бранкова Н., Левтерова В., Митов И., Кантарджиев Т., Кръстев З. *Helicobacter pylori* в устната кухина –предварителни проучвания. *Хепато-гастроентерол*. 2008; No.1: 3-10.

- 878) Bagirova M, Allahverdiyev AM, Abamor ES, Aliyeva H, Unal G, Tanalp TD. An overview of challenges to eradication of *Helicobacter pylori* infection and future prospects. Eur Rev Med Pharmacol Sci. 2017; **21**(9):2199-2219.
- ЦИТИРАНА: 67Б: Боянова Л.**, Илиева Ю, Владимиров Б, Гергова Г, Николов Р, Спасова З, Матева Л, Митова Р, Терзиев И, Митов И. Честота на *Helicobacter pylori* при възрастни пациенти с <sup>13</sup>С уреен дихателен тест. Обща мед. 2013, XV (4):22-25.
- 879) Best, L. M., Takwoingi, Y., Siddique, S., Selladurai, A., Gandhi, A., Low, B., ... & Gurusamy, K. S. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2018; (3).
- 880) Gurusamy, K. S., Yaghoobi, M., & Davidson, B. R. Non-invasive diagnostic tests for *Helicobacter pylori* infection. Cochrane Database of Systematic Reviews. 2016; (2).
- ЦИТИРАНА 51В:** McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskis L, Perez-Aisa A, Axon T, Buzas GM, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L**, Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): **Bacterial Resistance**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Gastroenterology, 2015; **148**(4): S-417. **Цитирана от:**
- 881) Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. The American journal of gastroenterology. 2017;**112**(2):212-239.
- ЦИТИРАНА 49В:** McNicholl AG, Tepes B, Gasbarrini A, **Boyanova L**, Leja M, Lerang F, Rokkas T, Kupcinskis L, Przytulski K, Katicic M, Machado JC. **Su1173** Pan-European Registry on *H. pylori* Management: Interim Analysis. Gastroenterology. 2014;**146**(5):S-395. **Цитирана от:**
- 882) Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY. First-line *Helicobacter pylori* eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2018;**67**(1):20-7.
- 883) Лазебник ЛБ, Бордин ДС. Диагностика и лечение инфекции *Helicobacter pylori* в России: результаты проспективной наблюдательной программы «КАЙДЗЕН». Эффективная фармакотерапия. 2016(15):12-23.
- 884) МКНЦДЗМ Ц. Эффективность и безопасность *Lactobacillus reuteri* DSMZ17648 у инфицированных *Helicobacter pylori*. Журнал «Лечащий Врач». 2017 (5-2016):106.
- ЦИТИРАНА 50В:** McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskis L, Perez-Aisa A, Axon T, Buzas GM, Castro M, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, Rodrigo L, **Boyanova L**, Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Bujanda L, Molina-Infante J, Caldas M, Ramas M, Donday MG, Megraud F, O'Morain CA, Gisbert JP. P02.01management (Hp-EuReg): **First-line treatments and interim analysis of 11 272 patients**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Helicobacter. 20:91, SEP 2015. **Цитирана от:**
- 885) Beaugerie L, Peyrin-Biroulet L. No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A Mirage Related to Propensity Bias?. Gastroenterology. 2017; **152**(1):304-306.
- 886) Дехнич, Н. Н., Тряпшыко, А. А., Трушин, И. В., Кузьменков, А. Ю., & Козлов, Р. С. Нифурател в эрадикации инфекции *Helicobacter pylori* у взрослых: результаты рандомизированного, сравнительного клинического исследования. Клиническая микробиология и антимикробная химиотерапия, 2020; 22(2).
- 887) Ивашкин ВТ, Маев ИВ, Лапина ТЛ, Шептулин АА, Трухманов АС, Абдулхаков РА, Алексеенко СА, Дехнич НН, Козлов РС, Клярская ИЛ, Курилович СА.. Лечение инфекции *Helicobacter pylori*: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2017; **27**(4):4-21.
- 888) Хлынов, И. Б., Акименко, Р. И., Воронова, Е. И., Гаранина, Е. В., Гурикова, И. А., Лосева, М. Э., ... & Фрезе, Е. Б. Роль *Lactobacillus reuteri* DSMZ17648 в эрадикационной терапии инфекции *Helicobacter pylori* у взрослых в реальной клинической практике. Лечащий врач, 2020; (2), 19-22.
- ЦИТИРАНА 51В:** McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskis L, Perez-Aisa A, Axon T, Buzas GM, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L**, Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): **Bacterial Resistance**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Gastroenterology, 2015; **148**(4): S-417. **Цитирана от:**
- 889) Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. ACG clinical guideline: treatment of *Helicobacter pylori* infection. Official journal of the American College of Gastroenterology/ ACGл 2017; 112(2), 212-239.
- 890) Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., & Tacconelli, E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018; 155(5), 1372-1382.
- ЦИТИРАНА: 53В:** McNicholl AG, Gasbarrini A, Tepes B, Castro-Fernandez M, Aisa AP, Bujanda L, Molina-Infante J, Lanis A, Vaira D, Rokkas T, Almela P, Medina E, Ortuño J, Michopoulos S, Domínguez-Cajal M, Lucendo AJ, Barrio J, Modolell I, Pozzati L, Ntoulis V, Perez-Lasala J, Georgopoulos SD, Rodrigo L, Vujasinovic M, Bordin DS, Machado JC, **Boyanova L**, Caldas M, Ramas M, Donday MG, Megraud F, O'Morain CA, Gisbert JP. Tu1327 Pan-European Registry on *H. pylori* Management (Hp-EuReg): **Interim Analysis of Non-Bismuth Quadruple Concomitant Treatment**. Gastroenterology. 2016; 150 (4 Supplement 1): Page S875. [http://www.gastrojournal.org/article/S0016-5085\(16\)32952-3/abstract](http://www.gastrojournal.org/article/S0016-5085(16)32952-3/abstract)
- Цитирана от:**
- 891) Ramírez FB, Núñez CG, Mas MT, Jiménez NR, Caballero FL. Criterios para la erradicación de *Helicobacter pylori*. FMC-Formación Médica Continuada en Atención Primaria. 2018;**25**(1):43-53.
- 892) Сафина ДД, Абдулхаков СР, Абдулхаков РА. Эрадикационная терапия *Helicobacter pylori*: настоящее и будущее. Экспериментальная и клиническая гастроэнтерология. 2016(11):84-93.



- ЦИТИРАНА: 54B:** Adrian G. McNicholl AG, Tepes B, Gasbarrini A, Aisa AP, Vaira D, Bordin DS, Lerang F, Castro-Fernandez M, Bujanda L, Leja M, Vujasinovic M, Rokkas T, Kupcinskas L, Veijola L, Shvets O, Buzás GM, Machado JC, **Boyanova L**, ..., Megraud F, O'Morain CA, Gisbert JP. Tu1328 Pan-European Registry on *H. pylori* Management (HP-EuReg): **Interim Analysis of First- and Second-Line Treatments**. Gastroenterology. 2016; 150 (4 Supplement 1): Page S875. **Цитирана от:**
- 893) Fallone, C. A., Moss, S. F., & Malfertheiner, P. Reconciliation of recent *Helicobacter pylori* treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019; 157(1), 44-53.
- 894) Jonaitis, P. *Helicobacter pylori* infekcijos gydymo metodų ir jų efektyvumo vertinimas. 2020
- 895) Сафина ДД, Абдулхаков СР, Абдулхаков РА. Эрадикационная терапия *Helicobacter pylori*: настоящее и будущее. Экспериментальная и клиническая гастроэнтерология. 2016(11):84-93.
- ЦИТИРАНА: 58B:** McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Castro M, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L**, Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): Interim Analysis of 8,271 Patients. Su1136. Gastroenterology. 2015 Apr 1;148(4):S-417. **Цитирана от:**
- 896) Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. The American journal of gastroenterology. 2017;112(2):212.
- 897) Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in *Helicobacter pylori*: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-82.
- ЦИТИРАНА: 71B:** Marteva-Proevska Y, Velinov T, Markovska R, Dobrikova D, Pavlov I, **Boyanova L**, Mitov I. Antibiotic combinations with colistin against carbapenem-resistant *Klebsiella pneumoniae* - in vitro assessment. J of IMAB. 2018;24(4):2258-2266. DOI: 10.5272/jimab.2018244.2258. **Цитирана от:**
- 898) Nagy TA, Crooks AL, Quintana JL, Detweiler CS. Clofazimine Reduces the Survival of *Salmonella enterica* in Macrophages and Mice. ACS infectious diseases. 2020; 6(5), 1238-1249.
- ЦИТИРАНА: 7M:** **Boyanova L**, Setchanova L, Gergova G, Kostianev T, Yordanov D, Popova C, Kotsilkov K, Mitov I. Microbiological diagnosis of the severe chronic periodontitis. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; 15, Book 2 (Part Dentistry (Oral and Dental Medicine): 89-94. [http://www.journal-imab-bg.org/en/vol-15\\_book-2.htm](http://www.journal-imab-bg.org/en/vol-15_book-2.htm) **Цитирана от:**
- 899) Kazi, M. M., & Bharadwaj, R. Microbiota of Chronic Periodontitis and their Association with Severity of the Disease. International Journal of Current Research and Review. 2017; 9(7), 28.
- 900) Sindagi, A. S., Anmol, G. K., Bellad, A. S., & Kulkarni, K. In-vitro antibacterial activity of neem, clove, and cinnamon against *Actinobacillus* sp., isolated from chronic periodontitis patients. Biomedicine. 2020; 40(2), 214-219.
- ЦИТИРАНА: 15M:** **Boyanova L**. Epidemiology of *H. pylori* infection. In *Helicobacter pylori*. Boyanova L. (ed.) Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011: 135-159. **Цитирана от:**
- 901) Bui D, Brown HE, Harris RB, Oren E. Serologic evidence for fecal-oral transmission of *Helicobacter pylori*. Am J Trop Med Hyg. 2016;94(1):82-8.
- 902) Seid A, Tamir Z, Kasanew B, Senbetay M. Co-infection of intestinal parasites and *Helicobacter pylori* among upper gastrointestinal symptomatic adult patients attending Mekanesalem Hospital, northeast Ethiopia. BMC research notes. 2018;11(1):144.
- ЦИТИРАНА 11-17M:** **Boyanova L**. (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011. **Цитирана от:**
- 903) Algaat SS, Lal SS. Molecular cloning of *iceA1* gene of *Helicobacter pylori* in relation to gastric cancer. International Journal of Scientific Engineering and Technology Research. 2016; 05(08): 1613-1619.
- 904) Breckan RK, Paulssen EJ, Asfeldt AM, Kvamme JM, Straume B, Florholmen J. The All-Age Prevalence of *Helicobacter pylori* Infection and Potential Transmission Routes. A Population-Based Study. Helicobacter. 2016;21(6):586-595.
- 905) Bruno D, Fanny B, Jeremy P, Mathilde G, Amandine F, Allais F, Le Blaye I. Higher levels of exhaled dimethylcyclopropane in patients with small intestinal bowel overgrowth, periodontitis when associated with a medical history of cancer. J Clin Case Stu 2018; 3(4): dx.doi.org/10.16966/2471- 4925.175.
- 906) Elshiekh HRM, Elrabat AMH, Abd EL Mohsen E. EL desoky, Zaky MM. Antibiotic sensitivity to *Helicobacter pylori* growth. Int J Curr Microbiol App Sci. 2017; 6(12):3999-4006.
- 907) Kaewpitoon SJ, Loyd RA, Rujirakul R, Panpimanmas S, Matrakool L, Tongtawee T, Kootanavanichpong N, Pengsaa P, Kompor P, Chavengkun W, Kujapun J, Norkaew J, Ponphimai S, Padchasuwan N, Polsripradist P, Eksanti T, Phatisena T, Kaewpitoon N. *Helicobacter* species are possible risk factors of cholangiocarcinoma. Asian Pac J Cancer Prev. 2016;17(1):37-44.
- 908) Kholeaf MEAG, Mostafa MK, Saad NM, Hassan MMN. Occurrence of *Helicobacter* species with special priority to *H. pylori* in hen's eggs. Assiut Vet Med J. 2018; 64(158): 22-30.
- 909) Lopes-de-Campos D, Pinto RM, Lima SAC, Santos T, Sarmiento B, Nunes C, Reis S. Delivering amoxicillin at the infection site - a rational design through lipid nanoparticles. Int J Nanomedicine. 2019;14:2781-2795.
- 910) Ombugadu D, Oladele OV, Onuoha SC, Omisope O, Ani A. Prevalence of *Helicobacter pylori* IGG and stool antigen detection from dyspeptic patients in Jos, Nigeria. African journal of clinical and experimental microbiology. 2018; 19(3): 177- 185.
- 911) Oti VB, Pennap GR, Dennis O, Ajegena AS, Adoga MP. Prevalence and predictors of *Helicobacter pylori* infection among patients attending a healthcare facility in North-Central Nigeria Asian Pac J Trop Dis 2017; 7(6):352-355.
- 912) Piyush AR, Khan R, Harris H, Maheshwari V. Diagnostic efficacy of different techniques for detection of *Helicobacter pylori* in upper gastrointestinal tract pathologies. International Journal of Contemporary Research and Review. 2017;8(06).
- 913) Venkatesh CS, Wong SK, Hassan AKR, Yan YW, Chan CP, Ebernesan B. The prevalence of *Helicobacter pylori* infection in patients undergoing oesophago-gastro-duodenoscopy in Perak, Malaysia. Asian Journal of Medicine and Health Sciences. 2019; 2(2):11-22.

- 914) Грищенко ЕГ, Петрова ММ, Гилюк АВ, Николаева НН. Генетическая изменчивость *Helicobacter pylori* и особенности гастродуоденальной патологии. ЭНИ Забайкальский медицинский вестник. 2017; № 4: 245- 257.

#### **В ЧУЖДЕСТРАННИ КНИГИ:**

- ЦИТИРАНА: 2А: Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against *Helicobacter pylori*. Lancet. 1991; 337: 1486. Цитирана от:**
- 915) Kim J. Culture. In *Helicobacter pylori*. Kim N. (ed.). Springer, 2016, pp.129-134.  
<https://books.google.com/books?isbn=9812877061>
- ЦИТИРАНА: 10А: Boyanova L, Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; 48: 705-706. Цитирана от:**
- 916) Battaglia S. ESSENTIAL OIL MONOGRAPH: Rose. 2020. [www.salvatorebattaglia.com.au](http://www.salvatorebattaglia.com.au)
- ЦИТИРАНА: 16А: Boyanova L, Osmanliev D, Petrov D, Mitov I, I. Usunova, Petrov S, Minchev Tz. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. Clin. Microbiol. Infect. 2000; 6: 622-624. Цитирана от:**
- 917) Kaynak S, Aydın R. Current concepts and management of severely traumatized eye: Open-globe injury with endophthalmitis. In Current Concepts and Management of Eye Injuries. Springer London. 2016, pp. 155-166.
- ЦИТИРАНА: 19А: Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of *Helicobacter pylori* growth in vitro by Bulgarian propolis: preliminary report. J. Med. Microbiol. 2003; 52: 417-419. Цитирана от:**
- 918) Ali S, Majid S, Yatoo AM, Ali MN, Rasool S, Ali S, ... & Rasool S. Clinico-Pharmacological Perspective of honey and propolis. In Therapeutic Applications of Honey and its Phytochemicals. Springer, Singapore. 2020, pp. 165-193.
- ЦИТИРАНА: 23А: Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. *Campylobacter* infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease and other chronic intestinal diseases. Diagn Microbiol Infect Dis. 2004; 49 (1): 71-74. Цитирана от:**
- 919) Backert S, Tegtmeier N, Croinin TO, Boehm M, Heimesaat MM. Human *campylobacteriosis*. In *Campylobacter*: Features, Detection, and Prevention of Foodborne Disease. Günter Klein (ed.) Elsevier, 2017, pp. 1-26.
- 920) Sederdahl BK, Anderson EJ. Other *Campylobacter* Species. In: Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018, pp. 903-904.
- ЦИТИРАНА: 25А: Boyanova L, Djambazov V, Gergova G, Iotov D, Petrov D, Osmanliev D, Minchev Z, Mitov I. Anaerobic microbiology in 198 cases of pleural empyema. A Bulgarian study. Anaerobe; 2004; 10 (5): 261-267. Цитирана от:**
- 921) Godfrey MS, Bramley KT, Detterbeck F. Medical and surgical management of empyema. In Seminars in respiratory and critical care medicine. Thieme Medical Publishers. 2019, Vol. 40, No. 03, pp. 361-374.
- 922) Hedberg M, Nord CE. Anaerobic Gram-positive non-sporeforming rods and anaerobic Gram-positive cocci. In Anaerobic Bacteria. © 2010-2017. E-Sun Technologies, <http://www.antimicrobe.org/b77.asp>
- 923) Meislich D, Feingold AR. Anaerobic Cocci. In: Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018, pp. 1018-1019.
- 924) Morelli L, Callegari ML, Patrone V. Prebiotics, Probiotics, and Synbiotics: A Bifidobacterial View. In: The Bifidobacteria and Related Organisms 2018, pp. 271-293.
- 925) Weissferdt A. Infectious Diseases of the Pleura. In Diagnostic Thoracic Pathology. Springer, Cham. 2020, pp. 661-675.
- ЦИТИРАНА: 26А: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains *in vitro* by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; 54 (Pt 5):481-483. Цитирана от:**
- 926) Jothi CEG. Ecotoxinil ® : a potent multi-species and multi- functional probiotic consortium for the efficient revitalization of aquaculture pond bottom ecosystem. Proceedings of National Seminar on Marine Resources NSMR'16. Department of Zoology, The M.D.T. Hindu Collge, 2016, pp.199-204.  
<http://darshanpublishers.com/pdfcopy/FINAL%20NSMR16%20Proceedings.pdf>
- 927) Younis K, Younis K, Ahmad S. Investigating the functional properties of pineapple pomace powder and its incorporation in buffalo meat products, in plant-based natural products: derivatives and applications (ed Shahid-ul-Islam), John Wiley & Sons, Inc., Hoboken, NJ, USA. 2017, pp.175-192.
- ЦИТИРАНА: 28А: Boyanova L, Kolarov R, Gergova G, Deliverska E, Madjarov J, Marinov M, Mitov I. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillo-Facial Surgery, Sofia, Bulgaria. J. Med. Microbiol. 2006; 55 (Pt 9): 1285-1289. Erratum in: J Med Microbiol. 2006; 55 (Pt 12): 1759-1760. Цитирана от:**
- 928) Al-Nawas B, Karbach J. Leitlinie odontogene Infektionen 170620. 2017.
- ЦИТИРАНА: 29А: Boyanova L, Kolarov R, Gergova G, Mitov I. *In vitro* activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe 2006; 12 (4):173-177. Цитирана от:**
- 929) Sojka M, Horniackova M, Bucekova M, Majtan V, Majtan J. Antibiofilm efficacy of honeybee products against wound biofilm. In: . Recent Clinical Techniques, Results, and Research in Wounds. Springer, Cham. 2018.  
[https://link.springer.com/chapter/10.1007/15695\\_2018\\_108#citeas](https://link.springer.com/chapter/10.1007/15695_2018_108#citeas)
- ЦИТИРАНА: 31А: Boyanova L, Lazarova E, Jeleu C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; 56(Pt 8):1081-1085. Цитирана от:**
- 930) Principles and Practice of Pediatric Infectious Diseases E-Book. Sarah S. Long, Charles G. Prober, Marc Fischer (eds.)- 2017.
- ЦИТИРАНА: 32А: Boyanova L, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. Expert Rev. Anti Infect. Ther. 2007; 5(4):685-701. Цитирана от:**
- 931) Brook I, Long SS. Anaerobic bacteria: classification, normal flora, and clinical concepts. In Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018; pp. 987-995.

- 932) Brook I. Antimicrobial resistance of anaerobic bacteria. In Antimicrobial Drug Resistance. Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D. (eds). Springer International Publishing. 2017, pp. 1007-1040.  
[https://link.springer.com/chapter/10.1007/978-3-319-47266-9\\_15](https://link.springer.com/chapter/10.1007/978-3-319-47266-9_15)
- 933) Brook I. *Bacteroides* and *Prevotella* species and other anaerobic Gram-negative bacilli. In Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018; pp. 1012-1014.
- ЦИТИРАНА: 35А: Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I.** Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58**(1):94-100. **Цитирана от:**
- 934) Challa S, Neelapu NRR. Association between horizontal gene transfer and adaptation of gastric human pathogen *Helicobacter pylori* to the host. In Horizontal Gene Transfer 2019: pp. 257-267. Springer, Cham.
- 935) Challa S, Dutta T, Bramhachari PV, Reddy NNR. Quorum sensing and multidrug resistance mechanism in *Helicobacter pylori*. In Implication of Quorum Sensing and Biofilm Formation in Medicine, Agriculture and Food Industry. Springer, Singapore, 2019, pp. 101-119.
- ЦИТИРАНА: 36А: Boyanova L, Stephanova-Kondratenko M, Mitov I.** Anti-*Helicobacter pylori* activity of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains: preliminary report. Lett Appl Microbiol. 2009; **48** (5): 579-584. **Цитирана от:**
- 936) Komatsu Y, Aiba Y, Nakano Y, Yasuhiro Koga Y. Probiotics, prebiotics, and biogenics for the stomach. Chapter 18, 2016, pp. 363-381.  
[https://www.researchgate.net/profile/Yasuhiro\\_Komatsu2/publication/305392756\\_Probiotics\\_Prebiotics\\_and\\_Biogenics\\_for\\_the\\_Stomach/links/578ccee08ae59aa66814750.pdf](https://www.researchgate.net/profile/Yasuhiro_Komatsu2/publication/305392756_Probiotics_Prebiotics_and_Biogenics_for_the_Stomach/links/578ccee08ae59aa66814750.pdf)
- 937) Techo, S., De Moreno De Leblanc, A. The Many Benefits of Lactic Acid Bacteria. 2019, pp. 163-193
- ЦИТИРАНА: 37А: Boyanova L.** Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; **58** (Pt 7): 930-935. **Цитирана от:**
- 938) Lee JY. Triple therapy. Chapter. *Helicobacter pylori*. Kim N. (ed.) Springer. 2016, pp. 427-436.  
[http://link.springer.com/chapter/10.1007/978-981-287-706-2\\_41](http://link.springer.com/chapter/10.1007/978-981-287-706-2_41)
- ЦИТИРАНА: 39А: Boyanova L, Mitov I.** Geographic map and evolution of primary *Helicobacter pylori* resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010; **8**(1):59-70. **Цитирана от:**
- 939) Doron SI, Beaulac KR, Dhand A, Snyderman DR. Mechanisms of Resistance in Metronidazole. In: Mayers D., Sobel J., Ouellette M, Kaye K, Marchaim D. (eds) Antimicrobial Drug Resistance. Springer, Cham, 2017.  
[https://link.springer.com/chapter/10.1007/978-3-319-46718-4\\_19](https://link.springer.com/chapter/10.1007/978-3-319-46718-4_19)
- 940) Kwon YH. Amoxicillin. Chapter *Helicobacter pylori*. Springer. 2016, pp. 387-396.  
[http://link.springer.com/chapter/10.1007/978-981-287-706-2\\_37](http://link.springer.com/chapter/10.1007/978-981-287-706-2_37)
- 941) Lee JY. Quadruple therapy. Chapter *Helicobacter pylori*. Springer. 2016, pp. 437-445.  
[http://link.springer.com/chapter/10.1007/978-981-287-706-2\\_42](http://link.springer.com/chapter/10.1007/978-981-287-706-2_42)
- 942) Lee JY. Triple therapy. Chapter *Helicobacter pylori*. Springer. 2016, pp. 427-436.  
[http://link.springer.com/chapter/10.1007/978-981-287-706-2\\_41](http://link.springer.com/chapter/10.1007/978-981-287-706-2_41)
- 943) Lee SM. Metronidazole. Chapter *Helicobacter pylori*. Springer. 2016, pp. 405-413.  
[http://link.springer.com/chapter/10.1007/978-981-287-706-2\\_39](http://link.springer.com/chapter/10.1007/978-981-287-706-2_39)
- ЦИТИРАНА: 41А: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I.** Association of *iceA* and *babA* genotypes in *Helicobacter pylori* strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010; **98** (3):343-350. **Цитирана от:**
- 944) Поливанова, Т. В., Каспаров, Э. В., & Вшивков, В. А. *Helicobacter pylori* инфекция у детей Сибири (монография). 2018. <https://www.elibrary.ru/item.asp?id=36538466>
- ЦИТИРАНА: 42А: Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I.** Trends in antibiotic resistance in *Prevotella* species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. Anaerobe. 2010; **16**(5): 489-492. **Цитирана от:**
- 945) Brook I. *Bacteroides* and *Prevotella* species and other anaerobic Gram-negative bacilli. In: Principles and Practice of Pediatric Infectious Diseases (Fifth Edition) 2018, pp. 1012-1014.
- ЦИТИРАНА: 45А: Boyanova L.** Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011; **6**(8): 843-846. **Цитирана от:**
- 946) Campuzano-Maya G. Chapter 3. *Helicobacter pylori* and hematologic diseases. In Extradigestive manifestations of *Helicobacter pylori* infection-an overview 2016. In Tech. Medicine "Extradigestive Manifestations of *Helicobacter pylori* Infection - An Overview", Bruna Maria Roesler (ed.), 2016.
- ЦИТИРАНА: 46А: Markovska R, Boyanova L, Yordanov D, Gergova G, Mitov I.** *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. Diagn Microbiol Infect Dis. 2011; **71**(4):335-340. **Цитирана от:**
- 947) Kabamba ET, Yamaoka Y. *Helicobacter pylori* and related virulence factors for gastrointestinal diseases. In Gastric Cancer. Springer, Singapore 2019, pp. 31-50.
- ЦИТИРАНА: 47А: Boyanova L, Mitov I.** Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012; **10**(4):407-409. **Цитирана от:**
- 948) Fleet M, Rahman PK. Probiotics and their health benefits. In: Microbial Functional Foods and Nutraceuticals. Vijai Kumar Gupta, Helen Treichel, Volha (Olga) Shapaval, Luiz Antonio de Oliveira, Maria G. Tuohy (eds.). John Wiley & Sons, Dec 26, 2017 – Science. 2017, pp. 267-279.
- 949) Millar MR, Wilks M. Modulation of the intestinal flora. In Walker's pediatric gastrointestinal disease. 6<sup>th</sup> edition. Kleinman RE, Goulet O-J, Mieli-vergani G (eds) People's Medical Publishing House. 2018.
- ЦИТИРАНА: 55А: Boyanova L.** Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. World J Microbiol Biotechnol. 2014; **30** (5):1633-1637. **Цитирана от:**

- 950) Chapter 14. Control de *Helicobacter pylori* con extractos vegetales. Andrews, H. E., Carvajal, Z. Y. G., & Márquez, E. G. (eds). Avances en la seguridad y actividad biológica de sustancias bioactivas y probióticos. 2017. [Avances%20en%20la%20seguridad%20y%20actividad%20biologica%20de%20sustancias.pdf](#)
- 951) Krynicka, P., Ochmanek, R., Strojewska, P., Brzeska, M., & Frydrych, A. Effect of nutrients on the treatment of helicobacter pylori/Wpływ składników pokarmowych na leczenie *helicobacter pylori*. Nauki Przyrodnicze i Medyczne: Najnowsze doniesienia dotyczące nauk medycznych i biotechnologicznych, IPKIN, Lublin, 2018, pp. 50. (159 pages)
- ЦИТИРАНА: Boyanova L. (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011**  
**Цитирана от:**
- 952) Testerman TL. *Helicobacter pylori*. In Vascular Responses to Pathogens. Felicity NE. Gavins, Karen Y. Stokes (eds.) Academic Press, UK, 2016, pp. 102.
- ЦИТИРАНА: 58A: Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015, 31: 4-10. Цитирана от:**
- 953) Auwaerter PG. *Bacteroides* species. Johns Hopkins ABX Guide. 2019. [https://www.hopkinsguides.com/hopkins/view/Johns\\_Hopkins\\_ABX\\_Guide/540053/3.0/Bacteroides\\_species](https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540053/3.0/Bacteroides_species)
- 954) Avdic E, Pham PA. Clindamycin. Johns Hopkins ABX Guide. 2018. [https://www.hopkinsguides.com/hopkins/view/Johns\\_Hopkins\\_ABX\\_Guide/540131/all/Clindamycin](https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540131/all/Clindamycin)
- 955) Brook I. Antibiotic-Resistant Pathogens in ear, nose, and throat infections. In Infections of the ears, nose, throat, and sinuses Springer, Cham. 2018, pp. 15-29.
- 956) Charnot-Katsikas A, Beavis KG. In vitro testing of antimicrobial agents. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods E-Book. Elsevier, St Louis, Missouri. 2017, pp. 1153-1170.
- 957) Hauser AR. Antibiotic basics for clinicians: The ABCs of choosing the right antibacterial agent (Book) Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent. 2018, pp. 1-336.
- 958) Lowman W. The value and interpretation of microbiological specimens in the management of cIAI. In Abdominal Sepsis 2018 (pp. 301-317). Springer, Cham.
- 959) Поляк МС. Антибиотики в лечении анаэробных заболеваний. Нестор-История, 2017. 192 стр. ISBN 978-5-4469-1149-3. <https://www.labyrinth.ru/books/585245/>
- ЦИТИРАНА: 60A: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. Diagn Microbiol Infect Dis 2015; 82(1):85-86. Цитирана от:**
- 960) Bogdanov S. Honey in Medicine. Chapter 9. In Book of Honey. Bee Product Science, www.bee-hexagon.net April 2016
- 961) Chakravorty S, Bhattacharya S, Bhattacharya D, Sarkar S, Gachhui R. Kombucha: a promising functional beverage prepared from tea. In Non-alcoholic beverages. Woodhead Publishing. 2019; pp. 285-327.
- 962) Szweda P. Antimicrobial activity of honey. Chapter 10. In Agricultural and Biological Sciences "Honey Analysis", Vagner de Alencar Arnaut de Toledo. 2017. ISBN 978-953-51-2880-9: <https://www.intechopen.com/books/honey-analysis/antimicrobial-activity-of-honey>
- 963) Wani RA, Bhat AA, Rasool I, Yousuf SM, Rasool S, Wani HA. Properties of honey: its mode of action and clinical outcomes. In Therapeutic Applications of Honey and its Phytochemicals. 2020, pp. 299-314.
- ЦИТИРАНА: 61A: Boyanova L, Kolarov R, Mateva L, Markovska R, Mitov I. Actinomycosis- a frequently forgotten disease. Future Microbiol. 2015; 10(4): 613–628. Цитирана от:**
- 964) Bonifaz A, Armas-Vázquez A, Tirado-Sánchez A. Fungal infections in diabetics. In: Dermatology and Diabetes. Springer, Cham, 2018, pp. 117-132.
- 965) Feingold AR, Meislich D. Anaerobic Gram-positive nonsporulating bacilli (including *Actinomyces*). In: Principles and practice of pediatric infectious diseases (Fifth Edition) 2018, pp. 1019-1022.
- 966) Müller S. Non-neoplastic lesions of the oral cavity. In Head and neck pathology (Third Edition) 2019, pp. 175-196.
- 967) Principles and practice of pediatric infectious diseases. E-Book. Sarah S. Long, Charles G. Prober, Marc Fischer (eds.). 2017. <https://books.google.com/books?isbn=0323461328>
- ЦИТИРАНА: 63A: Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;123(10):887-94. Цитирана от:**
- 968) Li J, Li XZ. Antimicrobial resistance and drug efflux pumps in *Helicobacter*. In Efflux-mediated antimicrobial resistance in bacteria. Adis, Cham. 2016, pp. 489-513.
- 969) Fuzi M, Chang-Ro Lee, Jung Hun Lee, Kwang Seung Park, Young Bae Kim, Byeong Chul Jeong, Sang Hee Lee. The Global Challenge Posed by the Multiresistant International Clones of Bacterial Pathogens. Fuzi M, Margaret Ip (eds). Frontiers. (e-book) 2017, pp.156.
- ЦИТИРАНА: 65A: Boyanova L, Evstatiev I, Gergova G, Yaneva P, Mitov I. Linezolid susceptibility in *Helicobacter pylori*, including strains with multidrug resistance. Int J Antimicrob Agents. 2015 Dec;46(6):703-706. Цитирана от:**
- 970) Geddes AM, Gould IM, Roberts JA, Lindsay Grayson M, Cosgrove SE. Ampicillin and amoxicillin (Book Chapter). In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition, 2017, pp. 100-135.
- 971) Li J, Li X-Z. Antimicrobial resistance and drug efflux pumps in *Helicobacter*. In Efflux-mediated antimicrobial resistance in bacteria. Springer International Publishing, 2016, pp. 489-513.
- 972) Sparham SJ, Howden BP. Linezolid (Book Chapter) In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition, 2017, pp. 1293-1347.
- ЦИТИРАНА: 66A: Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;48(1):56-62. Цитирана от:**

973) Angelov TA, Kovacheva-Slavova MD, Iliev HI, Valkov HY, Vladimirov BG. *Helicobacter pylori* Infection. In Gastritis-New Approaches and Treatments. IntechOpen. 2019.

**ЦИТИРАНА 73А: Boyanova L.** Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. *Anaerobe*. 2017; **44**:13-19. **Цитирана от:**

974) Anderson CJ, Kendall MM. *Salmonella enterica* serovar *Typhimurium* strategies for host adaptation. In Recent discoveries in human serious foodborne pathogenic bacteria: resurgence, pathogenesis, and control strategies. Chen L, Alali W (eds). 2019.

975) Plewig G, Melnik B, Chen W. Distinctive acne entities. In Plewig and Kligman's Acne and Rosacea. Springer, Cham. 2019, pp. 191-215.

976) Winter G, Hart RA, Charlesworth RP, Sharpley C. Gut Microbiome and Depression. The Oxford Handbook of the Microbiome-Gut-Brain Axis. Philip WJ Burnet (ed). 2020.

**ЦИТИРАНА: 75А. Boyanova L,** Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. *Diagn Microbiol Infect Dis*. 2017; **88**(3): 264-267.

977) Aldana AA, Trujillo OMH. Línea de investigación en *Helicobacter pylori* para la formación de recurso humano en ciencia, tecnología e innovación en el programa de microbiología. A Alvarez Aldana, OM Henao Trujillo (eds.) Risaralda, Colombia, Pereira. 2020.

**ЦИТИРАНА:77А: Boyanova L,** Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. *Lett Appl Microbiol*. 2017;**65**(6):469-474.doi: 10.1111/lam.12807

978) Oyeniran A, Gyawali R, Aljaloud SO, Krastanov Albrahim SA. Probiotic Characteristics and Health Benefits of the Yogurt Bacterium *Lactobacillus delbrueckii* sp. *bulgaricus*, Current Issues and Challenges in the Dairy Industry, Salam A. Ibrahim, Tahl Zimmerman and Rabin Gyawali, IntechOpen, DOI: 10.5772/intechopen.86939. 2020.

**ЦИТИРАНА 11-17М: Boyanova L.** (ed.) *Helicobacter pylori*. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011. **Цитирана от:**

979) Lopes D, Nunes C, Martins MCL, Sarmiento B, Reis S. Chapter 13.Targeting strategies for the treatment of *Helicobacter pylori* infections. In Nanobiotechnology in Diagnosis, Drug Delivery and Treatment. John Wiley & Sons, 2020. [http://iapc-obp.com/assets/files/165115\\_08\\_NBDD\\_13.pdf](http://iapc-obp.com/assets/files/165115_08_NBDD_13.pdf)

980) Testerman TL. Chapter 8 - *Helicobacter pylori*. In Vascular Responses to Pathogens. Academic Press, 2016: pp. 87-109.

#### **В ЧУЖДЕСТРАННИ ДИСЕРТАЦИИ:**

**ЦИТИРАНА: 2А: Megraud F, Boyanova L,** Lamouliatte H. Activity of lansoprazole against *Helicobacter pylori*. *Lancet*. 1991; **337**: 1486. **Цитирана от:**

981) Bekada DE. Intérêt des tests microbiologiques dans le cas de la gastrite B, maladie de Crohn et rectocolite hémorragique. Université d'Oran. 2019.

982) Macleod K. The effect of the proton pump inhibitor pantoprazole on the biology of *Campylobacter jejuni*. PhD thesis. University of Glasgow. 2016.

983) file:///C:/Users/07012017/Downloads/Okoleye+%2528M+Sc%2529+Microbiology.pdf

**ЦИТИРАНА: 10А: Boyanova L,** Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. *J. Med. Microbiol*. 1999; **48**: 705-706. **Цитирана от:**

984) El Gharbaoui A. Evolución y contraste del conocimiento etnofarmacológico (tradicional de plantas y usos medicinales) con perspectiva histórica en Marruecos oriental y Andalucía oriental, usando como base 'El Tratado de los Simples' de Ibn al-Baytar del siglo XIII. Universidad de Granada. 2017.

**ЦИТИРАНА: 13А: Boyanova L.** Comparative evaluation of two methods for testing metronidazole susceptibility of *Helicobacter pylori* in routine practice. *Diagn Microbiol Infect Dis*. 1999; **35** (1): 33 - 36. **Цитирана от:**

985) Ontsira Ngoyi EN. Resistance de *Helicobacter pylori* aux antibiotiques et d'autres substances antimicrobiennes. Aspects moléculaires des mécanismes de detection. L'Université de Bordeaux, France. 2016.

**ЦИТИРАНА: 14А: Boyanova L,** Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in *Helicobacter pylori* in Sofia, Bulgaria. *J. Med. Microbiol*. 2000; **49**: 415-418. **Цитирана от:**

986) Del Carmen Vergara MM. Expresión de HP0605 y HP0971 de bombas de eflujo en cepas de *Helicobacter pylori* resistentes a claritromicina aisladas de pacientes con patología gástrica. Chilpancingo, Guerrero, Enero de 2020.

**ЦИТИРАНА: 16А: Boyanova L,** Osmanliev D, Petrov D, Mitov I, I. Usunova, Petrov S, Minchev Tz. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. *Clin. Microbiol. Infect*. 2000; **6**: 622-624. **Цитирана от:**

987) El Moize Z. Traumatismes oculaires par projectiles de guerre au troisième millénaire." PhD diss., 2015. Université Mohamed V Rabat. file:///C:/Users/07012017/Downloads/M%20%20189%202015.pdf

**ЦИТИРАНА: 17А: Boyanova L,** Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarcheken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M. The status of antimicrobial resistance of *Helicobacter pylori* in eastern Europe. *Clin. Microbiol. Infect*. 2002; **8** (7): 388-396. **Цитирана от:**

988) Fernini F Moussa A. Gastrite a *Helicobacter pylori* chez l'enfant (Doctoral dissertation). Algeria, 2019.

989) Бабінець ОМ. Біологічні властивості пробіотиків після іммобілізації на ентеросорбентах і низькотемпературного зберігання. Інститут проблем кріобіології і кріомедицини. Національна Академія Наук України. Дисертація. Харків 2016.

**ЦИТИРАНА: 18А: Boyanova L,** Koumanova R, Gergova G, Popova M, Mitov I, Kovacheva Y, Derejian S, Katsarov N, Nikolov R, Krastev Z. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children. *J. Med. Microbiol*. 2002; **51**:786-790.

**Цитирана от:**

- 990) Fernini F, Moussa A. Gastrite a *Helicobacter pylori* chez l'enfant (Doctoral dissertation). 2019.
- ЦИТИРАНА ОТ: 19A: Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of *Helicobacter pylori* growth in vitro by Bulgarian propolis: preliminary report. J. Med. Microbiol. 2003; 52: 417-419. Цитирана от:**
- 991) Fadipe LA. Phytochemical and antibacterial investigations of the fruits of *Nauclea latifolia* Smith (family: *Rubiaceae*). Faculty Of Pharmaceutical Sciences, Ahmadu Bello University, Zaria Nigeria. 2016.
- 992) Illahi, M. F. In Silico Study of Propolis as a Potential Healing Agent for Gastric Ulcer (Doctoral dissertation, CAPITAL UNIVERSITY). 2020.
- 993) Márquez Morales, F. A. *Helicobacter pylori*: La historia de una bacteria muy peculiar. Universidad de Sevilla. 2019. idus.us.es
- 994) Suleman T. The antimicrobial and chemical properties of South African propolis. PhD diss., 2016.
- 995) Tarimda Yenilikçi Yaklaşımlar; Sürdürülebilir Tarım Ve Biyoçeşitlilik. Kağan Kökten (ed) Ankara, 2020.
- ЦИТИРАНА: 21A: Boyanova L. Influence of transport conditions and media on *Helicobacter pylori* isolation. J. Med. Microbiol. 2003; 52(Pt 12): 1129-1130. Цитирана от:**
- 996) Bayas Morejón IF. Aportaciones a la epidemiología de *Arcobacter* y *Helicobacter spp.*: Aplicación de métodos moleculares a su detección e identificación en alimentos (Doctoral dissertation). Universidad Politécnica de Valencia. 2016.
- ЦИТИРАНА: 23A: Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. *Campylobacter* infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease and other chronic intestinal diseases. Diagn Microbiol Infect Dis. 2004; 49 (1): 71-74. Цитирана от:**
- 997) Alrubaye, Bilal Ali, "Microbiota Metabolic Product Deoxycholic Acid Prevents *Campylobacter jejuni* chicken colonization through modulating ceca anaerobes". Theses and Dissertations. 2018.
- 998) Brunner, K. Early immunity to the *Campylobacter* genus-Insights into host and bacterial factors involved in health and disease (Doctoral dissertation, UCL-University College London). 2016.
- 999) Narváez Román NA. Análisis de polimorfismos del gen *flaA* en cepas de *Campylobacter jejuni* y *Campylobacter coli* mediante la técnica RFLP (Bachelor's thesis). 2018. Loca, Ecuador.
- ЦИТИРАНА: 26A: Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; 54 (Pt 5):481-483. Цитирана от:**
- 1000) Gonçalves GF. Efeito da própolis marrom e verde e de irrigantes endodônticos na resistência adesiva de pinos de fibra de vidro à dentina radicular. Dissertação. Cuiabá, 2017.
- 1001) Ketkar SS. Design and development of value added apiceutical products. PhD Thesis. Bharati Vidyapeeth University. 2015.
- 1002) Kikić A. The influence of propolis on fungal growth of *Sclerotinia sclerotiorum* and *Botrytis cinerea*. Master's thesis. Josip Juraj Strossmayer University of Osijek Faculty of agriculture. Osijek, Croatia. 2016.
- 1003) Márquez Morales, Felipe Andrés. "*Helicobacter pylori*: La historia de una bacteria muy peculiar." Master's Thesis Universidad de Sevilla. Departamento de Microbiología y Parasitología (2019).
- 1004) Moretti, FRRC. Identification of candidate resistance metabolites to *Leifsonia xyli* subsp. *xyli* in sugarcane through metabolomic profiling. Escola Superior de Agricultura Luiz de Queiroz. Piracicaba, 2017.
- 1005) Qiu S. Evaluating the antimicrobial and antibiofilm activity of a lipid extract from the giant kelp *Macrocystis pyrifera*. Doctoral dissertation, University of Otago. 2020.
- 1006) Romero Rivera MH. Interacciones entre compuestos mayoritarios anti-*Helicobacter pylori* presentes en propóleos de la Región del BioBio (Doctoral dissertation, Universidad de Concepción. Facultad de Ciencias Biológicas. Departamento de Microbiología). 2017.
- 1007) Soltani EK. Caractérisation et activités biologiques de substances naturelles, cas de la propolis (Doctoral dissertation). 2018.
- ЦИТИРАНА: 28A: Boyanova L, Kolarov R, Gergova G, Deliverska E, Madjarov J, Marinov M, Mitov I. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillo-Facial Surgery, Sofia, Bulgaria. J. Med. Microbiol. 2006, 55 (Pt 9): 1285-1289. Erratum in: J Med Microbiol. 2006; 55 (Pt 12): 1759-1760. Цитирана от:**
- 1008) Al-Nawas B, Karbach J. Odontogene Infektionen (S3). file:///C:/Users/07012017/Downloads/007-0061\_S3\_Odontogene\_Infektionen\_2017-11.pdf
- 1009) Barnard N. Prevalence of gram-negative infections in cervico-facial sepsis. University of the Western Cape. etd.uwc.ac.za 2019.
- 1010) Dias ACS. Infecções odontogênicas graves: etiologia microbiana, perfil de citocinas e de suscetibilidade a drogas antimicrobianas. 2016.
- 1011) Karthikeyan RA. Clinical study on Deep Neck Space Infections (Doctoral dissertation, Thanjavur Medical College, Thanjavur). 2020.
- ЦИТИРАНА: 29A: Boyanova L, Kolarov R, Gergova G, Mitov I. In vitro activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe 2006; 12 (4):173-177. Цитирана от:**
- 1012) Gonzales Carrillo GC. Eficacia antibacteriana in vitro del extracto etanólico de propóleo frente a la *Porphyromonas Gingivalis* Atcc 33277. Facultad de Odontología, Universidad Nacional, Lima - Perú. 2018.
- 1013) Kamble UK. Use of liquid chromatography for assay of flavonoids as key constituents and antibiotics as trace elements in propolis. Investigation into the application of a range of liquid chromatography techniques for the analysis of flavonoids and antibiotics in propolis; and extraction studies of flavonoids in propolis (Doctoral dissertation, University of Bradford). 2016.
- 1014) Kanaga Priyaa V. Comparative Evaluation of Antibacterial Efficacy of Manuka Honey, Indian Honey and Sodium Hypochlorite against *Enterococcus Faecalis* Biofilm: An Invitro study (Doctoral dissertation, Adhiparasakthi Dental College and Hospital, Melmaruvathur). 2020.
- 1015) Mahdjoubia L, Fatima Zohra B. L 'effet des polyphénols de la propolis de Tizirt sur l'hépatotoxicité induite par l'épirubicine chez les rats Wistar. Master en biologie, Université Abdelhamid Ibn Badis-Mostaganem, 2016.

- 1016) Tormos Esteve Ana. Estudio de la capacidad antimicrobiana de extractos de propóleos de diferentes orígenes. Valencia, 2019.  
**ЦИТИРАНА: 31А: Boyanova L, Lazarova E, Jelev C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; 56(Pt 8):1081-1085. Цитирана от:**
- 1017) Joosten, M. The zoonotic pathogen *Helicobacter heilmannii* from feline origin: aspects of virulence and gastric colonization (Doctoral dissertation, Ghent University). 2017.  
**ЦИТИРАНА: 32А: Boyanova L, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. Expert Rev. Anti Infect. Ther. 2007; 5(4):685-701. Цитирана от:**
- 1018) Chakor B. Abcès pulmonaire: Bactériologie et prise en charge. Dissertation. Université Mohammed V De Rabat. 2020  
**ЦИТИРАНА: 34А: Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; 60 (4): 409-415. Цитирана от:**
- 1019) Варванина СЭ. Оптимизация диагностики и лечения пациентов с заболеваниями слизистой оболочки полости рта, ассоциированными с *Helicobacter pylori*, до и после эрадикации. Диссертация Стоматология, Нижний Новгород. 2016.  
**ЦИТИРАНА: 37А: Boyanova L. Prevalence of multidrug-resistant *Helicobacter pylori* in Bulgaria. J. Med. Microbiol. 2009; 58 (Pt 7): 930-935. Цитирана от:**
- 1020) Varda Brkić D. Detekcija gena virulencije otoka patogenosti *cag* i gena *dupA* izolata *Helicobacter pylori* nakon višestruke neuspjele eradikacijske terapije (Doctoral dissertation, Sveučilište u Zagrebu). 2016.
- 1021) Калюжная ОА. Комплексная медицинская реабилитация больных с гастродуоденальной патологией с применением физических факторов (Doctoral dissertation, международная высшая школа). 2018.
- 1022) Приходько, М. Н. Стабильная стенокардия напряжения с сочетанием хронического *Helicobacter pylori*–ассоциированного гастрита: клинико-функциональные особенности, оптимизация терапии. Киров. 2020.  
**ЦИТИРАНА: 7М: Boyanova L, Setchanova L, Gergova G, Kostianev T, Yordanov D, Popova C, Kotsilkov K, Mitov I. Microbiological diagnosis of the severe chronic periodontitis. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; 15, Book 2 (Part Dentistry (Oral and Dental Medicine)): 89-94. [http://www.journal-imab-bg.org/en/vol-15\\_book-2.htm](http://www.journal-imab-bg.org/en/vol-15_book-2.htm) Цитирана от:**
- 1023) terhadap beberapa bakteri patogen periodontal secara in vitro. Universitas Sumatera Utara. Medan. 2017.  
**ЦИТИРАНА: 39А: Boyanova L, Mitov I. Geographic map and evolution of primary *Helicobacter pylori* resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010; 8(1):59-70. Цитирана от:**
- 1024) Alvarado Huertas LV, Bustos Fuentes SM. Identificación de *Helicobacter pylori* en aguas residuales del río Arzobispo (Bachelor's thesis). Pontificia universidad Javeriana Facultad de ciencias carrera de microbiología industrial. Bogotá, 2013.
- 1025) Arce Gómez, Angy Vanessa. Infección por *Helicobacter pylori* y la relación con el perfil lipídico. Bachelor's thesis, Universidad Técnica de Ambato-Facultad de Ciencias de la Salud-Carrera Laboratorio Clínico, 2016.
- 1026) Mathias F. Synthèse et évaluation biologique de nouveaux nitroimidazoles: challenges et recherche de nouvelles relations structure-activité (Doctoral dissertation, Aix-Marseille). 2017.
- 1027) Ontsira Ngoyi EN. Resistance de *Helicobacter pylori* aux antibiotiques et d'autres substances antimicrobiennes. Aspects moléculaires des mécanismes de detection. L'Université de Bordeaux, France. 2016.
- 1028) Ponce C, Luis J, Gómez A, Vanessa A. Infección por *Helicobacter pylori* y la relación con el perfil lipídico. Repositorio Universidad Técnica de Ambato. Ambato – Ecuador. 2016:
- 1029) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.
- 1030) Μητση, Ερμιόνη Ι. [Internal *Helicobacter pylori* transmission study in Epirus (Doctoral thesis)] Μελέτη ενδοοικογενειακής μετάδοσης ελικοβακτηριδίου του πυλωρού στην Ήπειρο (Doctoral thesis). ΙΩΑΝΝΙΝΑ 2016.  
**ЦИТИРАНА: 40А: Boyanova L, Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spasova Z, Mitov I. Two-decade trends in primary *H. pylori* resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010; 67: 319-326. Цитирана от:**
- 1031) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.
- 1032) Μητση, Ερμιόνη Ι. [Internal *Helicobacter pylori* transmission study in Epirus (Doctoral thesis)] Μελέτη ενδοοικογενειακής μετάδοσης ελικοβακτηριδίου του πυλωρού στην Ήπειρο (Doctoral thesis). ΙΩΑΝΝΙΝΑ 2016  
**ЦИТИРАНА: 41А: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Association of *iceA* and *babA* genotypes in *Helicobacter pylori* strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010; 98 (3):343-350. Цитирана от:**
- 1033) Delgado Arcentales, F. R. Comparación de genes de virulencia entre *helicobacter pylori* y otras especies de *Helicobacter* en pacientes ecuatorianos (Master's thesis, Quito). 2018.
- 1034) Нехаєнко, М. І. Клініко-патогенетичне обґрунтування диференційованої терапії хронічних гастродуоденітів у підлітків. Київ, 2018.  
**ЦИТИРАНА: 42А: Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I. Trends in antibiotic resistance in *Prevotella* species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. Anaerobe. 2010; 16(5): 489-492. Цитирана от:**
- 1035) Diaztagle Cadena, B. V., & Muñoz Gamboa, L. M. Prevalencia de los genes de resistencia antibiótica *cfxA*, *cfxA2*, *blaTEM*, *tetM*, *tetQ* y *ermF* en aislamientos orales de *Prevotella melaninogenica*. Bogotá DC. 2019
- 1036) Carey DE. The role of household antimicrobials in the proliferation of antibiotic resistance during anaerobic digestion. 2016. Dissertations (2009). Paper 639. Marquette University, Milwaukee, Wisconsin.
- 1037) Lloreda Rey LP. Efecto antibacteriano de una nanoemulsión de fialocianina de aluminio clorada sobre periodontopatógenos relevantes en el paciente diabético tipo 2: Estudio in vitro. (Trabajo de grado - Maestría) Universidad de Santander, 2019.
- 1038) Wikstén EJ. Peritonsillar Abscess-Aetiologiy, Diagnostics and Treatment. University of Helsinki, Faculty of medicine, Institute of Clinical Medicine, Doctoral dissertation. 2016.



- ЦИТИРАНА: 44A: Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I.** Benefits of *Helicobacter pylori* *cagE* genotyping in addition to *cagA* genotyping. A Bulgarian study. *Antonie Van Leeuwenhoek*. 2011; **100**(4):529-35. **Цитирана от:** 1039) Borjabad, A. C. Trabajo Fin de Máster. *Galleria mellonella* como modelo animal de la infección por *Helicobacter pylori* y para estudios de eficacia preclínica de nuevos antimicrobianos frente a este patógeno. Universidad Zaragoza. 2020
- ЦИТИРАНА: 45A: Boyanova L.** Role of *Helicobacter pylori* virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. *Future Microbiol*. 2011; **6**(8): 843-846. **Цитирана от:** 1040) Radovanović Spurnić AP. Ispitivanje epidemioloških, kliničkih i patohistoloških specifičnosti infekcije izazvane bakterijom *Helicobacter pylori* kod osoba inficiranim virusom humane imunodeficijencije (Doctoral dissertation, Univerzitet u Beogradu-Medicinski fakultet). Beograd, 2017.
- 1041) Нехаєнко, М. І. Клініко-патогенетичне обґрунтування диференційованої терапії хронічних гастродуоденітів у підлітків. Київ, 2018.
- ЦИТИРАНА: 48A: Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I.** Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. *J Med Microbiol*. 2012; **61**(Pt 1):85-93. **Цитирана от:** 1042) Morilla Morilla A. Epidemiología, diagnóstico molecular y estudio de resistencias de *Helicobacter pylori*. Universidad de Oviedo. 2018.
- 1043) Rodríguez-Batlloir Aran L. Detección y cuantificación de patógenos periodontales en pacientes con gingivitis mediante el uso de técnicas moleculares. Máster de Ciencias Odontológicas Universidad Complutense de Madrid. 2016.
- 1044) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.
- ЦИТИРАНА: 50A: Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I.** Significance of *Helicobacter pylori* *vacA* intermediate region genotyping—a Bulgarian study, *Diagn Microbiol Infect Dis* 2012; **74**(3):253-257. **Цитирана от:** 1045) Chong A. Examining whether *Helicobacter pylori* has a causal effect on cardiovascular disease and cancer. (thesis).University of Bristol. 2019.
- 1046) Stepanian Rozo, J. Análisis de genómica comparativa en aislamientos colombianos de *Helicobacter pylori*: enfoque asociado a virulencia, resistencia antibiótica y estructura poblacional. Bogotá. Noviembre, 2020.
- ЦИТИРАНА: 51A: Boyanova L, Mitov I.** Antibiotic resistance rates in causative agents of infections in diabetic patients. Rising concerns. *Expert Rev. Anti Infect. Ther*. 2013; **11** (4): 411-420. **Цитирана от:** 1047) Mottola C. Virulence characterization and antimicrobial resistance of major bacterial genera from diabetic foot infections. Universidade de Lisboa. 2017.
- 1048) Yilma S. Assessment of knowledge, attitude and intention to use long acting and permanent contraceptive methods among women in hiv chronic care, Addis Abeba, Ethiopia. College of Health Sciences School of Public Health. Diss. Addis Ababa University, 2016.
- ЦИТИРАНА: 53A: Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I.** Characterization of oral *Helicobacter pylori* strain by 4 methods. *Diagn Microbiol Infect Dis* 2013; **77** (4): 287-288. **Цитирана от:** 1049) Dawson EM. The characterisation of dynammin-like proteins in the gastric pathogen *Helicobacter pylori* (Doctoral dissertation). University of Technology Sydney, Australia. 2018.
- ЦИТИРАНА: 55A: Boyanova L.** Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. *World J Microbiol Biotechnol*. 2014; **30** (5):1633-1637. **Цитирана от:** 1050) Andrews HE, Carvajal ZY, Márquez EG. Avances en la seguridad y actividad biológica de sustancias bioactivas y probióticos. 2017.
- ЦИТИРАНА: 56A: Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I.** *Helicobacter pylori* susceptibility to fosfomycin, rifampin and five usual antibiotics for *H. pylori* eradication. *Diagn Microbiol Infect Dis* 2014; **79**:358–361 **Цитирана от:** 1051) Kuffour EO. The unending war between HIV and the intrinsic innate and adaptive immune system: dissecting the role of USP18 (UBP43) and *H. pylori* coinfection. Heinrich Heine University Düsseldorf, Düsseldorf. 2019.
- 1052) Samson M. Analysis of antibacterial activity of *Terminalia sericea* and *Combretum imberbe* two combretaceae species from Namibia. TheE University of Namibia. 2019.
- 1053) Williams KF. Investigating the effect of antibiotic exposure on the prevalence of antibiotic-resistant *H. pylori* infection and the incidence of anti-*H. pylori* treatment failure in Northern Canadian communities. PhD diss., University of Alberta, 2016.
- ЦИТИРАНА: 58A: Boyanova L, Kolarov R, Mitov I.** Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. *Anaerobe*. 2015, **31**: 4-10. **Цитирана от:** 1054) Cherkaoui, A. Imipenem Heteroresistance in Nontypeable *Haemophilus influenzae* (Doctoral dissertation, University of Geneva). 2019.
- 1055) Litterio BM. Detección del determinante genético (*cfiA*) de la resistencia a carbapenems y su entorno molecular en aislamientos clínicos de bacilos gram negativos anaerobios 2016. (Doctoral dissertation, Universidad de Buenos Aires).
- 1056) Plach M. Evolution of substrate specificity and protein-protein interactions in three enzyme superfamilies. fakultät für biologische und vor-klinische medizin der Universität Regensburg. 2017.
- 1057) Urbán E. Klinikailag fontos humán patogén anaerob baktériumok diagnosztikája és antibiotikum rezisztencia vizsgálata (Doctoral dissertation, SZTE ÁOK). 2020.
- 1058) Wirsing T. Untersuchung des in-vitro Resistenzverhaltens parodontalpathogener Keime gegenüber Amoxicillin, Metronidazol und Clindamycin (Doctoral dissertation). 2019.
- ЦИТИРАНА: 59A: Boyanova L.** Susceptibility of anaerobes to fusidic acid and fosfomycin. *Int J Antimicrob Agents*. 2015; **45**(5):560-561. **Цитирана от:**

1059) Popović J. Fosfomicin u liječenju infekcija uzrokovanih višestruko otpornim bakterijama (Doctoral dissertation, University of Zagreb. School of Medicine. Chair of Infectious Diseases). 2018.

**ЦИТИРАНА: 60A: Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I.** Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. *Diagn Microbiol Infect Dis* 2015; **82**(1):85-86. **Цитирана от:**

1060) Popović, Josipa. Fosfomicin u liječenju infekcija uzrokovanih višestruko otpornim bakterijama. Diss. University of Zagreb. School of Medicine. Chair of Infectious Diseases., 2018.

**ЦИТИРАНА: 62A: Kotsilkov K, Popova C, Boyanova L, Setchanova L, Mitov I.** Comparison of culture method and real-time PCR for detection of putative periodontopathogenic bacteria in deep periodontal pockets. *Biotechnol. Equip.* 2015; doi: 10.1080/13102818.2015.1058188 [http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c\\_ntmko](http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c_ntmko) **Цитирана от:**

1061) Ambrosio Elejalde, N. Bacteriemias de origen periodontal: validación de técnicas microbiológicas. Madrid, 2020

1062) Fernandes LS. Climate change impact on agricultural practices: reuse of municipal reclaimed water and treated greywater and respective implications for crop irrigation and human health. Thesis for Master of Science Degree. Biological Engineering, Universidade de Lisboa., 2019.

1063) Herrera González, D. Efecto de unas membranas nanoestructuradas, cargadas o no con doxiciclina, para la liberación controlada de fármacos, en un modelo de biofilm oral in vitro. Universidad Complutense De Madrid. 2018.

1064) Kannosh IY. Prisustvo oralnih patogenih mikroorganizama u ateromu i trombu pacijenata sa aterosklerozom i infarktom miokarda (Doctoral dissertation, Univerzitet u Beogradu-Biološki fakultet). 2020.

1065) Rodríguez-Batlloir Aran, L. Detección y cuantificación de patógenos periodontales en pacientes con gingivitis mediante el uso de técnicas moleculares. Universidad Complutense de Madrid. 2016.

1066) Olmeda VO. Efecto de unas membranas nanoestructuradas, cargadas o no con doxiciclina, para la liberación controlada de fármacos, en un modelo de biofilm oral in vitro. Olmeda VO. Efecto de unas membranas nanoestructuradas, cargadas o no con doxiciclina, para la liberación controlada de fármacos, en un modelo de biofilm oral in vitro. Máster en ciencias odontológicas, Universidad Complutense De Madrid, Madrid. 2018.

1067) Ragha Malika, S. Microbial Analysis of red complex organisms of the whole saliva in patients with gingivitis and gingival recession using next generation sequencing (Doctoral dissertation, Ragas Dental College and Hospital, Chennai). 2020.

1068) Rodríguez-Batlloir Aran, L. Detección y cuantificación de patógenos periodontales en pacientes con gingivitis mediante el uso de técnicas moleculares. Universidad Complutense de Madrid. 2016.

**ЦИТИРАНА: 63A: Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I.** Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. *APMIS*. 2015; **123**(10):887-94. **Цитирана от:**

1069) Dias DJ. Assessing antibiotic resistance in Gram negative bacteria from animals and the wider environment. Dissertação para obtenção do Grau de Doutor em Biologia, Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa, 2016.

1070) García MH. Colonización por enterobacterias productoras de carbapenemasas durante el proyecto europeo R-GNOSIS: epidemiología, estructura poblacional y caracterización molecular (Doctoral dissertation, Universidad Complutense de Madrid). 2018.

1071) Mouftah Ali SFM. The role of plasmids and clones in the emergence of carbapenem resistant enterobacteriaceae in the United Arab Emirates. Dissertations. 90. 2019.

**ЦИТИРАНА 64A. Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I.** Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. *APMIS*. 2015; **123**(10):887-894. **Цитирана от:**

1072) Yousfi H. Developpement de nouvelles strategies therapeutiques pour pallier l'urgence de la resistance aux antibiotiques. These de doctorat (Maladies infectieuses). Aix-Marseille Universite. 2019.

**ЦИТИРАНА: 65A: Boyanova L, Evstatiev I, Gergova G, Yaneva P, Mitov I.** Linezolid susceptibility in *Helicobacter pylori*, including strains with multidrug resistance. *Int J Antimicrob Agents*. 2015; **46**(6):703-706. **Цитирана от:**

1073) Popović J. Fosfomicin u liječenju infekcija uzrokovanih višestruko otpornim bakterijama. Master's thesis Zagreb, 2018.

**ЦИТИРАНА: 67A: Boyanova L, Markovska R, Yordanov D, Gergova G, Mitov I.** Clarithromycin resistance mutations in *Helicobacter pylori* in association with virulence factors and antibiotic susceptibility of the strains. *Microb Drug Resist*. 2016; **22**(3):227-232. **Цитирана от:**

1074) Tiago Gomes da Silva Benigno. Resistência genotípica primária Do *H. pylori* à claritromicina e associação com genótipos de virulência do *H. pylori* no nordeste do Brasil. Universidade Federal Do Ceará, Fortaleza, 2020.

**ЦИТИРАНА: 68A: Boyanova L, Ilieva J, Gergova G, Mitov I.** Levofloxacin susceptibility testing against *Helicobacter pylori*: evaluation of a modified disk diffusion method compared to E test. *Diagn Microbiol Infect Dis*. 2016; **84**(1):55-56. **Цитирана от:**

1075) Arévalo Granda JV. Genotipificación de *Klebsiella pneumoniae* mediante el análisis de secuencias de Locus Múltiples (MLST) en una colección de aislados clínicos provenientes de infecciones sistémicas de dos hospitales de referencia del Ecuador. Bachelor's thesis, Universidad de las Fuerzas Armadas ESPE. Carrera de Ingeniería en Biotecnología., 2018.

1076) Otero LL. Características del microbioma gástrico e intestinal en relación al estado de *Helicobacter pylori* en una población pediátrica (Doctoral dissertation, Universidad Complutense de Madrid). Madrid, 2017.

1077) Wilkinson, D. J. High throughput genomic analysis of *Helicobacter pylori* within-host diversity (Doctoral dissertation, Nottingham Trent University). 2019.

**ЦИТИРАНА: 71B: Marteva-Proevska Y, Velinov T, Markovska R, Dobrikova D, Pavlov I, Boyanova L, Mitov I.** Antibiotic combinations with colistin against carbapenem-resistant *Klebsiella pneumoniae* - in vitro assessment. *J of IMAB*. 2018; **24**(4):2258-2266. DOI: 10.5272/jimab.2018244.2258. **Цитирана от:**

1078) De Souza RC. Caracterização fenotípica e molecular dos mecanismos de resistência aos beta-lactâmicos em linhagens clínicas de *Klebsiella pneumoniae* isoladas do Amazonas. São Carlos – SP. 2018.

- ЦИТИРАНА 72A:** Markovska R, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Kaneva R, Mitev V, Mitov I. Isolation of *Escherichia coli* ST131 producing KPC-2 in Bulgaria. *Infect Dis (Lond)*. 2017; **49**(5): 429-431. **Цитирана от:** 1079) Duprilot M. Étude comparative du clade émergent de *Escherichia coli* ST131 O25b H4 de son clade progéniteur: fitness in vitro et in vivo et formation de biofilm (Doctoral dissertation, Université de Paris). 2019.
- ЦИТИРАНА 73A:** **Boyanova L**. Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. *Anaerobe*. 2017; **44**:13-19. **Цитирана от:** 1080) Azad A. The role of catecholamines in human chronic wounds. 2018.
- 1081) Gannesen A. "Structure et composition de biofilms mono-et multispécies de bactéries cutanées et environnementales: effets des cosmétiques et de certains autres composés biologiquement actifs." PhD diss., Normandie, 2018.
- 1082) Kuntzel L. Troubled love: The downside of love and possible ways to fix it (Doctoral dissertation). 2019.
- 1083) Otero LL. Características del microbioma gástrico e intestinal en relación al estado de *Helicobacter pylori* en una población pediátrica. Tesis doctoral. Universidad Complutense de Madrid; 2017.
- 1084) Volgers C. Beyond communication: membrane vesicle release during macrophage infection by common respiratory pathogens. Maastricht University. 2017:
- ЦИТИРАНА: 75A.** **Boyanova L**, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. *Diagn Microbiol Infect Dis*. 2017; **88**(3): 264-267.
- 1085) Buitrago Gómez, M. A., Díaz Ramírez, L., & Mejía Romero, M. Comparación de la concordancia entre métodos para la detección de la resistencia en aislamientos de *Helicobacter pylori* (Doctoral dissertation, Universidad Libre Seccional Pereira). 2018.
- 1086) Meincheim, I. Taxa de erradicação do *Helicobacter pylori* e fatores associados em indivíduos de uma clínica do município de Florianópolis. Medicina-Pedra Branca. Universidade do Sul de Santa Catarina. 2018.
- ЦИТИРАНА: 76A.** Markovska R, Stoeva T, **Boyanova L**, Stankova P, Pencheva D, Keuleyan E, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Kaneva R, Mitov I. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing *K. pneumoniae* isolates. *Diagn Microbiol Infect Dis*. 2017; **89**(4):310-313.
- 1087) Davies, Y. M. (2018). Virulência e resistência aos antimicrobianos de *Klebsiella* spp isoladas de psitácidos com doença respiratória (Doctoral dissertation, Universidade de São Paulo).
- 1088) Mouftah Ali SFM. The role of plasmids and clones in the emergence of carbapenem resistant enterobacteriaceae in the United Arab Emirates. Dissertations. 90. 2019.
- ЦИТИРАНА:77A:** **Boyanova L**, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. *Lett Appl Microbiol*. 2017;**65**(6):469-474.doi: 10.1111/lam.12807
- 1089) Oyeniran, Ayowole Caleb. A Modified RCM medium for the growth of *Lactobacillus bulgaricus*. PhD Thesis. North Carolina Agricultural and Technical State University.2019.
- ЦИТИРАНА:78A:** **Boyanova L**. Direct Gram staining and its various benefits in the diagnosis of bacterial infections. *Postgrad Med*. 2018;**130**(1):105-110. doi: 10.1080/00325481.2018.1398049.
- 1090) Guzmán Hernández, X. Características de la microbiota cultivable de la piel de *Ambystoma ordinarius* en cautiverio. Universidad Michoacana de San Nicolas de Hidalgo. 2020.
- ЦИТИРАНА: 79A:** Markovska R, **Boyanova L**, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori* *cag* pathogenicity island (*cagPAI*) integrity and significance of its individual genes. *Infect Genet Evol*. 2018;**59**: 167-171..
- 1091) Wilkinson DJ. High throughput genomic analysis of *Helicobacter pylori* within-host diversity (Doctoral dissertation, Nottingham Trent University). 2019.
- ЦИТИРАНА:80A:** Nagy E, **Boyanova L**, Justesen US; ESCMID Study Group of Anaerobic Infections. How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories? *Clin Microbiol Infect*. 2018;**24**(11):1139-1148. doi: 10.1016/j.cmi.2018.02.008.
- 1092) Никольский, В. И. Современные тенденции в диагностике и лечении больных острыми гнойно-воспалительными заболеваниями параректальной клетчатки. 2020.
- ЦИТИРАНА 86A:** Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. *Infect Genet Evol*. 2019; **69**:61-67. **Цитирана от:**
- 1093) Mahon, B. The role of the aquatic environment in the spread of antimicrobial resistance of public health significance (Doctoral dissertation, NUI Galway). 2020.
- ЦИТИРАНА 92A:** **Boyanova L**, Markovska R, Mitov I. Multidrug resistance in anaerobes. *FutureMicrobiol*. 2019; **14**(12):1055–1064.. **Цитирана от:**
- 1094) George S. Evaluation of the prevalence and transmission of asymptomatic *Clostridioides difficile* Carriage in the Hamilton In-patient setting using multi-level modelling. PhD Thesis. 2020.
- ЦИТИРАНА 11-17M:** **Boyanova L., Mitov, I. & Vladimirov, B., 2011. Boyanova L. (ed.) Helicobacter pylori**. Caister Academic Press (ISBN: 978-1-904455-84-4), Norfolk, UK, 2011. **Цитирана от:**
- 1095) Breckan RK. *Helicobacter pylori* infection in the 21st century Epidemiology, transmission and clinical aspects. A dissertation for the degree of PhD. The ArcticUniversity of Norway. 2016.
- 1096) Chávez MJX. Prevalencia de la infección activa por *Helicobacter pylori* en los expendedores callejeros de alimentos de Champerico y El Asintal, Retalhuleu. Química Bióloga. Universidad de San Carlos de Guatemala, Guatemala, 2018.
- ЦИТИРАНА 49B:** McNicholl AG, Tepes B, Gasbarrini A, **Boyanova L**, Leja M, Lerang F, Rokkas T, Kupcinskas L, Przytulski K, Katicic M, Machado JC. **Su1173** Pan-European Registry on *H. pylori* Management: Interim Analysis. *Gastroenterology*. 2014;**146**(5):S-395. **Цитирана от:**

1097) Налетов, А. В. Хроническая гастродуоденальная патология, ассоциированная с *Helicobacter pylori* у детей: особенности патогенеза, диагностика, лечение (Doctoral dissertation. Донецкий национальный медицинский университет им. М. Горького, Донецк). 2017.

**ЦИТИРАНА 51В.** McNicholl AG, Gasbarrini A, Tepes B, Bordin DS, Lerang F, Leja M, Rokkas T, Vaira D, Shvets O, Kupcinskas L, Perez-Aisa A, Axon T, Buzas GM, Simsek I, Katicic M, Machado JC; Lamy V, Przytulski K, **Boyanova L**, Bytzer P, Beglinger C, Cappelle LG, Goldis A, Veijola L, Vujasinovic M, Huerta A, Perez-Lasala J, Caldas M, Ramas M, Megraud F, O'Morain CA, Gisbert JP. Pan-European Registry on *H. pylori* Management (HP-EuReg): **Bacterial Resistance**. XXVIIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. Nicosia, Cyprus, September 24–26, 2015. Gastroenterology, 2015; **148**(4): S-417.. **Цитирана от:**

1098) Márquez Morales FA. *Helicobacter pylori*: La historia de una bacteria muy peculiar. Trabajo Fin de Máster. Universidad de Sevilla. 2019.

## **В БЪЛГАРСКИ СПИСАНИЯ:**

**ЦИТИРАНА: 10А: Boyanova L**, Neshev G. Inhibitory effect of rose oil products on *Helicobacter pylori* growth in vitro: preliminary report. J. Med. Microbiol. 1999; **48**: 705-706. **Цитирана от:**

1099) Chobanova S, Penchev IG, Atanasoff A, Ribarski S, Karkelanov N. Chemical composition, technological and organoleptic characteristics of meat from chicken broilers, fed with supplement of rose petal meal. Bulgarian Journal of Agricultural Science. 2019; 25(Suppl. 3), 81-84.

**ЦИТИРАНА: 31А: Boyanova L**, Lazarova E, Jelev C, Gergova G, Mitov I. *Helicobacter pylori* and *Helicobacter heilmannii* in untreated Bulgarian children over a period of 10 years. J Med Microbiol. 2007; **56**(Pt 8):1081-1085. **Цитирана от:**

1100) Панов В. *Helicobacter pylori* и устната кухина. Дентамедика. 2017; №9: 10-11.

**ЦИТИРАНА: 53А: Boyanova L**, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. Diagn Microbiol Infect Dis 2013; **77** (4): 287-288 **Цитирана от:**

1101) Panov V. Oral malodor and *Helicobacter pylori*. In Варненски медицински форум (Varna Medical Forum). 2017; 6(2):131-134.

**ЦИТИРАНА: 63А: Markovska R**, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015;**123**(10):887-94. **Цитирана от:**

1102) Veselin Dobrinov. Multilocus sequence typing of multi-drug resistant bacteria in the era of whole genome sequencing. Probl. Inf. Parasit. Dis. 2017; 45 (2):11-24.

**ЦИТИРАНА: 66А: Boyanova L**, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;**48**(1):56-62. **Цитирана от:**

1103) Angelov, I.T., Churchev, S., Valkov, H., (...), Golemanov, B., Vladimirov, B. Advanced diagnosis and treatment of the *Helicobacter pylori* infection. General Medicine. 2020; 22(1): 51-56.

1104) Димитров Д, Гоцева А. Ерадикация на *Helicobacter pylori*. Индикации и терапевтични режими. MedInfo. 2018; 9.

1105) Петров П, Петров Б. Съвременен подход при диагноза и лечение на Хеликобактер пилори инфекцията. Med Post. 2017; III(21): 46-51.

**ЦИТИРАНА: 75А. Boyanova L**, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. Diagn Microbiol Infect Dis. 2017; 88(3): 264-267. .

1106) Angelov, I.T., Churchev, S., Valkov, H., (...), Golemanov, B., Vladimirov, B. Advanced diagnosis and treatment of the *Helicobacter pylori* infection. General Medicine 2020; 22(1):51-56.

**ЦИТИРАНА: 7М: Boyanova L**, Setchanova L, Gergova G, Kostianev T, Yordanov D, Popova C, Kotsilkov K, Mitov I. Microbiological diagnosis of the severe chronic periodontitis. Journal of IMAB- Annual Proceeding (Scientific Papers) 2009; 15, Book 2 (Part Dentistry (Oral and Dental Medicine): 89-94. [http://www.journal-imab-bg.org/en/vol-15\\_book-2.htm](http://www.journal-imab-bg.org/en/vol-15_book-2.htm) **Цитирана от:**

1107) Kazi MM, Bharadwaj R. Microbiota of chronic periodontitis and their association with severity of the disease. Int J Cur Res Rev. 2017; 2017; 9(7):28.

## **В БЪЛГАРСКИ ДИСЕРТАЦИИ:**

**ЦИТИРАНА: 77А: Boyanova L**, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. Lett Appl Microbiol. 2017;**65**(6):469-474.doi: 10.1111/lam.12807

1108) Пенка Младенова Петрова ПМ. Молекулярно-биологични изследвания на нови бактериални гликозид-хидролази с промишлено приложение. Дисертация за дн. БАН, Институт по микробиология „Стефан Ангелов“, София 2019.

**ЦИТИРАНА: 53А: Boyanova L**, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. Diagn Microbiol Infect Dis 2013; **77** (4): 287-288. **Цитирана от:**

1109) Панов В. Промени в оралната среда и общи заболявания (Дисертация за „доктор“ Медицински университет Варна. 2016.

**ЦИТИРАНА: 60А: Boyanova L**, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. Diagn Microbiol Infect Dis 2015; **82**(1):85-86. **Цитирана от:**

1110) Йорданов ДВ. *Helicobacter pylori*–фактори на вирулентност, резистентност и серопревалиране. Дисертация за „доктор“. МУ-София, 2017.

**ЦИТИРАНА: 63A:** Markovska R, Stoeva T, Schneider I, **Boyanova L**, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. APMIS. 2015; **123**(10):887-94. **Цитирана от:**

1111) Kuyumdzchieva, G. N. Epidemiological Typing and Mechanisms of Antibiotic Resistance in Clinically Relevant *Klebsiella pneumoniae* Isolated at St. Marina University Hospital–Varna (Doctoral dissertation, Medical University of Varna (Bulgaria). 2019.

1112) Неделчева, Г. Епидемиологично типизиране и механизми на антибиотична резистентност в клинично значими *Klebsiella pneumoniae*, изолирани в УМБАЛ „Света Марина“, Варна (Doctoral dissertation). 2019.

**ЦИТИРАНА 86A:** Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. Infect Genet Evol. 2019; 69:61-67. **Цитирана от:**

1113) Kuyumdzchieva, GN. Epidemiological Typing and Mechanisms of Antibiotic Resistance in Clinically Relevant *Klebsiella pneumoniae* Isolated at St. Marina University Hospital–Varna (Doctoral dissertation, Medical University of Varna (Bulgaria). 2019.

## **В БЪЛГАРСКИ КНИГИ:**

**ЦИТИРАНА: 26A: Boyanova L**, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 *Helicobacter pylori* strains *in vitro* by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol. 2005; **54** (Pt 5):481-483. **Цитирана от:**

1114) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов“ Варна. 2016. 200 стр. ISBN: 9786197137835.

**ЦИТИРАНА: 27A: Boyanova L**, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in *Helicobacter pylori* strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol. 2006; **55**: 65-68. **Цитирана от:**

1115) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов“ Варна. 2016. 200 стр. ISBN: 9786197137835.

**ЦИТИРАНА: 33A: Boyanova L**. Detection of *Helicobacter pylori* infection in symptomatic Bulgarian adults. Clin. Microbiol. Infect. 2007; **13** (9): 908-914. **Цитирана от:**

1116) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов“ Варна. 2016. 200 стр. ISBN: 9786197137835.

**ЦИТИРАНА: 34A: Boyanova L**, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of *Helicobacter pylori* resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; **60**(4): 409-415. **Цитирана от:**

1117) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов“ Варна. 2016. 200 стр. ISBN: 9786197137835.

**ЦИТИРАНА: 38A: Boyanova L**, Markovska R, Yordanov D, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I. High prevalence of virulent *Helicobacter pylori* strains in symptomatic Bulgarian patients. Diagn Microbiol Infect Dis. 2009; **64**(4): 374-380. **Цитирана от:**

1118) Панов В. *Helicobacter pylori* и устната кухина. Издателство: Медицински университет „Проф.д-р Параскев Стоянов“ Варна. 2016. 200 стр. ISBN: 9786197137835.